Pathophysiology and Clinical Applications of Nitric Oxide
Part B
The Endothelial Cell Research Series A series of significant reviews of basic and clinical research related to the endothelium. Edited by Gabor M.Rubanyi, Berlex Biosciences, Richmond, California. Volume One Endothelium-Derived Hyperpolarizing Factor edited by Paul M.Vanhoutte Volume Two Endothelial Modulation of Cardiac Function edited by Malcolm J.Lewis and Ajay M.Shah Volume Three Estrogen and the Vessel Wall edited by Gabor M.Rubanyi and Raymond Kauffman Volume Four Modern Visualisation of the Endothelium edited by J.M.Polak Volume Five Pathophysiology and Clinical Applications of Nitric Oxide edited by Gabor M.Rubanyi Volumes in Preparation Mechanical Forces and the Endothelium P.I.Lelkes Vascular Endothelium in Human Physiology and Pathophysiology P.Vallance and D.Webb Morphogenesis of Endothelium W.Risau This book is part of a series. The publisher will accept continuation orders which may be cancelled at any time and which provide for automatic billing and shipping of each title in the series upon publication. Please write for details.
Pathophysiology and Clinical Applications of Nitric Oxide Part B Edited by
Gabor M.Rubanyi Berlex Biosciences Richmond, California USA
harwood academic publishers Australia • Canada • China • France • Germany • India Japan • Luxembourg • Malaysia • The Netherlands Russia • Singapore • Switzerland
This edition published in the Taylor & Francis e-Library, 2005. “To purchase your own copy of this or any of Taylor & Francis or Routledge’s collection of thousands of eBooks please go to www.eBookstore.tandf.co.uk.” Copyright © 1999 OPA (Overseas Publishers Association) N.V. Published by license under the Harwood Academic Publishers imprint, part of The Gordon and Breach Publishing Group. All rights reserved. No part of this book may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage or retrieval system, without permission in writing from the publisher. Printed in Singapore. Amsteldijk 166 1st Floor 1079 LH Amsterdam The Netherlands British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library. ISBN 0-203-30372-5 Master e-book ISBN
ISBN 0-203-34370-0 (Adobe eReader Format) ISBN: 90-5702-415-2 (Print Edition) ISSN: 1384-1270
DEDICATION
During the printing of this book we received the news of the award of the 1998 Nobel Prize in Medicine to Dr Robert Furchgott, Dr Louis Ignarro and Dr Ferid Murad for their pioneering work in the discovery of nitric oxide as a novel mediator of biological functions. In the name of all contributors to this book and numerous other scientists in the field we congratulate Bob, Lou and Ferid on this great personal accomplishment and we would like to dedicate this volume to them. The Nobel Prize also reflects a well-deserved appreciation of the entire field, some important recent progress of which is presented here.
CONTENTS
Preface
ix
Contributors
xi
Part B II. Nitric Oxide and Pathophysiology of Diseases 13
Nitric Oxide and Its Role in Hemostasis E.M.Battinelli, M.R.Trolliet and J.Loscalzo
228
14
Hypertension E.Nava and T.F.Luscher
248
15
Pulmonary Hypertension J.Dupuis, D.Langleben and D.J.Stewart
263
16
Atherosclerosis: Role of NO J.P.Cooke and P.S.Tsao
279
17
Nitric Oxide in Myocardial and Splanchnic Ischaemia/Reperfusion A.M.Lefer and R.Scalia
296
18
Nitric Oxide and Circulatory Shock C.Thiemermann
317
19
Kidney Diseases P.Gross, H.Dorniok, D.Reimann and M.Plug
328
20
The Role of Nitric Oxide in Preterm Labour and Pre-eclampsia R.E.Garfield, I.Buhimschi, G.R.Saade and K.Chwalisz
342
21
Multiple Sclerosis J.E.Merrill
367
22
Regulation of Nitric Oxide and Inflammatory Mediators in Human Osteoarthritis-Affected Cartilage: Implication for Pharmacological Intervention A.R.Amin, M.G.Attur and S.B.Abramson
389
23
The Role of Nitric Oxide in Rheumatoid Arthritis M.Stefanovic-Racic and C.H.Evans
404
24
Gastrointestinal Function in Shock A.L.Salzman
415
vii
III. Therapeutic Applications 25
Nitric Oxide Donors J.A.Hrabie and L.K.Keefer
442
26
Nitric Oxide Inhalation AM.Atz and D.L.Wessel
458
27
Nitric Oxide Synthase Inhibitors J.F.Parkinson, J.J.Devlin and G.B.Phillips
491
28
The Pharmacology of Peroxynitrite-Dependent Neurotoxicity Blockade J.S.Althaus, G.J.Fici and P.F.Von Voigtlander
508
29
Hemoglobin: Its Role as a Nitric Oxide Scavenger S.R.Fischer and D.L.Traber
524
30
Therapeutic Implications of Recombinant Endothelial Nitric Oxide Synthase Gene Expression in Cerebral and Peripheral Arteries A.F.Y.Chen, T.O'Brien and Z.S.Katusic
540
31
Gene Therapy Approaches with iNOS E.Tzeng and T.R.Billiar
554
Index
572
Part A 1
The Beginnings of Research on Nitric Oxide in Biology: A Historical Perspective R.F.Furchgott
1
I.
Generation and Biological Actions of Nitric Oxide
2
Structural Variations on a Theme of Nitric Oxide Production by Three Isoforms of Nitric Oxide Synthase B.S.Masters, P.Martásek and L.J Roman
17
3
Nitric Oxide Synthase Gene Regulation K.K.Wu
39
4
Localization and Subcellular Targeting of Nitric Oxide Synthases G.García-Cardena and W.C.Sessa
51
5
Molecular Mechanisms of Peroxynitrite Reactivity A.J.Gow and H.Ischiropoulos
59
6
Nitric Oxide, Peroxynitrite and Poly (ADP-Ribose) Synthetase: Biochemistry and Pathophysiological Implications C.Szabó
69
7
Nitric Oxide and Gene Transcription J.K.Liao and P.Libby
99
viii
8
Nitric Oxide and the Regulation of Vasoactive Genes D.V.Faller
121
9
Cyclooxygenase: An Important Transduction System for the Multifaceted Roles of Nitric Oxide D.Salvemini
155
10
Regulation of Nitric Oxide Synthase Expression and Activity by Hemodynamic Forces B.E.Sumpio, B.O.OluwoleX.Wang and M.A.Awolesi
171
11
Nitric Oxide Synthase Regulation by 17p-Estradiol K.Kauser and G.M.Rubanyi
195
12
Mice Deficient in eNOS and nNOS Isoforms P.L.Huang
209
Index
I/1
PREFACE
The identification that nitric oxide (NO) mediates endothelium-dependent vasodilation and that NO is synthesized by nitric oxide synthase (NOS) from L-arginine represented key discoveries of the 1980s. These observations opened the way to unprecedented research activity in the early 1990s which led to new insights into the physiology and pathophysiology of numerous biological and disease processes. Research on NO has continued at a high pace in the past 5 years and it is by now clear that in addition to the cardiovascular system, NO is implicated in the function and disease of several other organs and systems as well (e.g., inflammatory diseases in the brain, joints, lung and gut; immunological disorders, cancer, diseases of the reproductive organs, etc.). It is also evident that we are entering into a new phase of NO research: several of the basic research observations are turning into novel therapeutic principles, and these are being pursued in clinical trials. Selective inhibitors of nitric oxide synthase isoforms are being discovered, novel NO-donors are being developed and the first reports on gene therapy approaches have been published—just to name a few examples which illustrate the point. Athough some excellent books have been published in the past about NO research, this work is the first that summarizes the quantum leap from basic sciences to clinical applications of novel therapeutic principles emerging from this decade-long research activity. The book is divided into two parts. Part A starts with a historical perspective written by Dr Robert Furchgott. His cornerstone observation in 1980 about the essential role of the endothelium in acetylcholineinduced vasorelaxation undoubtedly represented the start of this whole field. The rest of this volume is dedicated to the theme Generation and Biological Actions of Nitric Oxide. Leading experts give state-of-theart overviews of various aspects of this theme, including the description of NOS function and regulation, the biological actions of NO, and the functional consequences of NOS gene knock-out in mice.
x
Part B has two sections. The first of these describes the known role of NO (its deficiency and/or excess) in the pathophysiology of diseases, such as those of the cardiovascular, kidney, reproductive, nervous and skeletal systems. The second section of Part B summarizes the recent progress achieved with therapeutic applications of NO. This section describes, among other topics, the discovery and therapeutic application of new NO donors, the therapeutic use of NO inhalation, selective inhibitors of NOS isoforms, and gene therapy approaches with both the constitutive and inducible forms of NOS. Based on the scope, the excellent contributions by the leading experts, and the very efficient and professional work of the publisher, I believe this book on the pathophysiology and clinical application of nitric oxide is a one-of-a-kind work which will be of interest and benefit to both the experts working in the field and interested professionals of a wide variety of disciplines.
CONTRIBUTORS
Abramson, Steven B Department of Rheumatology and Medicine Hospital for Joint Diseases Rm. 1401, 301 East 17th Street New York, NY 10003 USA Althaus, John S CNS Diseases Research Unit 7251 Pharmacia and Upjohn Inc. 301 Henrietta Street Kalamazoo, MI 49001 USA Amin, Ashok R Department of Rheumatology and Medicine Hospital for Joint Diseases Rm. 1600, 301 East 17th Street New York, NY 10003 USA Attur, Mukundan G Department of Rheumatology and Medicine Hospital for Joint Diseases
Rm. 1600, 301 East 17th Street New York, NY 10003 USA Atz, Andrew M Cardiac Intensive Care Unit Children’s Hospital, Farley 653 300 Longwood Avenue Boston, MA 02115 USA Awolesi, Mark A Department of Surgery (Vascular) Yale University School of Medicine 333 Cedar Street, FMB 137 New Haven, CT 06510 USA Battinelli, Elisabeth M Department of Medicine and Biochemistry Whitaker Cardiovascular Institute Boston University School of Medicine 80 E Concord Street, W-507 Boston, MA 02118–2394
xii
USA Billiar, Timothy R Department of Surgery University of Pittsburgh 479 Scaife Hall Pittsburgh, PA 15261 USA Buhimschi, Irina Department of Obstetrics and Gynecology University of Texas Medical Branch Medical Research Building, Rm. 11.104 301 University Boulevard Galveston, TX 77555–1062 USA Chen, Alex FY Department of Anesthesiology and Pharmacology Mayo Clinic St Mary’s Hospital 200 First Street SW Rochester, MN 55905 USA Chwalisz, Kristof Research Laboratories Schering AG Berlin Germany Cooke, John P Division of Cardiovascular Medicine Stanford University School of Medicine 300 Pasteur Drive, CVRC Stanford, CA 94305–5406 USA Devlin, James J Department of Immunology and Pharmaceuticals Discovery Berlex Biosciences 15049 San Pablo Avenue Richmond, CA 94804–0099 USA Dorniok, Heike Department of Medicine Universitätsklinikum CG Carus Fetscherstrae 76
D-01307 Dresden Germany Dupuis, Jocelyn Terrence Donnelly Heart Centre St Michael’s Hospital 30 Bond Street, Rm. 712-B Toronto, Ontario Canada M5B 1W8 Evans, Christopher H Room C-313 Presbyterian University Hospital 200 Lothrop Street Pittsburgh, PA 15261 USA Faller, Douglas V Cancer Research Center, Rm. K701 Boston University Medical Campus 80 East Concord Street Boston, MA 02118 USA Fici, Gregory J CNS Diseases Research Unit 7251 Pharmacia and Upjohn Inc. 301 Henrietta Street Kalamazoo, MI 49001 USA Fischer, Stefanie R Investigational Intensive Care Unit The University of Texas Medical Branch 610 Texas Avenue Galveston, TX 77555–0833 USA Furchgott, Robert F Department of Pharmacology SUNY Health Science Center at Brooklyn 450 Clarkson Avenue, PO Box 29 Brooklyn, NY 11203 USA García-Cardeña, Guillermo Department of Pharmacology Yale University School of Medicine Boyer Center for Molecular Medicine 295 Congress Avenue
xiii
New Haven, CT 06536–0812 USA Garfield, Robert E Department of Obstetrics and Gynecology University of Texas Medical Branch Medical Research Building, Rm. 11.104 301 University Boulevard Galveston, TX 77555–1062 USA Gow, Andrew J University of Pennsylvania Medical Center 1 John Morgan Building 3620 Hamilton Walk Philadelphia, PA 19104–6068 USA Gross, Peter Department of Medicine Universitätsklinikum CG Carus FetscherstraBe 76 D-01307 Dresden Germany Hrabie, Joseph A SAIC Frederick National Cancer Institute—Frederick Cancer Research and Development Center Bldg. 469–2, PO Box B Frederick, MD 21702 USA Huang, Paul L Cardiovascular Research Center Massachusetts General Hospital—East 149 East 13th Street, 4th Floor Charlestown, MA 02129–2060 USA Ischiropoulos, Harry University of Pennsylvania Medical Center 1 John Morgan Building 3620 Hamilton Walk Philadelphia, PA 19104–6068 USA Katusic, Zvonimir S Departments of Anesthesiology and Pharmacology Mayo Clinic
St Mary’s Hospital 200 First Street SW Rochester, MN 55905 USA Kauser, Katalin Department of Cardiovascular Research Berlex Biosciences 15049 San Pablo Avenue Richmond, CA 94804–0099 USA Keefer, Larry K Chemistry Section Laboratory of Comparative Carcinogenesis National Cancer Institute—Federick Cancer Research and Development Center Building 538 Frederick, MD 21702–1202 USA Langleben, David Jewish General Hospital 3755 Cote St Catherines Rd Montreal, Quebec Canada H3T 1E2 Lefer, Allan M Department of Physiology Jefferson Medical College Thomas Jefferson University 1020 Locust Street Philadelphia, PA 19107–6799 USA Liao, James K. Atherosclerosis and Vascular Medicine Unit Brigham and Womens Hospital and Harvard Medical School 221 Longwood Avenue, LMRC-316 Boston, MA 02115–5817 USA Libby, Peter Atherosclerosis and Vascular Medicine Unit Brigham and Womens Hospital and Harvard Medical School 221 Longwood Avenue, LMRC-316 Boston, MA 02115–5817
xiv
USA Loscalzo, Joseph Department of Medicine and Biochemistry Whitaker Cardiovascular Institute Boston University School of Medicine 80 E Concord Street, W-507 Boston, MA 02118–2394 USA Lüscher, Thomas F Division of Cardiology University Hospital Bern Römistrasse 100, CH 8091 Zürich Switzerland Martasek, Pavel The Robert A Welch Foundation Department of Biochemistry The University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive San Antonio, TX 78284–7760 USA Masters, Bettie Sue The Robert A Welch Foundation Department of Biochemistry The University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive San Antonio, TX 78284–7760 USA Merrill, Jean E Hoechs Marion Roussel Inc. Route 202–206 PO Box 6800 Bridgewater NJ 08807–0800 USA Nava, Eduardo Department of Physiology Univeristy of Murcia School of Medicine Murcia Spain O’Brien, Timothy Divisions of Endocrinology and Metabolism
Mayo Clinic St Mary’s Hospital 299 First Street SW Rochester, MN 55905 USA Oluwole, Babalola O Department of Surgery (Vascular) Yale University School of Medicine 333 Cedar Street, FMB 137 New Haven, CT 06510 USA Parkinson, John F Department of Immunology and Pharmaceuticals Discovery Berlex Biosciences 15049 San Pablo Avenue Richmond, CA 94804–0099 USA Phillips, Gary B Department of Immunology and Pharmaceuticals Discovery Berlex Biosciences 15049 San Pablo Avenue Richmond, CA 94804–0099 USA Plug, Maria Department of Medicine Universitätsklinikum CG Carus Fetscherstrae 76 D-01307 Dresden Germany Reimann, Doreen Department of Medicine Universitätsklinikum CG Cams Fetscherstrae 76 D-01307 Dresden Germany Roman, Linda J The Robert A Welch Foundation Department of Biochemistry The University of Texas Health Science Center at San Antonio 7703 Floyd Curl Drive
xv
San Antonio, TX 78284–7760 USA Scalia, Rosario Department of Physiology Jefferson Medical College Thomas Jefferson University 1020 Locust Street Philadelphia, PA 19107–6799 USA Sessa, William C Department of Pharmacology Yale University School of Medicine Boyer Center for Molecular Medicine 295 Congress Avenue New Haven, CT 06536–0812 USA Rubanyi, Gabor M Berlex Biosciences 15049 San Pablo Avenue Richmond, CA 94804–0099 USA Saade, George R Department of Obstetrics and Gynecology University of Texas Medical Branch Medical Research Building, Rm. 11.104 301 University Boulevard Galveston, TX 77555–1062 USA Stefanovic-Racic, Maja Room C-313 Presbyterian University Hospital 200 Lothrop Street Pittsburgh, PA 15261 USA Stewart, Duncan J Terrence Donnelly Heart Centre St Michael’s Hospital 30 Bond Street, Rm. 712-B Toronto, Ontario Canada M5B 1W8 Salvemini Daniela Searle Research and Development c/o Monsanto Company
800 N.Lindbergh Boulevard St Louis, MO 63167 USA Sumpio, Bauer E Department of Surgery (Vascular) Yale University School of Medicine 333 Cedar Street, FMB 137 New Haven, CT 06510 USA Salzman, Andrew L Division of Critical Care Medicine Children’s Hospital Medical Center 3333 Burnet Avenue Cincinatti, OH 45229–3039 USA Szabó, Csaba Division of Critical Care Medicine Children’s Hospital Medical Center 3333 Burnet Avenue Cincinatti, OH 45229–3039 USA Thiemermann, Christoph The William Harvey Research Institute St Bartholomew’s Hospital and the Royal London School of Me dicine and Dentistry Charterhouse Square London, EC1M 6BQ UK Traber, Daniel L Investigational Intensive Care Unit The University of Texas Medical Branch 610 Texas Avenue Galveston, TX 77555–0833 USA Trolliet, Maria R Department of Medicine and Biochemistry Whitaker Cardiovascular Institute Boston University School of Medicine 80 E Concord Street, W-507 Boston, MA 02118–2394 USA Tsao, Philip S Division of Cardiovascular Medicine
xvi
Stanford University School of Medicine 300 Pasteur Drive, CVRC Stanford, CA 94305–5406 USA Tzeng, Edith Department of Surgery University of Pittsburgh 497 Scaife Hall Pittsburgh, PA 15261 USA Von Voigtlander, Philip F CNS Diseases Research Unit 7251 Pharmacia and Upjohn Inc. 301 Henrietta Street Kalamazoo, MI 49001 USA Wang, Xiujie Department of Surgery (Vascular) Yale University School of Medicine 333 Cedar Street, FMB 137 New Haven, CT 06510 USA Wessel, David L Cardiac Intensive Care Unit Children’s Hospital, Farley 653 300 Long wood Avenue Boston, MA 02115 USA Wu, Kenneth K Division of Hematology Department of Internal Medicine University of Texas at Houston Medical School 6431 Fannin, MSB 5.016 Houston, TX 77030 USA
Nitric Oxide and Pathophysiology of Diseases
13 Nitric Oxide and Its Role in Hemostasis Elisabeth M.Battinelli, Maria R.Trolliet and Joseph Loscalzo Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, Boston, Masssachusetts 02118, USA
Nitric oxide (NO) is a short-lived, free radical gas that is found in a variety of cell types and organ systems. In vascular hemostasis, NO is important for preventing platelet activation, adhesion, and aggregation. NO may play a role in the development of hemostatic disorders that occur when NO availability is altered. In this chapter, we discuss the importance of NO in the hemostatic response with particular emphasis on the pathogenesis of thrombotic and hemorrhagic diatheses. Key words: Fibrinolysis, hemostasis, nitric oxide, thrombosis INTRODUCTION Hemostasis depends, in part, on the ability to form a protective platelet plug in the event of vascular injury and thereby prevent excessive blood loss. A poorly controlled or excessive hemostatic response, however, can be manifested as hemorrhage or thrombosis, respectively. The primary hemostatic response is dependent upon platelets and products of the endothelium that modulate platelet function. One mediator that has been shown to have antiplatelet activity is nitric oxide (NO). Under resting conditions the endothelium is stimulated by flow to produce NO, which can regulate platelet adhesion and aggregation (Pohl and Busse, 1989; Cooke et al., 1991; de Graaf et al., 1992). The production of NO leads to activation of soluble guanylyl cyclase with a concomitant increase in cGMP, which is a principal mediator of the effects of NO. NO can inhibit platelet adhesion and aggregation, and can also induce disaggregation of previously aggregated platelets (Radomski and Moncada, 1991a,b; Radomski et al., 1987a,b,c). Thus, in different
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
229
disease states in which less or more nitric oxide is being produced by the vasculature, platelet function may be adversely altered. The platelet response may also be modulated in patients with cardiovascular disease who use organic nitrates, such as nitroglycerin, which act as NO donors. While lack of NO may lead to thrombosis, an excess of NO may be detrimental such that platelet aggregation is impaired and a bleeding diathesis results. In this chapter we will provide evidence for the importance of NO in regulating platelet function and hemostasis, and illustrate hemostatic disorders that arise when NO production or bioactivity is altered. PATHOGENESIS OF THROMBOSIS The process of thrombus formation involves the interaction of elements in the vessel wall with platelets and activated coagulation factors (Figure 13–1). In arteries, a thrombus may occlude the vessel resulting in decreased or absent blood flow to tissues, potentially leading to ischemia or infarction. One of the most important rheologie properties of flowing blood that regulates hemostasis is the blood’s tendency to move in a pattern of concentric, cylindrical laminae, termed laminar flow (Goldsmith et al., 1986). These laminae are arranged such that a gradient exists within the vessel, with the greatest velocities found in the laminae closest to the center of the vessel and the lowest velocities found near the vessel wall. Because of cell size and charge properties, the laminae in the center of the vessel are enriched in red blood cells while the laminae closest to the vessel wall are enriched in platelets. Since the blood velocity is relatively low in the vicinity of the vessel wall, platelets have a long residence time in that domain, thereby allowing for rapid activation should the vessel become damaged. Another hemodynamic factor that is important for understanding the hemostatic function of platelets is shear rate (defined as the product of blood viscosity and shear stress), which is determined by the velocity gradient in the vessel. According to Poiseuille’s Law, velocity is inversely proportional to the crossectional area of a vessel or a vascular bed. Thus, blood velocity is highest in those vessels that have the smallest crossectional area, such as the aorta. Capillaries have the largest crossectional area, and, therefore, the lowest velocities. Large vessels with high velocities have higher rates of shear than do small vessels with low velocities. Increases in the shear rate lead to an increase in platelet deposition, while low shear rates are associated with preferential fibrin deposition (Loscalzo, 1994). Under normal circumstances, platelet activation is suppressed. There are three known endothelial products that inhibit platelet activation: cyclooxygenase and lipooxygenase metabolites, such as prostacyclin and 13-hydroxyoctadecadienoic acid (13-HODE) respectively; ecto-nucleotidase ADP diphosphohydrolase (ecto-ADPase); and nitric oxide (Radomski et al., 1987b; Moncada, 1982; Buchanan et al., 1991). Prostacyclin has been shown to inhibit platelet aggregation (Radomski et al., 1987a), while 13HODE regulates the adhesiveness of the vessel wall, modulating integrin receptor expression (Buchanan et al., 1991). The ecto-nucleotidases metabolize ADP to AMP and adenosine, resulting in a decrease in platelet recruitment and activity by the dinucleotide agonist (Marcus et al., 1993); this molecule has recently been identified as CD39 (Marcus et al., 1997). The role of NO as an inhibitor of platelet aggregation will be elucidated next.
Correspondence: Joseph Loscalzo, Whitaker Cardiovascular Institute, Boston University School of Medicine, 80E. Concord Street, Room W507, Boston, MA 02118–2394, USA. Tel: (617) 638–4890; Fax: (617) 638–4066
230
ELISABETH M.BATTINELLI ET AL.
Figure 13-1. A simplified scheme of the hemostatic response.
Platelet Adhesion Adhesion of platelets to the subendothelial matrix following vascular injury (or contact with foreign surfaces in the blood) is the initial event in the process of thrombosis. Binding interactions occur between glycoproteins found on the platelet surface and the connective tissue of the subendothelium. Some of these glycoproteins include: GPIb/IX/V, GPIa/IIa, and GPIIb/GPIIIa. GPIb, which noncovalently complexes with GPIX and GPV, is the main surface receptor for the adhesion of platelets to the subendothelium. Adhesion is mediated by von Willebrand factor (vWF), which links the platelet integrin to collagen in the subendothelium (Vaughan, 1996). After these components come into contact, vWF undergoes a conformational change that is essential for the platelet and subendothelium to remain in contact. Direct binding of the platelet to collagen is mediated by GPIa/IIa.
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
231
Figure 13-2. Representation of the normal pathways of coagulation.
Platelet Recruitment and Aggregation After adhesion to the subendothelial matrix, the platelet initiates a series of reactions that include release of adenosine 5'-diphosphate (ADP) and serotonin (5-HT) from densegranules; and release of a-granule constituents, including fibrinogen, vWF, vitronectin, fibronectin, thrombospondin, platelet factor 4, and platelet-derived growth factor (PDGF) (Vaughan, 1996). At the same time, the eicosanoid thromboxane A2 (TxA2) is formed from arachidonic acid via membrane-bound phospholipase C. Through the release of ADP, 5-HT, and TXA2, more platelets are recruited to the area. Platelet recruitment occurs through the GPIIb/GPIIIa complex, also known as the fibrinogen receptor, which undergoes a calcium-dependent conformational change to become active (George et al., 1984; Ginsberg et al., 1988). Its ligand, fibrinogen, has two different sequences that can directly interact with platelets, including two RGD sequences in the a chain and a dodecapeptide sequence near the carboxyterminus of the chain (Hawiger et al., 1982). Plateletto-platelet linkages thereby form with fibrinogen as the bridge between GPIIb/IIIa molecules on adjacent platelets. Simultaneously, the platelet aggregate activates the coagulation cascade via the assembly of prothrombinase on the platelet surface. This series of reactions leads to further platelet aggregation by the production of yet another platelet agonist, thrombin (Loscalzo, 1994). Thrombin is produced by cleavage of its inactive precursor prothrombin in the common pathway of the coagulation cascade (Figure 13–2). This reaction occurs through the action of activated factor X (Xa) and activated factor V (Va) along with calcium and phospholipid cofactors. Factor X activation can occur through either the intrinsic or extrinsic pathways. The intrinsic pathway is activated by contact of the blood with subendothelial structures like collagen or basement membrane components in areas of vessel damage. Factor VII undergoes a conformational change to expose its active site, which converts the zymogen prekallikrein to kallikrein and converts factor XI to activated factor XI (XIa). Next, factor XIa converts the zymogen factor IX into activated factor IX (IXa) that, in turn, activates factor X (Colman et al., 1984). The extrinsic pathway is activated when the
232
ELISABETH M.BATTINELLI ET AL.
membrane proteolipid, tissue factor, is either exposed in the subendothelium to flowing blood or induced to form on the surface of endothelial cells or vascular smooth muscle cells by inflammatory mediators such as cytokines and endotoxin. Tissue factor activates factor VII directly, which then activates factor X of the common pathway as described above (Wilcox et al., 1989; Marmur et al., 1991). In recent years, the exclusivity of the intrinsic and extrinsic coagulation pathways has been questioned. Crosstalk between early events in these pathways has been identified that both complicates our understanding of clotting mechanisms and adds yet another level of redundancy to hemostatic defense. The platelet plug that forms in response to vascular injury is not stable. The fibrin meshwork formed by the action of thrombin on fibrinogen is required in order to add stability. Fibrin is produced when the serine protease thrombin cleaves the A and B chains of fibrinogen. Fibrin can then be further stabilized through transamidation reactions by factor XIIIa, which itself is generated by the action of thrombin on factor XIII (Loscalzo, 1994). Endothelial Defense Mechanisms If the hemostatic response were to occur inappropriately or without proper regulation, pathological thrombosis could result. The endothelium and the platelet itself release mediators that attenuate the hemostatic response, providing a mechanism of defense against unbridled hemostasis and thrombus formation. Two such mediators are prostacyclin and nitric oxide. Prostacyclin has been shown to inhibit platelet activation through cAMP-dependent mechanisms, while NO impairs platelet adhesion and activation, in part, by an increase in cGMP (Moncada et al., 1982; Radomski et al., 1990). The endothelium itself is also able to regulate thrombosis by degrading any prothrombotic vasoactive amines present in the blood, inactivating thrombin, and inducing expression of thrombomodulin, a thrombinbinding surface protein that facilitates thrombin-dependent activation of protein C, a naturally occurring anticoagulant that degrades factors Va and VIIIa (Esmon et al., 1993). The fluidity of the blood is also maintained by endothelial surface glycosaminoglycans that catalyze the binding of the anticoagulant serine protease inhibitors (serpins), antithrombin III and heparin cofactor II, to specific coagulation proteins, such as thrombin, thereby attenuating coagulation and platelet activation (Rosenberg et al., 1994). The endothelium also contributes to thrombus dissolution by producing molecules essential for fibrinolysis, including plasminogen activators. Fibrinolysis Plasmin, the fibrinolytic counterpart to thrombin, is the principal mediator of fibrinolysis. This enzyme is converted from its plasma zymogen plasminogen by plasminogen activators, including tissue-type plasminogen activator (t-PA) and the urokinase-type plasminogen activators, all of which are serine proteases. Plasmin, once formed, cleaves fibrin leading to the dissolution of the fibrin clot or the thrombus. The mechanism by which platelets regulate fibrinolysis has not been established. Platelets can directly bind plasminogen and t-PA, leading to enhanced activity of plasminogen (Adelman et al., 1988). Platelet granules contain a myriad of substances that can regulate the fibrinolytic response, including plasminogen activator inhibitor-1 (PAI-1), 2-antiplasmin, Cl esterase inhibitor, and 2-macroglobulin, all of which are inhibitors of fibrinolysis (Ouimet and Loscalzo, 1994) (Figure 13–3). PAI-1 is one of the most important modulators of fibrinolysis, representing 60% of the plasminogen activator inhibitory activity in plasma (Ouimet and Loscalzo, 1994). Other roles for platelets in fibrinolysis include facilitation of clot retraction,
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
233
Figure 13-3. Molecules involved in plasminogen activation and its subsequent conversion to plasmin. Solid lines indicate activation; dashed lines indicate inhibition.
potentiation of plasminogen activation, modulation of fibrinolysis in the microenvironment by secretion of a-granule contents, and protection from factor XIIIa inactivation. Plasmin has been shown to have the ability both to activate and inhibit platelets (Niewiarowski et al., 1973; Guccione et al., 1985). High concentrations of plasmin can act as a platelet agonist, yet low concentrations of plasmin lead to inhibition of platelet aggregation. At very high concentrations, plasmin modifies the platelet GPIIIa fibrinogenbinding domain leading to impaired fibrinogen binding and platelet aggregation, thus providing an explanation for the dichotomous actions of plasmin on platelet functional responses (Pasche et al., 1991). In addition to the endothelial and fibrinolytic systems discussed above, other systems also exist to limit the extent of thrombosis. Anithrombin III is a serpin that inhibits the formation of fibrin by inhibiting thrombin as well as other coagulation factors, including factors IXa, Xa, XIa, and XIIa (Rosenberg et al., 1973). Heparin and endothelial heparan sulfate potentiate the anticoagulant actions of antithrombin III by catalyzing the binding of this serpin to these serine proteases (Bjork et al., 1976). Proteins C and S provide another mechanism of anticoagulation. Protein C is activated by the thrombomodulin-thrombin complex, and in its active form is able to inactivate factors Va and VIIIa (Clouse et al., 1986). Protein S is a cofactor for activated protein C, which has the added ability to potentiate fibrinolysis by complexing to plasminogen activator inhibitor -1 and enhancing plasminogen activation by t-PA. NITRIC OXIDE SYNTHESIS Nitric oxide synthesis occurs in both the vascular endothelium and the platelet. NO is produced when the terminal guanidino nitrogen of L-arginine undergoes a 5-electron oxidation to form L-citrulline and NO (Palmer et al., 1988; Nathan, 1992) (Figure 13–4). This reaction is catalyzed by the nitric oxide synthase (NOS) family of enzymes. There are two main isoform classes of NOS, a constitutive NOS (cNOS) and inducible NOS (iNOS, Nos2 gene product), although the distinction between these isoform classes has been recently blurred by the finding that the “constitutive” endothelial isoform (eNOS or Nos3 gene product) can be upregulated by exercise and the “inducible” isoform is constitutively expressed in the kidney (Green et al., 1996; Markewitz et al., 1993). The differences between these isoforms are shown in Table 13–1. Constititutive NOS is found in vascular endothelial cells (eNOS) as well as in neuronal cells (nNOS, No si gene product) and is regulated by Ca2+ and calmodulin. Ca2+ is released from intracellular stores when acetylcholine or bradykinin stimulates inositol 1,4,5-triphosphate (IP3) binding to endoplasmic reticulum receptors with the subsequent release of intracellular Ca2+. This increase in Ca2+ leads to its binding to calmodulin, which then binds to and activates cNOS (Dinerman et al., 1993; Bredt et al., 1990; Busse et al.,
234
ELISABETH M.BATTINELLI ET AL.
Table 13±1. Characterization of inducible a nd constitutive nitric acid synthases.
Figure 13±4. Diagram of nitric oxide synthesis by nitric oxide synthase (NOS).
1990; Mayer et al., 1989). The production of NO by cNOS is, therefore, rapid, transient, and continuous until the Ca2+ level returns to baseline. Inducible NOS has been found in many cell types including the macrophage, and the neutrophil (Marietta et al., 1988; Yui et al., 1991). Inducible NOS is stimulated by exposure to bacterial endotoxin or cytokines (Drapier et al., 1988; Stuehr et al., 1987; Ding et al., 1988), and its activity is not dependent upon Ca2+ concentration, but, rather, is regulated at the transcriptional level (Xie et al., 1992). The production of NO by iNOS is delayed in comparison to production by cNOS, but the amounts of NO generated and the duration of its production by this isoform far exceed those of cNOS. The mechanism of activation of NO synthase in the endothelial cell has not been elucidated. Since the constitutive form of NO synthase is Ca2+-dependent, it has been postulated that this cation is responsible for the activation of NO synthase in vivo (Xie et al., 1992). The process of endothelial activation may lead to activation of Ca2+ channels leading to an increase in intracellular calcium, thereby regulating expression of NO synthase and NO production.
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
235
NITRIC OXIDE AND GUANYLYL CYCLASE The enzyme guanylyl cyclase has been shown to mediate, in part, the platelet inhibitory actions of NO. NO binds to the heme moiety of guanyly cyclase and induces a conformational change that displaces the iron out of the plane of the porphyrin ring (Ignarro, 1986). This effect results in the enzymatic conversion of guanosine 5'-triphosphate to cyclic guanosine 3',5'-monophosphate (cGMP) with concomitant stimulation of cGMP-dependent protein kinase. Cyclic GMP-dependent protein kinase phosphorylates intracellular enzyme targets that are responsible for regulation of intracellular calcium levels. Regulation of calcium level in platelets has been suggested as one mechanism of action of guanylyl cyclase. The mechanisms of action of cGMP-dependent protein kinase are many, including inhibition of platelet fibrinogen binding to the GPIIb/IIIa receptor, inhibition of phosphorylation of myosin light chains and of protein kinase C, and stimulation of phospholipase A2- and C-mediated responses (Radomski et al., 1991a,b). Cyclic GMP itself inhibits receptor-mediated calcium influx in platelets. An increase in soluble guanylyl cyclase leads to a reduction of intracellular Ca2+ in platelets through cGMP-mediated inhibition of Ca2+ release from intracellular stores, an increased rate of Ca2+ extrusion, and decreased Ca2+ entry from extracellular stores (Nakashima et al., 1986; Matsuoki et al., 1989; Morgan and Newby, 1989; Geiger et al., 1992; Johansson and Hayness, 1992). An inhibitor of guanylyl cyclase, 1H-(1,2,4) oxadiazolo (4,3-a) quinoxalin1-one, blocks these cGMP-dependent effects resulting in an increase in platelet aggregation (Moro et al., 1996). Inhibition of cGMP-mediated platelet responses can also occur through cyclic nucleotide phosphodiesterases, which can degrade cGMP. Radomski and colleagues showed that M+B 22984, a cGMP phosphodiesterase inhibitor, can potentiate L-arginine mediated anti-platelet effects (Radomski et al., 1990). PLATELETS AND NITRIC OXIDE Nitric oxide synthase isoforms exist in human platelets (Muruganandam et al., 1994). An eNOS-like isoform has been isolated from platelets and appears to require similar co-factors as does eNOS itself. The molecular size of this constitutively expressed NOS was found to be 80 kDa in contrast to the 130-kDa protein found in endothelial cells, which could represent either differential splicing of the Nos3-like transcript or be the result of post-translational processing. An isoform of NOS homologous with iNOS has also been characterized in platelets. Since the platelet is anucleate with a minimal pool of mRNA (Djaffar et al., 1991), and thus able to synthesize only modest amounts of protein, most platelet proteins are derived from its precursor cell, the megakaryocyte. The megakaryocyte expresses both constitutive and inducible NOSs (Lelchuk et al., 1992). Release of NO from the platelet has recently been established (Zhou et al., 1995). Stimulation of NO synthase, dependent upon L-arginine, leads to activation of soluble guanylyl cyclase and, thereby, increases cGMP, with concomitant inhibition of platelet aggregation (Radomski et al., 1990). Freedman and colleagues have recently demonstrated that NO can also inhibit platelet recruitment to a growing platelet thrombus (Freedman et al., 1997). L-arginine has been shown to inhibit platelet aggregation in vivo and in vitro. A single, saturable, sodium-independent transporter system for movement of L-arginine into human platelets has recently been postulated (Vasta et al., 1995). Radomski (1990) showed that L-arginine inhibited platelet aggregation induced by ADP and arachidonic acid. Yet, inhibition of thrombin-induced aggregation occurred only when other platelet antagonists were present, including prostacyclin and cGMP phosphodiesterase inhibitors. The mechanism underlying NO’s ability to regulate platelet aggregation is currently under investigation. Platelet agonists induce aggregation by increasing intracellular calcium levels via stimulation of the inositol
236
ELISABETH M.BATTINELLI ET AL.
3-phosphate pathway. NO’s ability to regulate intracellular calcium levels through cGMP and cGMPdependent protein kinase has, therefore, been postulated as its mechanism of action, as described above. Recently, a molecular mechanism of how NO may modulate platelet aggregability via cGMP has been proposed. Reep and colleagues have suggested that phosphorylation of the signaling molecule rap 1 in platelets is induced by NO stimulation of guanylyl cyclase and activation of cGMP-dependent protein kinase (Reep et al., 1996). They showed that incubation with S-nitroso serum albumin leads to inhibition of collagen-stimulated platelet aggregation that was correlated with phosphorylation of rap 1 in a dosedependent manner. These data suggest that cGMP leads to activation of a signaling cascade within the platelet that results in modulation of platelet aggregation. It appears that NO released from both endothelial cells and platelets regulates the platelet response and prevents thrombus formation. NO from endothelial cells suppresses platelet adhesion and aggregation. When stimulated with bradykinin, endothelial cells release NO in amounts sufficient to inhibit platelet adhesion, as is the case when NO is released under constant flow conditions in coronary and pulmonary vessels (Venturini et al., 1989; Pohl et al., 1989). Endothelial NO decreases aggregation of platelets immediately downstream from where it is released, suggesting that the endothelium is responsible for regulating platelets in its vicinity as opposed to platelets at a distance from the endothelial source of NO (De Graaf et al., 1992). Release of endothelial NO in vivo by cholinergic stimulation and by substance P leads to inhibition of platelet aggregation induced by collagen or ADP (Humphries et al., 1990). NO from the endothelial cell has also been shown to have the ability to disaggregate preformed platelet aggregates (Radomski et al., 1987a). One of the mechanisms by which endothelial NO can regulate platelet function has recently been elucidated by Murohara and colleagues (1995). P selectin is normally present in the Weibel-Palade bodies found in endothelial cells and also in the -granules of platelets. Once the endothelial cell is activated, the granules fuse with the plasma membrane and P selectin is rapidly translocated to the extracellular surface. NO synthase inhibitors, such as L-NAME, induce endothelial P-selectin expression on the endothelial cell surface in the rat mesenteric circulation in vivo. This suggests that NO regulates adhesion of platelets to the endothelium by decreasing expression of the P selectin needed for initial attachment of the platelet to the endothelium. Michelson and colleagues have shown that S-nitroso-N-acetylcysteine can markedly inhibit upregulation of P-selectin on the platelet surface (Michelson et al., 1996). Murohara and colleagues elucidated the mechanism of P-selectin expression by suggesting that thrombin stimulation leads to an increase in P-selectin on the surface of platelets through the activation of phosphoinositol-specific phospholipase C (PLC), which leads to an increase in intracellular Ca2+ and activation of phosphorylation cascades within the platelet. They have shown that phorbol myristylacetate (PMA), a PKC activator, stimulates rapid P-selectin expression. Also, N,N,N-trimethylsphingosine, an inhibitor of PKC, has been shown to inhibit P-selectin expression on thrombin-stimulated cells. Since it has also been shown that NO and cGMP inhibit PKC activity, the authors postulated that NO may regulate PKC through phosphorylation by a cGMP-dependent kinase and, therefore, leads to down regulation of P-selectin expression on the surface of both platelets and endothelial cells. Other blood-borne cell types have also been found to release NO, possibly augmenting the vascular NO pool provided by the platelet and the endothelial cell. The contribution of NO released from neutrophils in the regulation of platelet function in vivo has not been established; however, it has been shown that human neutrophils and mononuclear cells release a factor that has a similar pharmacological profile as NO with the ability to inhibit platelet aggregation (Salvemini et al., 1989). The neutrophil itself can be regulated by NO, with NO inhibiting adhesion and chemotaxis of stimulated cells. (Kubes, 1991; Moilanen, 1993).
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
237
Effect of S-Nitrosothiols on Platelet Aggregation NO reacts with thiols in the presence of oxygen to produce S-nitrosothiols. In plasma, S-nitrosothiols are the primary redox state of NO (Stamler et al., 1992). S-nitrosothiols have been suggested to be a more stable source of NO in plasma, in contrast to free NO, and, therefore, S-nitrosothiols have been postulated to be a storage pool of NO. S-nitrosothiols activate platelet soluble guanylyl cyclase and elevate cGMP levels, leading to inhibition of platelet aggregation (Mellion et al., 1985). Loscalzo and colleagues showed that nitroglycerin and nitroprusside can inhibit platelet aggregation at pharmacologically achievable concentrations in vivo and this effect is potentiated by thiols (Loscalzo and Welch, 1995). Mendelsohn and colleagues showed that S-nitroso-N-acetylcysteine, an S-nitrosothiol compound, decreased the intracellular calcium flux in response to ADP stimulation leading to inhibition of fibrinogen binding in activated platelets, an effect accompanied by a rise in intracellular cGMP (Mendelsohn et al., 1990). Keaney and colleagues showed that endogenous NO can react with serum albumin to form S-nitroso-albumin, which was shown to have antiplatelet properties (Keaney et al., 1993). Simon and colleagues bolstered the importance of S-nitrosothiols in platelet function by showing that the platelet surface is able to facilitate the release of NO from S-nitrosothiols (Simon et al., 1993). Synergy of NO with other Platelet Inhibitors Other factors produced by the endothelial cell and the platelet work in concert with NO to potentiate inhibition of platelet activation and aggregation. Some of these factors include PGI2, PGD2, and t-PA (Radomski and Moncada, 1991a,b; Loscalzo, and Vaughn, 1987). It appears, however, that no single factor is able to limit the activated-platelet response; rather the synergy of several factors is essential for limiting platelet aggregation optimally. Prostacyclin synthesis by endothelial cells is stimulated by mechanical injury, PDGF, and bradykinin (Gerrard and White, 1982). Prostacyclin, a potent inhibitor of aggregation, is a very weak inhibitor of platelet adhesion, and NO does not synergize with prostacyclin as an inhibitor of adhesion. Prostacyclin’s ability to limit platelet adhesion appears to be regulated by cGMP-dependent responses as opposed to its usual mechanism of action through cAMP-dependent responses. Radomski and colleagues have shown that NO and PGI2 do not act synergistically to inhibit adhesion since there is no antiadhesive actions of PGI2 (Radomski et al., 1987a). In the clinical realm, inhibition of NO production in vivo decreases the ability of aspirin to attenuate platelet aggregation (Golino et al., 1992). NO and prostacyclin appear to synergize with each other through an NO-induced increase in cGMP with subsequent inhibition of cGMP-inhibited cAMP phosphodiesterase (PDE), resulting in potentiation of prostacyclin’s cAMPmediated antiplatelet effects (Maurice and Haslam, 1990). The actions of NO can also be potentiated by protective mechanisms within the platelet. Superoxide anions produced by damaged endothelial cells, leukocytes, and smooth muscle cells can inactivate NO through the formation of peroxynitrite, which is further metabolized to nitrite and nitrate. Peroxynitrite is very highly reactive and able to cause cell toxicity through lipid peroxidation and nitrosation of protein tyrosyl residues. Moro has demonstrated that peroxynitrite stimulates platelet aggregation and limits NO and prostacyclin’s ability to impair aggregation (1994). Superoxide dismutase (SOD), an enzyme which catalyzes the dismutation of Superoxide into water and hydrogen peroxide, can protect NO from oxidative inactivation by superoxide. SOD potentiates the ability of NO to prevent adhesion and aggregation of platelets induced by thrombin in vivo. Administration of superoxide dismutase to damaged and stenotic carotid arteries leads to a decrease in thrombus formation at the site of vascular damage (Meng et al, 1995).
238
ELISABETH M.BATTINELLI ET AL.
THROMBOSIS AND NO DEFICIENCY Decreased production of NO can lead to thrombosis. Clinical evidence substantiates the antiplatelet role of NO. Endothelial damage induced by laser injury leads to inhibition of NO release and, consequently, platelet aggregation (Rosenblum et al., 1987). Nishimura and colleagues showed that nitric oxide synthase blockade in vivo enhances the accumulation of activated platelets in areas of endothelial damage within brain pial arterioles (Nishimura et al., 1991). L-Nitroarginine methyl ester (L-NAME), an inhibitor of NO synthesis, potentiates the pulmonary accumulation and prolongs the disaggregation of [111In]-labeled platelets induced by ADP, PAF, and thrombin in vivo (Radomski and Moncada, 1991a,b). In experimental coronary stenosis in rabbits, massive platelet adhesion and formation of aggregates on the surface of the damaged endothelium was observed in those animals treated with NG-monomethyl-L-arginine (L-NMMA), another inhibitor of nitric oxide synthesis, prior to the production of the stenosis (Herbaczynska-Cedro et al., 1991). Folts and colleagues used a canine model of coronary artery stenosis to demonstrate that intravenous nitroglycerin, an organic nitrate, can improve ischemia associated with acute coronary artery disease by inhibition of platelet thrombus formation (Folts et al., 1991). In addition, the antithrombotic effects of nitrates are potentiated by pretreatment of the animals with reduced thiols such as N-acetylcysteine. Impaired NO synthesis has been demonstrated in hypertension (Cadwgan and Benjamin, 1991) and in diabetes mellitus (Calver et al., 1992), and this deficiency could be involved in the thrombotic complications that occur in these disease processes. In addition, studies with inhibitors of NOS have shown that decreased generation of NO in vivo can lead to platelet and polymorphonuclear leukocyte activation and thrombosis (May et al., 1991; Herbaczynska-Cedro et al., 1991; Golino et al., 1992; Yao et al., 1992). When L-NMMA was given to healthy subjects and platelet function monitored in vivo, hemostasis was disturbed and platelets became activated as measured by the increase in plasma levels of markers of platelet activation, including -thromboglobulin and platelet factor 4 (Bodzenta-Lukaszyk,1994). We recently studied two brothers with a cerebral thrombotic disorder and found that their platelets could not be inhibited by NO. The activity of the antioxidant enzyme, plasma glutathione peroxidase, was found to be decreased in the patients’ plasma, accounting for their insensitivity to NO. Addition of exogenous glutathione peroxidase led to restoration of platelet inhibition by NO. The mechanism of action of glutathione peroxidase involves reduction of lipid hydroperoxides to their corresponding alcohols. Granule secretion following platelet activation results in release of eicosanoids, including lipid hydroperoxides, which are then reduced by glutathione peroxidase (Freedman et al., 1995). Impaired metabolism of lipid hydroperoxides, as occurs when glutathione peroxidase activity is decreased, can lead to an increase in hydroperoxyl radical concentration which can, in turn, react with and reduce bioactive NO. These reactions thus impair the ability of NO to inhibit platelet activation, leading to a thrombotic propensity (Freedman et al., 1996). Previously, Freedman and colleagues had shown that glutathione peroxidase can potentiate the ability of the naturally occurring S-nitrosothiol, S-nitroso-glutathione, to inhibit platelets (Freedman et al., 1995). NO AND ATHEROTHROMBOSIS Thrombosis is a major determinant of atherosclerosis. In humans and animals with atherosclerosis, the ability of the endothelium to synthesize bioactive NO is greatly reduced (Chester et al., 1990). Impaired NO production may promote atherosclerosis by several mechanisms. Mitogens, like PDGF, have been postulated to be responsible for the proliferation of smooth muscle cells within atherosclerotic lesions (Radomski and Moncada, 1991a,b). Mitogen activity can be reduced by suppressing their release from
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
239
stimulated platelets, an effect supported by NO. Administration of L-arginine, the substrate for NOS, was found to restore impaired production of NO, decrease activation of platelets and leukocytes, and limit the extent of the vascular lesions associated with this disease in an animal model of hypercholesterolemia (Dexter et al., 1991; Cooke and Tsao, 1992). Vascular injury occurs when balloon angioplasty is performed to treat occlusive arterial lesions. Angioplasty results in endothelial denudation and varying degrees of smooth muscle cell injury. Normally, endothelial injury exposes the procoagulant molecules located in the subendothelium, leading to platelet adhesion, aggregation, and thrombosis. Marks and colleagues found that local administration of a relatively stable S-nitrosothiol, polyS-nitroso-bovine serum albumin, can inhibit intimai proliferation and platelet deposition after denuding arterial injury (Marks et al., 1995). Another group used balloon injury to denude the endothelium of rat carotid arteries, thereby limiting the ability of the endothe lium to produce NO (von der Leyen et al., 1995). They restored NO production by using gene transfer techniques to deliver the Nos3 gene to the site of vascular injury, leading to inhibition of neointimal lesion formation. In coronary bypass grafting, either an artery or a vein may be used as a new conduit. It has been suggested that more effective release of NO by arterial vessels may be responsible for greater patency of arterial grafts than venous bypass grafts (Luscher et al., 1989). Production of NO is stimulated by ADP and other agents in the internal mammary artery but not in the saphenous vein. Thus, the lower NO synthesis rate in the saphenous vein coronary bypass grafts may explain the patency differences. Atherosclerotic plaques have been demonstrated to contain the cytokines, IL-1 and TNF- (Arbustini et al., 1991). These cytokines can induce iNOS in cells within the plaque, so that they may be partly involved in the balance between prothrombotic and antithrombotic processes by this mechanism. In injured arteries, vascular smooth muscle cell iNOS is rapidly induced within one day of injury. This leads to inhibition of platelet adhesion and maintenance of blood flow in the injured vessel (Yan et al., 1996). Yet, production of NO via iNOS has also been shown to produce cellular toxicity via peroxynitrite generation. Peroxynitrite, which decreases the bioavailability of NO, has been observed to produce nitrostyrosine at sites of endothelial injury in atherosclerotic lesions (Kooy et al., 1994). Lipoproteins that may be present in atherosclerotic lesions can also regulate NO activity. Low-density lipoprotein (LDL) can decrease the bioactivity of NO by an unknown mechanism (Flavahan et al., 1992). Possible explanations for this decreased activity include inhibition of NOS activity by LDL, inactivation of NO itself, or changes in NO metabolism. In addition, LDL may decrease the uptake of L-arginine into platelets, and this may lead to a decrease in the NOS activity, thereby promoting thrombosis (Chen et al., 1994). The presence of high-density lipoproteins (HDL), however, is beneficial since HDL decreases platelet activitity by increasing NOS activity in platelets. NO AND BLEEDING DIATHESES Lipopolysaccharide (LPS or endotoxin) is responsible for the development of septic shock associated with bacterial infection. Severe hypotension and disturbances in the hemostatic balance are among the major clinical symptoms of septicemic reactions. The bleeding diathesis in sepsis is believed to be caused by disseminated intravascular coagulation with consumption coagulopathy, fibrinolysis, and thrombocytopenia (Radomski and Moncada, 1991a,b). Stimulation of endothelial cells with LPS and interferon- , a cytokine produced during inflammatory reactions, results in expression of iNOS. This enzyme is responsible for producing large amounts of NO which are sufficient to inhibit platelet aggregation. Shultz and Raij (1992) reported that LPS can induce production of endogenous NO, which is critical for preventing LPS-induced platelet-dependent renal thrombosis. Another consequence of septic shock that is due to upregulation of
240
ELISABETH M.BATTINELLI ET AL.
NOS enzymes is hypotension. Keaney and colleagues used methylene blue—an inhibitor of guanylyl cyclase and of NOS, and also a direct NO oxidant—to reduce NO production and restore mean arterial pressure in a rabbit model of LPS-induced hypotension (Keaney et al., 1994). Bleeding complications that accompany endotoxemia may, thus, result from upregulated expression of iNOS in vascular cells and leukocytes. Hemostatic defects, including prolonged bleeding times and decreased platelet adhesion and aggregation, also occur in uremia. In uremia, metabolites of the urea cycle accumulate, including L-arginine, which may account for the increased NO production in these patients (Radomski and Salas, 1995). Bode-Boger and colleagues showed that L-arginine increases the excretion of NO byproducts, including nitrate. They demonstrated that the addition of L-arginine to the diets of hypercholesterolemic rabbits increases the ratio of L-arginine to the endogenous NO synthase inhibitor assymetric dimethylarginine (ADMA) thereby restoring urinary nitrate excretion (Bode-Boger et al., 1996). It has been shown that the prolonged bleeding times in uremie rats can be normalized by systemic administration of L-NMMA. NO donors activate the plasma fibrinolytic system in peripheral vascular disease patients by inhibiting the release of PAI-1 (Gryglewski, 1993). Gryglewski reported that PGI2 synergizes with the NO donor molsidomine to increase the activity of the fibrinolytic system in patients with peripheral vascular disease. This cooperative effect is attributed to PGl2’s ability to release t-PA from cells coupled with the NO donor’s ability to inhibit release of the antifibrinolytic molecule, PAI-1. This work has been substantiated by the results of Korbut and colleagues, who showed that SIN-1, an NO donor, can also inhibit release of PAI-1 from platelets (Korbut et al., 1993). Inhalation of NO results in an increase in the template bleeding time (Hogman et al., 1993). Simon and colleagues (Simon et al., 1995) found that inhibition of NO production by L-NMMA shortens the bleeding time modestly. In vitro, the effects of NO were significantly different, resulting in a significant decrease in platelet activation or aggregation. PHARMACOLOGICAL ROLE OF NO DONORS IN VASCULAR THROMBOSIS Organic nitrates have been used for over a century in the treatment of cardiovascular disease. The potential benefit of nitroglycerin as an inhibitor of platelet aggregation was first observed in 1967 by Hampton (Loscalzo and Welch, 1995). Organic nitrates by themselves are weak inhibitors of aggregation in vitro; however, following ADP stimulation, nitroglycerin has been shown to be a potent inhibitor of aggregation ex vivo (Chirkov et al., 1993). Intravenous administration of nitroglycerin and isosorbide mononitrates can lead to inhibition of the platelet activation (Wallen et al., 1994); these agents have also been shown to inhibit thrombosis in animals (Werns et al., 1994; Plotkine et al., 1991). Patients suffering from myocardial infarction and treated with nitroglycerin show a decrease in platelet adhesion and aggregation in comparison to patients not given this agent (Diodati et al., 1990). Kuritzky showed that nitroglycerin can disaggregate platelet-rich thrombi in the retinal circulation (Kuritzky et al., 1984). The effectiveness of the organic nitrates correlates with the extent of vascular injury. An animal model in which arterial injury is induced in pigs by balloon angioplasty showed increased inhibition of platelet deposition in the injured area after treatment with nitroglycerin in comparison to pigs with milder injury treated with nitroglycerin (Lam et al., 1988). Loscalzo showed that nitroglycerin requires intracellular reduced thiols in its mechanism of platelet inhibition (Loscalzo, 1985). The requirement of thiols as potentiators of organic nitrates may also be beneficial for limiting or targetting the effects of NO. It would be useful to inhibit platelet aggregation using organic nitrates without evoking the deleterious effects that NO has on blood pressure. Radomski and
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
241
colleagues have shown that S-nitrosoglutathione is able to inhibit platelet aggregation without altering blood pressure in rats (Radomski et al., 1992). Similar results have been obtained by intraarterial injections of Snitrosoglutathione (de Belder et al., 1994). Organic nitrites may also affect preformed platelet aggregates. Stamler showed that nitrogylcerin can disaggregate platelet aggregates (Stamler et al., 1989). Others have shown that nitroglycerin can reduce platelet adhesion to injured vessels (Lam et al., 1988). NO donors that do not require metabolic breakdown include sodium nitroprusside, SIN1, molsidomine, and S-nitroso-N-acetylpenicillamine (SNAP). Nitroprusside has been shown to inhibit platelet aggregation in vivo and in vitro (Levin et al., 1982). Molsidomine and SIN-1 lead to inhibition of thrombosis in jugular and mesenteric venous systems in patients suffering from myocardial infarction and controls (Wautier et al., 1989). Molsidomine and isosorbide dinitrate synergize with prostacyclin and prostaglandin E1 to inhibit platelet activation (Sinzinger et al., 1992). SNAP has been shown to inhibit prostaglandin synthesis by inhibiting lipooxygenase, a key enzyme for arachidonic acid metabolism to oxidized eicosanoid derivatives in human platelets (Maccarrone et al., 1996) The beneficial properties of aspirin in limiting platelet aggregation and thrombosis have been well established (Patrono, 1994). In an attempt to improve upon the antiplatelet actions of aspirin, while limiting the negative gastric mucosal effects that occur with prolonged treatment, Wallace and colleagues studied the activity of a nitric oxide-releasing, gastricsparing aspirin derivative. The nitroxybutylester derivative of aspirin (NCX 4215) was seven times more potent than aspirin in limiting platelet aggregation in vitro without inducing gastric mucosal injury. NCX 4215 was found to release NO in the presence of platelets and to increase platelet levels of cGMP (Wallace et al., 1995). CONCLUSIONS In this chapter we have reviewed the importance of nitric oxide in regulating hemostasis. Our understanding of the role of NO in the hemostatic system has dramatically increased in this past decade. Advances in knowledge of the molecular mechanisms by which NO modulates the hemostatic response will lead to the development of novel therapeutic strategies to prevent the pathological processes of NO-deficient thrombotic disorders and NO-dependent bleeding diatheses. ACKNOWLEDGMENTS The authors wish to thank Stephanie Tribuna for her help in the preparation of this manuscript. REFERENCES Adelman, B., Rizk, A. and Manners, E. (1988) Plasminogen interactions with platelets in plasma. Blood, 72, 1530–1535. Arbustini, E., Grasso, M, Diegli, M. and Pucci, A. (1991) Coronary atherosclerotic plaques with and without thrombus in ischaemic heart syndromes: a morphologic, immunohistochemical and biochemical study. American Journal of Cardiology, 68, 36B–149B. Bjork, I. and Nordenman, B. (1976) Acceleration of the reaction between thrombin and antithrombin III by nonstoichiometric amounts of heparin. European Journal of Biochemistry, 68, 507–511. Bode-Boger, S.M., Boger, R.H., Krenke, S., Junher, W. and Frolich, J.C. (1996) Elevated L-arginine/ dimethylarginine ratio contributes to enhanced NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochemical and Biophysical Research Communications, 219, 598–603.
242
ELISABETH M.BATTINELLI ET AL.
Bodzenta-Lukaszyk, A., Gabryelewicz, A., Lukaszyk, A., Bielawiec, M., Konturek, J.W. and Domschke, W. (1994) Nitric oxide synthase inhibition and platelet function. Thrombosis Research, 75, 667–672. Bredt, D.S. and Snyder, S.H. (1990) Isolation of nitric oxide synthase, a calmodulin-requiring enzyme. Proceedings of the National Academy of Sciences USA, 87, 682–685. Busse, R. and Mulsch, A. (1990) Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Letters, 265, 133–136. Buchanan, M.R. and Brister, S.J. (1991) Antithrombotics and the lipoxygenase pathway. In Antithrombotics, edited by A.G.Herman, pp. 159–180. Kluwer Academic Publishers. Cadwgan, T. and Benjamin, N. (1991) Reduced platelet nitric oxide synthesis in essential hypertension. Journal of Vascular Biology, 3, 455A. Calver, A., Collier, J. and Vallance, P. (1992) Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. Journal of Clinical Investigation, 90, 2548–2554. Chen, L. and Mehta, J.L. (1994) High density lipoprotein antagonizes the stimulatory effect of low density lipoprotein on platelet function by affecting L-arginine-nitric oxide pathway. Circulation, , 90, I-30. Chester, A.H., O’Neil, G.S., Moncada, S., Tadjkarimi, S. and Yacoub, M.H. (1990) Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet, 336, 897–900. Chirkov, Y.Y., Naujalis, R., Sage, E. and Horowitz, Y.D. (1993) Antiplaelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. Journal of Cardiovascular Pharmacology, 21, 384– 389. Clouse, L.H. and Comp, PC. (1986) The regulation of hemostasis: the protein C system. New England Journal of Medicine, 314, 1298–1304. Colman, R.W. (1984) Surface-mediated defense reactions. The plasma contact activation system. Journal of Clinical Investigation, 73, 1249–1253. Cooke, J.P., Rossitch, E., Jr., Andon, N.A., Loscalzo, J. and Dzau, V.J. (1991) Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. Journal of Clinical Investigation, 88, 1663– 1671. Cooke, J.P. and Tsao, P. (1992) Cellular mechanisms of atherogenesis and the effects of nitric oxide. Current Opinion in Cardiology , 7, 799–804. de Belder, A.J., MacAlli ster, R., Radomski, M.W., Moncada, S. and Vallance, P.I. (1994) Effects of Snitrosoglutathione in the human forearm circulation. Evidence for selective inhibition of platelet activation. Cardiovascular Research, 28, 691–694. De Graaf, J.C., Banga, J.D., Moncada, S., Palmer, R.M.J., de Groot, P.G. and Sixma, J.J. (1992) Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation, 85, 2284–2290. Dexter, H., Zeiher, A.M., Meinzer, K. et al (1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet, 338, 1546–1550. Dinerman, J.L., Lowenstein, C.J. and Snyder, S.H. (1993) Molecular mechanisms of nitric oxide regulation. Circulation Research, 73, 217–222. Ding, A.H., Nathan, C.F. and Steuhr, D.J. (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Journal of Immunology, 141, 2407–2412. Diodati, J., Theroux, P., Latour, J.G., Lacoste, L., Lam, J.Y. and Waters, D. (1990) Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and acute myocardial infarction. American Journal of Cardiology, 66, 683–688. Djaffar, I., Vilette, D., Bray, P.E and Rosa, J.P. (1991) Quantitative isolation of RNA from human platelets. Thrombosis Research, 62, 127–135. Drapier, J.C. and Hibbs, J.B. (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. Journal of Immunology, 140, 2829–2838. Esmon, C.T. (1993) Molecular events taht control the protein C anticoagulant pathway. Thrombosis and Haemostasis, 70, 29–35. Flavahan, N.A. (1992) Atherosclerosis or lipoprotein-induced endothelial dysfunction. Circulation, 85, 1927– 1938.
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
243
Folts, J.S., Stamler, J.S. and Loscalzo, J. (1991) Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed dog coronary arteries. Circulation, 83, 2122–2127. Freedman, I.E., Frei, B., Welch, G.N. and Loscalzo, J. (1995) Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosomiols. Journal of Clinical Investigation, 96, 394–400. Freedman, I.E., Loscalzo, J., Benoit, S.E., Valeri, C.R., Barnard, M.R. and Michelson, A.D. (1996) Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. Journal of Clinical Investigation, 97, 1–9. Freedman, I.E., Loscalzo, J., Barnard, M.R., Alpert, C, Keaney, J.F., Jr. and Michelson, A.D. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. Journal of Clinical Investigation, 100, 350–356. Geiger, J., Nolte, C., Butt, E., Sage, S.O. and Walter, U. (1992) Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium-elevation in human platelets. Proceedings of the National Academy of Sciences USA, 89, 1031–1035. George, J.N., Nurden, A.T. and Phillips, D.R. (1984) Molecular defects in interactions of platelets with the vessel wall. New England Journal of Medicine, 311, 1084. Gerrard, J.M. and White, J.G. (1992) Prostaglandins and thromboxanes: ‘middlemen’ in modulating platelet function in hemostasis and thrombosis. In Progress in Hemostasis and Thrombosis, Vol. 4, edited by T.H. Spaet, pp. 87–126. New York: Grunne & Stratton. Ginsberg, M.H., Loftus, J.C. and Plow, E.F. (1988) Cytoadhesions, integrins, and platelets. Thrombosis and Haemostasis, 59, 1–6. Goldsmith, H.L. and Turitto, V.T. (1986) Rheological aspects of thrombosis and haemostasis: Basic principles and applications. Thrombosis and Haemostasis, 55, 415–35. Golino, P., Capelli-Bigazzi, M., Ambrosio, G., Ragni, M., Russolillo, E., Condorelli, M. et al (1992) Endotheliumderived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circulation Research, 71, 1447–1456. Green, D.J., Fowler, D.T., O’Driscoll, S.G., Blanksby, B.A. and Taylor, R.R. (1996) Endothelium-derived nitric oxide activity in forearm vessels of tennis players . Journal of Applied Physiology, 81, 943–948. Gryglewski, R.J. (1993) Interactions between nitric oxide and prostacyclin. Seminars in Thrombosis and Hemostasis, 19, 158–166. Guccione, M.A., Kinlough-Rathbone, R.L., Packham, M.A., Harfenist, E.J., Rand, M.L., Greenberg, J.P. et al (1985) Effects of plasmin on rabbit platelets. Thrombosis and Haemostasis, 53, 8–14. Harker, L.A. (1994) Disorders of Hemostasis: Thrombosis. Williams Hematology, 5th Edition, edited by M.A. Beutler, B.L.Lichtman, B.S.Coller, T.J.Kipps, pp. 4485–4508. Philadelphia: Saunders. Hawiger, J., Timmons, S., Kloczewiak, M., Strong, D.B. and Doolittle, R.F. (1982) Chains of human fibrinogen possess sites reactive with human receptors (platelet aggregation/adhesion/antibody probe). Proceedings of the National Academy of Sciences USA, 79, 2068–2071. Herbaczynska-Cedro, K., Lembowicz, K. and Pytel, B. (1991) NG-monomethyl-L-arginine increases platelet deposition on damaged endothelium in vivo. A scanning electron microscopy study . Thrombosis Research, 64, 1–9. Högman, M., Frostell, C., Arnberg, H. and Hedenstierna, G. (1993) Bleeding time prolongation and NO inhalation. Lancet, 341, 1664–1665. Humphries, R.G., Tomlinson, W., O’Connor, S.E. and Leff, P. (1990) Inhibition of collagen- and ADP-induced platelet aggregation by substance P in vivo, Involvement of endothelium-derived relaxing factor. Journal of Cardiovascular Pharmacology, 16, 292–297. Ignarro, L.J., Adams, J.B., Horowitz, P.M. and Wood, K.S. (1986) Activation of soluble guanylyl cyclase by NOhemoproteins involves NO-heme exchange. Journal of Biological Chemistry, 261, 4997–5002. Johansson, J.S. and Hayness, D.H. (1992) Cyclic GMP increases the rate of the calcium reflux extrusion pump in intact human platelets but has no direct effect on the dense tubular calcium accumulation system. Biochimica et Biophysica Acta, 1105, 40–50.
244
ELISABETH M.BATTINELLI ET AL.
Keaney, J.F., Jr., Simon, D.I., Stamler, J.S., Jaraki, O., Scharfstein, J., Vita, J. et al (1993) NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. Journal of Clinical Investigation , 91, 1582–1589. Keaney, J.F., Jr., Puyana, J.-C., Francis, S., Loscalzo, J.F., Stamler, J.S. and Loscalzo, J. (1994) Methylene blue reverses endotoxin-induced hypotension. Circulation Research, 74, 1121–1125. Kooy, N.W. and Royall, J.A. (1994) Agonist-induced peroxynitrite production from endothelial cells. Archives of Biochemistry and Biophysics, 310, 352–359. Korbut, R., Ocetkiewicz, A. and Gryglewski, R.J. (1993) Nitric oxide complements prostacyclin in the regulation of endothelial thromboresistance under flow conditions. Methods and Findings in Experimental and Clinical Pharmacology, 15, 179–181. Kubes, P., Suzuki, M. and Granger, D.N. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proceedings of the National Academy of Sciences USA, 88, 4651–655. Kuritzy, S. (1990) Nitroglycerin to treat acute loss of vision. New England Journal of Medicine, 323, 1428. Lam, J.Y.T., Chesebro, J.H. and Fuster, V. (1988) Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. Circulation, 78, 712–716. Lelchuk, R., Radomski, M.W., Martin, J.F. and Moncada, S. (1992) Constitutive and inducible nitric oxide synthases in human megakaryoblastic cells. Journal of Pharmacology and Experimental Therapeutics, 262, 1220–1224. Levin, R.L., Weksler, B.B. and Jaffe, E.A. (1982) The interaction of sodium nitroprusside with human endothelial cells and platelets: nitroprusside and prostacyclin synergistically inhibit platelet function. Circulation, 66, 1299–1307. Loscalzo, J. (1985) N-acetylcysteine potentiates inhibition of platelet aggregation by nitroglycerin. Journal of Clinical Investigation, 76, 703–708. Loscalzo, J. and Vaughan, D.E. (1987) Tissue plasminogen activator promotes platelet disaggregation in plasma. Journal of Clinical Investigation, 79, 1749–1755. Loscalzo, J. (1994) Pathogenesis of thrombosis. In Williams Hematology, 5th Edition, edited by M.A.Beutler, B.L.Lichtman, B.S.Coller, T.J.Kipps, pp. 4485–508. Philadelphia: Saunders. Loscalzo, J. and Welch, G. (1995) Nitric oxide and its role in the cardiovascular system. Progress in Cardiovascular Diseases, XXXVIII, 87–104. Luscher, T.F., Yang, Z., Diederich, D. and Buhler, FR. (1989) Endothelium-derived vasoactive substances: potential role in hypertension, atherosclerosis, and vascular occlusion. Journal of Cardiovascular Pharmacology, 14, S63– S69. Maccarrone, M., Corasaniti, M.T., Guerrieri, P., Nistico, G. and Finazzi Agro, A. (1996) Nitric oxide-donor compounds inhibit lipoxygenase activity. Biochemical and Biophysical Research Communications, 219, 128–133. Marcus, A.J. and Safier, L.B. (1993) Thromboregulation: multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB Journal, 7, 516–522. Marcus, A.J., Broekman, M.J., Drosopoulos, J.H.F., Islam, N., Alyonycheva, T.N., Safier, L.B. et al. (1997) The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. Journal of Clinical Investigation, 99, 1351–1360. Marks, D.S., Vita, J.A., Folts, J.S., Keaney, J.F, Jr., Welch, G.N. and Loscalzo, J. (1995) Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment witha protein adduct of nitric oxide. Journal of Clinical Investigation, 96, 2630–2638. Marletta, M.A., Yoon, P.S., lyengar, R., Leaf, C.D. and Wishnok, J.S. (1988) Macrophage oxidation of L-arginine to nitrite and nitrate:nitric oxide is an intermediate. Biochemistry, 27, 8706–8711. Markewitz, B.A., Michael, J.R. and Kohan, D.E. (1993) Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells. Journal of Clinical Investigation, 91, 2138–2143. Marmur, J.D., Wax, S. and Nichtberger, S. (1991) The tissue factor gene is highly regulated by growth factors in vascular smooth muscle. Blood, 78, 396a. Matsuoka, I., Nakahata, N. and Nakanishi H. (1989) Inhibitory effect of 8-bromo cyclic GMP on an extracellular Ca2+dependent arachidonic acid liberation in collagen-stimulated rabbit platelets. Biochemical Pharma cology, 38, 1841–1847.
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
245
Maurice, D.H. and Haslam, RJ. (1990) Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Molecular Pharmacology, 37, 671–681. May, G.R., Crook, P., Moore, P.K. and Page, C.P. (1991) The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation. British Journal of Pharmacology, 102, 759–763. Mayer, B., Schmidt, K., Humbert, P. and Bohme, E. (1989) Biosynthesis of endothelium-derived relaxing factor: A cytosolic enzyme in porcine endothelial cells Ca2+ −dependently converts L-arginine into an activator of soluble guanylyl cyclase. Biochemical and Biophysical Reserach Communications, 164, 678–685. Mellion, B.T., Ignarro, L.J., Ohlstein, E.H., Pontecorvo, E.G., Hyman, A.L. and Kadowitz, P.J. (1981) Evidence for the inhibitory role for guanosine 3'-5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood, 57, 946–955. Mendelsohn, M.E., O’Neill, S., George, D. and Loscalzo, J. (1990) Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcycsteine. Journal of Biological Chemistry, 265, 19028–19034. Meng, Y., Trachtenburg, J., Ryan, U.S. and Abendschein, D. (1995) Potentiation of endogenous nitric oxide with superoxide dismutase inhibits platelet-mediated thrombosis in injured and stenotic arteries. Journal of the American College of Cardiology, 25, 269–275. Michelson, A.D., Benoit, S.E., Furman, M.I., Breckwoldt, W.L., Rohrer, M.J., Barnard, M.R. and Loscalzo, J. (1996) Effects of nitric oxide/EDRF on platelet surface glycoproteins. American Journal of Physiology, 270 (Heart and Circulatory Physiology 39), H1640–H1648. Moilanen, E., Vuorinen, P., Metsa-Ketela, T. and Vapaatalo, H. (1993) Inhibition by nitric oxide donors of human polymorphonuclear leukocyte functions. British Journal of Pharmacology, 109, 852–858. Moncada, S. (1982) Biological importance of prostacyclin. British Journal of Pharmacology, 76, 3–31. Morgan, R.O. and Newby, A.C. (1989) Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochemical Journal, 258, 447–54. Moro, M.A., Darley-Usmar, V.M., Goodwin, D.A., Read, N.G., Zamora-Pino, R., Feelisch, M., Radomski, M.W. and Moncada, S. (1994) Paradoxical fate and biological action of peroxynitrite on human platelets. Proceedings of the National Academy of Sciences, 91, 6702–6706. Moro, M.A., Russell, R.J., Cellek, S., Lizasoain, L, Su, Y., Darley-Usmar, V.M., Radomski, M.W. and Moncada, S. (1996) cGMP mediates the vascular and platelet actions of nitric oxide Confirmation using an inhibitor of the soluble guanylyl cyclase. Proceedings of the National Academy of Science , 93, 1480–1485. Murahora, T., Parkinson, S.J., Waldman, S.A. and Lefer, A.M. (1995) Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 2068–2075. Muruganandam, A. and Mutus, B. (1994) Isolation of nitric oxide synthase from human platelets. Biochimica et Biophysica Acta, 1200, 1–6. Nakashima, S., Tohmatsu, T., Hattori, H. et al. (1986) Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelets. Biochemical and Biophysical Research Communications, 135, 1099–1104. Nathan, C. (1992) Nitric oxide is a secretory product of mammalian cells. FASEB Journal, 6, 3051–3064. Niewiarowski, S., Senyi, A.F. and Gilles, P. (1973) Plasmin-induced platelet aggregation and platelet release action. Journal of Clinical Investigation, 52, 1647–1659. Nishimura, H., Rosenblum, W.I., Nelson, G.H. and Boynton, S. (1991) Agents that modify EDRF formation alter antiplatelet properties of brain arteriolar endothelium in vivo. American Journal of Physiology, 261 (Heart and Circulatory Physiology 30), H15–H21. Ouimet, H. and Loscalzo, J. (1994) Fibrinolysis. In Thrombosis and Hemorrhage, edited by J.Loscalzo, A. Schafer, pp. 127–143. Blackwell Scientific Publications, Boston. Palmer, R.M.J., Ashton, D.S. and Moncada, S. (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (London), 333, 664–666.
246
ELISABETH M.BATTINELLI ET AL.
Pasche, B., Collins, L., Ouimet, H., Francis, S. and Loscalzo, J. (1994) Modulation of platelet function by plasmin and fibrin(ogen) degradation products during thrombolysis. Blood, 83, 404–414. Patrono, C. (1989) Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends in Pharmacology Science, 10, 453–458. Plotkine, M., Allix, M., Guillou, J. and Boulu, R. (1991) Oral administration of isosorbide dinitrate inhibits arterial thrombosis in rats. European Journal of Pharmacology, 201, 115–116. Pohl, U. and Busse, R. (1989) EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circulatory Research, 65, 1798–1803. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1987a) The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. British Journal of Pharmacology, 92, 639–646. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1987b) Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet, 2, 1057–1058. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1987c) The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochemical and Biophysical Research Communications, 148, 1482– 1489. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1990) An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proceedings of the National Academy of Sciences USA, 87, 5193–5197. Radomski, M.W. and Moncada, S. (1991a) Role of nitric oxide in endothelial cell-platelet interactions. In Antithrombotics, Pathophysiological Rationale for Pharmacological Interventions, edited by A.G.Herman, pp. 27–48. Dordrecht: Kluwer. Radomski, M.W. and Moncada, S. (1991b) Role of nitric oxide in endothelial cell-platelet interactions. In Antithrombotics, edited by A.G.Herman, pp. 27–48, Kluwer Academic Publishers.The Netherlands. Radomski, M.W., Rees, D.D., Dutra, A. and Moncada, S. (1992) S-Nitroso-glutathione inhibits platelet activation in vitro and in vivo. British Journal of Pharmacology, 107, 745–749. Radomski, M.W. and Salas, E. (1995) Biological significance of nitric oxide in platelet function. In Nitric Oxide: A Modulator of Cell-Cell Interactions in the Microcirculation, edited by P.Kubes, pp. 43–75, R.G.Landes Company. Reep, B.R. and Lapetina, E.G. (1996) Nitric oxide stimulates the phosphorylation of raplb in human platelets and acts synergistically with iloprost. Biochemical and Biophysical Research Communications, 219, 1–5. Rosenberg, R.D. and Damus, P.S. (1973) The purification and mechanism of action of human antithrombinheparin cofactor. Journal of Biological Chemistry, 248, 6490–6505. Rosenberg, R.D. and Bauer, K.A. (1994) The heparin-antithrombin system: a natural anticoagulant mechanism. In Hemostasis and Thrombosis, edited by R.W.Coleman, J.Hirsch, V.J.Marder, E.W.Salmon, pp. 837– 860. Philadelphia, PA: Lippincott. Rosenblum, W.I., Nelson, G.H. and Povlishock, J.T. (1987) Laser-induced endothelial damage inhibits endotheliumdependent relaxation in the cerebral microcirculation of the mouse. Circulation Research, 60, 169– 176. Salvemini, D., de Nucci, D.E., Gryglewski, R.J. and Vane, J.R. (1989) Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proceedings of the National Academy of Sciences USA, 86, 6328–6332. Shultz, P.J. and Raij, L. (1992) Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. Journal of Clinical Investigation, 90, 1718–1725. Simon, D.I., Stamler, J.S., Jaraki, O., Keaney, J.F., Jr., Osborne, J.A., Francis, S.A., Singel, D.J. and Loscalzo, J. (1993) Antiplatelet properties of protein S-nitrosothiols dervied from nitric oxide and endotheliumderived relaxing factor. Arteriosclerosis and Thrombosis, 13, 791–799. Simon, D.I., Stamler, J.S., Loh, E., Loscalzo, J., Francis, S.A. and Creager, M.A. (1995) Effect of nitric oxide synthase inhibition on bleeding time in humans. Journal of Cardiovascular Pharmacology, 26, 339–342. Sinzinger, H., Virgolini, I., O’Grady, J., Rauscha, F. and Fitscha, P. (1992) Modification of platelet function by isosorbide dinitrate in patients with coronary artery disease. Thrombosis Research, 65, 323–335. Stamler, J.S., Mendelsohn, M.E., Amarante, P., Smick, D., Andon, N., Davies, P.P., Cooke, J.P. and Loscalzo, J. (1989) N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circulation Research, 65, 789–795.
NITRIC OXIDE AND ITS ROLE IN HEMOSTASIS
247
Stamler, J.S., Jaraki, O., Osborne, J., Simon, D.I., Keaney, J.F., Jr., Vita, J.A. et al. (1992) Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proceedings of the National Academy of Sciences USA, 89, 7674–7677. Steuhr, D.J. and Marletta, M.A. (1987) Induction of nitrite/nitrate synthesis in murine by BCG infection, lymphokines or interferon. Journal of Immunology, 139, 518–525. Turitto, V.T., Weiss, J.H., Zimmerman, T.S. and Sussman, I.I. (1985) Factor VIII/von Willebrand factor in subendothelium mediates platelet adhesion. Blood, 65, 823–831. Vasta, V, Meacci, E., Farnararo, M. and Bruni, P. (1995) Identification of a specific transport system for Larginine in human platelets. Biochemical and Biophysical Research Communications, 206, 878–884. Vaughan, D., Schafer, A. and Loscalzo, J. (1996) Normal Mechanisms of Hemostasis and Fibrinolysis. In Vascular Medicine, A textbook of vascular biology and diseases, 2nd edition, edited by J. Loscalzo, M. Creager, Dzau, V.J., pp. 207–216. Boston: Little Brown, von der Leyen, H.E., Gibbons, G.H., Morshita, R., Lewis, N.P., Zhang, L., Nakajima, M. et al. (1995) Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proceedings of the National Academy of Sciences USA, 92, 1137–1147. Venturini, C.M., Del Vecchio, P.J. and Kaplan, J.E. (1989) Thrombin induced platelet adhesion to endothelium is modified by endothelial derived relaxing factor (EDRF). Biochemical and Biophysical Research Communications, 159, 349–354. Wallace, J.L., McKnight, W, Soldato, P.D., Baydoun, A.R. and Cirino, G. (1995) Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. Journal of Clinical Investigation, 96, 2711– 2718. Wallen, N.H., Larsson, P.T., Broijersen, A., Andersson, A. and Hjemdahl, P. (1994) Effects of oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers. British Journal of Clinical Pharmacology, 72, 575–579. Wautier, J.L., Weill, D., Kadeva, H., Maclouf, J. and Soria, C. (1989) Modulation of platelet function by SIN1A. Journal of Cardiovascular Pharmacology, 14, S111–S114. Werns, S.W., Rote, W.E., Davis, J.H., Guevara, T. and Lucchesi, B.R. (1994) Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis. American Heart Journal, 127, 727–737. Wilcox, J.N., Smith, K.M., Schwartz, S.M. and Gordon, D. (1989) Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proceedings of the National Academy of Sciences USA, 86, 2839–2843. Xie, Q.W., Cho, X.J., Calaycay, J., Mumford, R.A., Swiderek, K.M., Lee, T.D. et al (1992) Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science, 256, 599–604. Yan, Z-q., Yokota, T., Zhang, W. and Hansson, G.K. (1996) Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circulation Research, 79, 38–44. Yao, S.K., Ober, J.C., Krishnaswami, A., Ferguson, J.J., Anderson, H.V., Golino, P. et al. (1992) Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endotheliuminjured arteries. Circulation, 86, 1302–1309. Yui, Y, Hattori, R., Kosuga, K. et al. (1991) Calmodulin-independent nitric oxide synthase from rat polymorphonuclear neutrophils. Journal of Biological Chemistry, 266, 3369–3371. Zhou, Q., Hellermann, G.R. and Solomonson, L.R (1995) Nitric oxide release from resting platelets. Thrombosis Research, 77, 87–96.
14 Hypertension Eduardo Nava1 and Thomas F.Lüscher2 1
Department of Physiology, University of Murcia School of Medicine, Murcia, Spain. 2Division
of Cardiology, University Hospital, Zürich, Switzerland
The endogenous release of nitric oxide (NO) contributes to the maintenance of blood pressure and this, in turn, is a stimulus for NO production. The role of NO in hypertension is very controversial. Recent research work is showing the existence of profound differences in the role of NO depending on the model of hypertension. In genetic and renovascular hypertension, the production of NO is increased probably as a compensatory mechanism against the overproduction of different vasoconstrictors. In genetic hypertension, however, the bioactivity of NO is diminished. In salt-sensitive hypertension, NO production is impaired probably due to a deficiency of the substrate for NO synthase. In human essential hypertension, pharmacological experiments reveal an impaired NO dilator mechanism. NITRIC OXIDE AND THE REGULATION OF BLOOD PRESSURE Since its discovery, an increasing body of evidence shows that NO is a widespread biological mediator implicated in many physiological and pathophysiological processes (Moncada and Higgs, 1993). Nitric oxide is synthesized from L-arginine by a family of enzymes called NO synthases (Figure 14–1). One isoform of these is a Ca++-dependent enzyme (endothelial NO synthase, eNOS) which is constitutively expressed in endothelial cells (Busse and Mülsch, 1990) and plays a crucial role in the regulation of blood pressure and vascular tone (Rees et al., 1989; Vallance et al., 1989). Definite proof of the role of NO in the maintenance of blood pressure is the fact that mice lacking the gene for eNOS develop hypertension (Huang et al., 1995). Inhibitors of NO production cause endothelium-dependent contractions of isolated arteries, decrease blood flow and induce pronounced and sustained hypertension when infused intravenously or
HYPERTENSION
249
Figure 14±1. The L-arginine/NO pathway in the blood vessel wall. sGC=soluble guanylate cyclase; cGMP =cyclic 3',5'guanosine monophosphate; LPS=lipopolysaccharide; TNF=tumor necrosis factor; IL-1= interleukin Ib; cNOS/ iNOS=constitutive/inducible NO synthase; ADMA=asymmetrical dimethylarginine; L-NMMA=monomethyl-Larginine; L-NAME=nitro-L-arginine methylester.
given orally in vivo (Rees et al, 1989, 1991; Vallance et al., 1989; Takase et al., 1994). Thus, the cardiovascular system is exposed to a continuous NO-dependent vasodilator tone and withdrawal of it mimics many features of human hypertension including target organ damage (Palmer et al., 1992; Blot et al., 1994). In situations of NO deprivation, which can be simulated by treating animals chronically with NO synthesis inhibitors, the endothelium can replace the functional abilities of NO provided antihypertensive treatment is supplied (Takase et al., 1996). This is probably because the endothelium increases the release of alternative relaxing factors which in normal conditions are not present. The activity of eNOS is modulated by shear stress on the endothelial surface and by a variety of receptoractivated agonists as well as hormones (Sessa et al., 1994; Schmidt et al., 1990; Weiner et al., 1994). It is not totally clear, however, whether variations in blood pressure per se can affect the release of endotheliumderived NO. Kelm and colleagues have suggested that only fluctuations in blood flow, but not in blood pressure can stimulate eNOS (Kelm et al., 1991). Nevertheless, studies performed in our lab demonstrate that acute, pharmacologically-induced, drops in blood pressure cause NO release to decrease (Figure 14–2,
Correspondence: Thomas F.Lüscher, M.D., Professor of Medicine, Cardiology University Hospital, CH-8091 Zürich, Switzerland. Tel: +41 1 255 2121; Fax: +41 1 255 4251.
250
EDUARDO NAVA AND THOMAS F.LÜSCHER
Figure 14±2. Effects of lowering blood pressure with a continuous infusion of prostacyclin or adenosine on the plasma concentration of nitrate. The decrease in plasma nitrate suggests a downregulation of NO production when blood pressure diminishes, (from Nava et al. (1996c), by permission).
Nava et al., 1996c) and, on the contrary, elevations in pressure are followed by an increased production (Figure 14–3, Nava et al., 1994), suggesting that high blood pressure upregulates NO production and vice versa. The kidney plays a pivotal role in the long-term regulation of blood pressure. A large number of studies evidence the capacity of the kidney to produce NO and its relevant role in renal function (Salazar et al., 1993; Cowley et al., 1995; Biondi et al., 1992; Fenoy et al., 1995). It has been demonstrated that the kidney is very sensitive to the reduction of NO as low doses of NOS inhibitors reduce sodium and water excretion without affecting renal hemodynamics or systemic arterial pressure (Salazar et al., 1993). Within the kidney, the medulla, which is importantly involved in pressure-induced natriuresis (Cowley et al., 1992), produces most of the NO-dependent cyclic GMP (Biondi et al., 1992). There are increasing grounds for believing that NO participates in the control of renal medullary blood flow. Firstly, NOS inhibitors decrease medullary, but not cortical blood flow, when selec lively applied in the medullary interstitial space and this is associated with sodium retention and development of hypertension (Cowley et al., 1995). Also, treatment with these inhibitors blunts the pressure-natriuresis response by impairing the renal medullary vasodilation produced by increasing arterial pressure (Fenoy et al., 1995). We have recently presented evidence showing that Ca++-dependent NOS activity is considerably higher in the renal medulla than in the renal cortex and that the activity in the renal medulla is also much higher than in the heart and aorta (Figure 14–4, Nava et al., 1996a). These results indicate that the renal medulla has a greater potential to produce NO compared to the renal cortex or cardiovascular tissues involved in blood pressure regulation. Because NO appears to be highly relevant for renal function it is conceivable that small alterations in the renal NO production, which do not affect systemic vascular tone, lead to hypertension because of an impaired regulation of sodium and water excretion (see part 4).
HYPERTENSION
251
Figure 14±3. Effects of angiotensin II (3 ug kg−1min-1, solid lines),, substance P (3 ug kg−1min−1, dotted lines),, and prostacyclin (0.3–0.6 mg kg−1min−11, dashed lines) on blood pressure (closed symbols) and plasma nitrate (open symbols). Plasma nitrate concentration follows the changes in blood pressure caused by angiotensin II and prostacyclin. For substance P, however, there is an inverse relation between blood pressure and plasma nitrate. * statistically significant (p <0.05) compared to basal levels (from Vava et al. (1994), by permission).
NITRIC OXIDE IN SPONTANEOUS HYPERTENSION The SHR is a widely used model of genetic hypertension (Kurtz et al., 1994). The capacity of SHR vessels to relax has been a matter of controversy long before endothelium-derived relaxing factor (EDRF) was known. Spector et al. (1996) showed that the SHR vessels relax better than their normotensive counterparts from WKY rats. In contrast, Cohen and Berkowitz (1976) found relaxations to the same agonists diminished in the SHR. The role of the endothelium in the SHR has shown to be quite peculiar from the very initial studies after EDRF was described. Endothelium-dependent responses to pharmacological (Konishi et al., 1983; Lüscher et al., 1986; Tesfamariam et al., 1998; Diederich et al., 1990; Li and Joshua 1993) or mechanical stimuli (Koller and Huang, 1994; 1995) are often, but not always (Angus et al., 1992; Li and Bukoski, 1993) found defective. It has been suggested that this impairment could be due to a diminished smooth muscle ability to relax (Cohen and Berkowitz, 1976; Konishi and Su, 1983), to an excessive production of prostanoidcontractile factor(s) rather than a depressed release of relaxing factors (Lüscher and Vanhoutte, 1986; Diederich et al., 1990) or to a decrease in endothelium-derived hyper-polarizing factor (Hayakawa et al., 1993). Therefore, the role of NO in this form of hypertension is unclear and the numerous existing reports are often contradictory. For example, in vitro studies using NOS inhibitors to test the ability of the endothelium to generate NO have shown that the SHR produces less NO (Li and Joshua, 1993; GilLongo et al., 1996). However, in vivo studies display a variety of results: less NO production (Schleiffer et al., 1991), equal production (Yamazaki et al., 1991) and more production (Gil-Longo et al., 1996; Lacolley et al., 1991). Measurements of the stimulated release of NO by assessment of the depressor responses to endothelium-dependent vasodilators also confront the in vitro results (Schleiffer et al., 1991; Yamazaki et al., 1991). Direct measurements of NO or NO-related substances has led to no definitive conclusion. Research works done in the heart suggest an increased production of NO in the SHR (Kelm et al., 1995;
252
EDUARDO NAVA AND THOMAS F.LÜSCHER
Figure 14±4. Ca2+-dependent NO synthase (NOS) activity in the kidney (a) and the heart and aorta (b) in normotensive Wistar-Kyoto rats (WKY, white bars) and spontaneously hypertensive rats (SHR, black bars). In both strains of rats the activity was much higher in the renal medulla. In the medulla and heart of the SHR the activity was significantly higher than in the same tissues of the WKY. *p<0.05 compared to the same kind of tissue of the WKY. (From Nava et al. (1996a), by permission).
Nava et al., 1995b). The kidney of these rats may release normal (Hayakawa et al., 1993) or increased amounts of NO (Nava et al., 1996a). Cultured endothelial cells from SHR appear to generate less NO (Malinski et al., 1993) and the aortic endothelium shows a rarefied staining of eNOS antibodies that worsens with ageing (Cuevas et al., 1996). On the contrary, Sawada et al. find changes in serum concentration of NO metabolites upon stimulation with acetylcholine unaltered in the SHR (Sawada et al., 1994). Smooth muscle cyclic GMP has been reported to be increased (Papapetropoulos et al., 1994), normal (Arnal et al., 1993), diminished (Amer et al., 1988) or both depending on the vessel studied (Amer et al., 1974). Table 14–1 resumes the different findings on the biology of NO in the SHR. The biology of the endothelium in the SHR is indeed very intriguing and our research has been devoted to this model of hypertension for many years. In the late eighties we demonstrated that the impaired relaxations of aortic segments from SHR are not caused by a deterred production of EDRF but instead, by an increased release of prostanoid contractile factors (Figure 14–5, Lüscher and Vanhoutte, 1986, 1988). With the advent of the NO age and using new methodologies we have confirmed the initial observations on the release of EDRF in this form of hypertension. NOS is indeed upregulated in the heart (Nava et al., 1995b), kidney (Nava et al., 1996a) and mesenteric resistance arteries (Nava et al., 1995a) obtained from SHR. Moreover, the concentration of the oxidative product of NO, nitrate, is higher in hypertensive rats as compared to normotensive controls (Nava et al., 1995a). Thus, the basal release of NO is increased in rats with spontaneous hypertension. Hayakawa et al., (1993) have confirmed our findings: they report that, although the vasoactive effects of acetylcholine in the kidney are actually abnormal, the measured release of NO from renal vessels is not diminished but slightly higher in the SHR. Treatment with inhibitors of the endothelium-
HYPERTENSION
253
Table 14±1. Status of the endothelial function in a wide variety of studies and experimental approaches found over the years. P = pharmacological study; A = analytical study of NO or NO-related substances; vt = in vitro study; vv = in vivo study; A = augmented; N = normal; D = diminished.
derived hyperpolarizing factor (EDHF) bring the vasoactive effects of acetylcholine to a normal status, suggesting that, in the SHR, an increased EDHF production, but not a decreased NO, occurs (Hayakawa et al., 1993). Further studies carried out in our lab have demonstrated that the accumulation of cyclic GMP in the heart and mesenteric resistance arteries is similar in WKY and SHR (Nava et al., 1995a). Moreover, the NOdependent vasodilator tone, assessed by the blood pressure effects of L-NAME, is not higher in hypertensive rats as would be expected in a situation in which the production of NO is increased. Thus, endogenously-produced NO, otherwise increased in SHR, is inefficacious in this condition. Probably an additional event takes place that prevents NO to accomplish its normal hemodynamic functions. The hypertrophied and fibrotic intimal layer of hypertensive vessels (Lindop et al., 1994) may represent a physical barrier for NO accounting for the blunted hemodynamic actions of NO. Also the chemical environment that NO encounters, such as oxidative stress can determine its fate as the results from Nakazono et al. (1991) and Tschudi et al. (1996) suggest. The mechanism by which high blood pressure leads to an increased production of NO is not clear yet. It is known that the release of NO by endothelial cells can be altered by changes in shear stress (Buga et al., 1991) and that mRNA and protein for cNOS can be induced by mechanical forces different from shear forces (Awolesi et al., 1995). It is plausible that not only shear stress, but also other mechanical factors such as blood pressure and pulsatile stretch contribute to this phenomenon. As mentioned before, we found that acute increases in blood pressure do enhance the release of NO, suggesting that pressure per se is a stimulus for eNOS (Figures 14–2, 14–3, Nava et al., 1994).
254
EDUARDO NAVA AND THOMAS F.LÜSCHER
Figure 14±5. Different mechanisms of endothelial dysfunction in genetic (i.e. spontaneous; left) and salt-induced hypertension of the rat (right). ACh=acetylcholine; ADP=adenosine diphosphate; cGMP=cyclic 3',5'-guanosine monophosphate; NE=noradrenaline; 5-HT=5-hydroxytryptamine (serotonin); PGH2=prostaglandin H2.;EDCF=endothelium-derived contracting factor. (Modified from Lüscher and Vanhoutte (1980), by permission).
isolated coronary vessels is augmented in the SHR (Kelm et al., 1995). We have recently found that the activity of constitutive NOS is higher in endothelium of hearts from adult SHR (Nava et al., 1995b). Very young prehypertensive SHRs have, in contrast, lower cNOS activity than the normotensive, indicating that the increased activity of cNOS in these cells is indeed related to hypertension (Figure 14–6, Nava et al., 1995b). Later studies showed that the augmented activity of cNOS in the hypertensive heart happens at the expense of the left ventricle where the highest differential pressure in the cardiovascular system is found (Nava et al., 1995b). These observations demonstrate that high blood pressure upregulates NOS in the heart. It appears that cardiac NOS activity remains unchanged within the normotensive blood pressure range, and that there is a pressure threshold above which upregulation of the enzyme takes place. An enhanced production of NO in the hypertensive heart probably acts as a compensatory mechanism by decreasing myocardial contractility and causing vascular dilatation. Nitric oxide in the hypertensive heart may also protect from hypertrophy. High blood pressure causes cardiac hypertrophy and fibrosis which often leads to left ventricular failure (Anversa et al., 1993). Nitric oxide, which is also a potent inhibitor of smooth muscle cell growth and migration (Dubey and Lüscher, 1993), might protect the heart from these deleterious effects of hypertension. Studies performed in kidneys from SHR show that the activity of Ca2+-dependent NOS in the medulla, where the long-term control of blood pressure takes place, is higher than in the normotensive counterparts (Figure 14–4, Nava et al., 1996a). This observation discards the possibility that hypertension in the SHR is related to a NO-dependent inability of the renal medulla to handle water and sodium (Cowley et al., 1995). The mechanism responsible for the enhancement of the NOS activity in the renal medulla of SHR is not known. It could be a compensatory response to high arterial pressure or to an increased release of certain vasoactive substances. Indeed, the altered renal function of the SHR could be secondary to an increased production of these factors (Lu et al., 1994; Kato et al., 1995). Very recent discoveries from our lab
HYPERTENSION
255
Figure 14±6. Blood pressure (a) and activity of constitutive NO synthase (cNOS; b) in hearts of spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto rats (WKY) at age 3 weeks (young) and 18 weeks (adult). The increased activity of cNOS appears to be related to the hypertensive status of of the animals and not to age or strain differences. *,**p<0.05 and p<0.01 versus normotensives, p<0.01 versus young animals, (from Nava et al. (1995b), by permission).
demonstrate that the increased activity of NOS in the medulla of SHR occurs at the expense of neuronal NOS (nNOS) rather than eNOS as would have been expected (Nava et al., 1996b). Using immunocytochemistry we have seen that nNOS stains collecting tubular cells suggesting that the SHR kidney may compensate high blood pressure by enhancing the transport mechanism of ions between the interstitium and the tubules. NITRIC OXIDE IN RENOVASCULAR HYPERTENSION Renovascular hypertension is as controversial as genetic hypertension. We and others have observed that endothelium-dependent vascular relaxation is impaired suggesting a diminished production of EDRF (Dohi et al., 1991 ; Lockette et al., 1986). Nakamura and Prewitt found that stimulated and also basal release of NO are deficient in 1K1C hypertensive rats (Nakamura and Prewitt, 1992). However, Sigmon and Beierwaltes have demonstrated that treatment with an inhibitor of NO synthesis affects similarly clipped
256
EDUARDO NAVA AND THOMAS F.LÜSCHER
and non clipped kidneys as well as normotensive controls (Sigmon and Beierwaltes, 1994). They concluded that in this model of hypertension, the endothelium is not dysfunctional but is a critical component in the adaptation to increased blood pressure. Interestingly, Pucci et al., (1994) have proven that vasodilatation in aortic coarctation-induced hypertension is mediated by NO while in salt-induced hypertension, it is not. Recent studies show higher amounts of cyclic GMP and NO metabolites in 1K1C hypertensive rats compared to sham operated rats (Figure 14–7, Dubey et al., 1996). Thus, the latest trend is towards the believing that the production of NO is increased in renovascular hypertension to compensate high blood pressure as occurs in genetic hypertension. NITRIC OXIDE IN SALT-SENSITIVE HYPERTENSION We reported ten years ago that Dahl salt-sensitive rats have impaired endothelium-depend-ent relaxations, however no release of vasoconstrictor prostanoids could be demonstrated as in the SHR (Figure 14–4, Lüscher and Vanhoutte, 1988; Lüscher et al., 1987). This suggested that a decreased EDRF production contributed to the pathogenesis of this form of hypertension. Chen and Sanders have reported that inhibition of NO synthesis causes a higher increase in blood pressure in normotensive rats than in Dahl salt-sensitive rats, suggesting that the synthesis of NO is lower in these animals (Chen and Sanders, 1991, 1993). They also demonstrate that NO production, as assessed by the pharmacological effects of NO inhibitors, improves by increasingly feeding NaCl to salt-resistant Dahl rats and administration of L-arginine is effective in lowering blood pressure in the salt-sensitive strain, but not the salt-resistant or the SHR (Chen and Sanders, 1991). In this line Ikeda et al., (1995) have demonstrated that neuronal NOS activity is lower in kidneys from saltsensitive Dahl rats as compared to salt-resistant. Hayakawa et al., (1993) have performed interesting experiments demonstrating that renal blood vessels from Dahl salt-sensitive rats display a reduced response to acetylcholine which is accompanied by a decreased release of NO. These findings contrast with those in the SHR, were the impaired responses to acetylcholine are accompanied by a normal or even increased production of NO (see part 2). Studies on the biology of NO in other models of saltsensitive hypertension have provided results which point to similar directions. Blood vessels from DOCA salt-sensitive hypertensive rats elicit impaired endothelium-dependent relaxations (Voorde and Leusen, 1986) and cyclic GMP accumulation is diminished (Otsuka et al., 1988) suggesting that a decreased production of NO may be involved. Hayakawa and coworkers (1993) have demonstrated that these impaired relaxations are paralleled by a diminished release of NO from perfused kidney vessels. Beneficial effects of treatment with L-arginine on endothelial function have also been shown (Hayakawa et al., 1994; Laurant et al., 1995) in this model of hypertension. Rees and colleagues have recently reported that another model of saltsensitive hypertension, the Sabra hypertensive-prone rat, shows a decreased activity of cNOS in aortic endothelial cells and the concentration of nitrate in plasma is lower than in the Sabra hypertensive-resistant rat (Figure 14–8, Rees et al., 1996). They conclude that a decrease in NO generation plays a role in the susceptibility of Sabra hypertensive-prone rat to develop hypertension and that the resistance to hypertension of the Sabra hypertensive-resistant strain is related to increased NO generation. Thus, saltsensitive hypertension may be partly caused by a diminished production or activity of NO, which is an important factor in the kidney’s ability to excrete water and sodium (Salazar et al., 1993). Studies in humans reveal that the ability of L-arginine to produce NO is diminished in salt-sensitive patients when being salt-loaded (Higashi et al., 1996). This finding discourages the possible plans for treating saltsensitive hypertension with L-arginine, as studies in animals had suggested (Chen and Sanders, 1991; Hayakawa et al., 1994; Laurant et al., 1995).
HYPERTENSION
257
Figure 14±7. Graph showing circulating NO metabolites in platelet-poor serum obtained from paired groups of normotensive 1K rats and hypertensive 1K1C rats 2,3,4, and 5 wekks after clipping. *p<0.05 compared to corresponding value for 1K. (From Dubey et al (1996), by permission).
Figure 14±8. (a). Blood pressure response to L-NMMA and; (b) plasma concentrations of NO metabolites in the Sabra hypertension-resistant (open symbols) and hypertension-prone (closed symbols) rat. The smaller response of the hypertension-prone rats to L-NMMA indicates a diminished NO-dependent vasodilatory tone. *p<0.05 (Modified from Rees et al., (1996), by permission).
NITRIC OXIDE IN HUMAN HYPERTENSION Human experimentation has shown so far a diminished production of NO, both basal (Calver et al., 1992; Panza et al., 1993b) or stimulated (Figure 14–9, Panza et al., 1990; Linder et al., 1990). However, most of the studies have been performed measuring the changes in forearm blood flow in response to NO inhibitors or vasodilators and few direct measurements of NO release have been done. Benjamin and colleagues have reported an altered NO synthesis in platelets in essential hypertension (Cadwgan and Benjamin, 1993) and a diminished production of NO as assessed by urinary nitrate (Benjamin et al., 1995). Studies carried out by
258
EDUARDO NAVA AND THOMAS F.LÜSCHER
Figure 14±9. Changes in forearm vascular resistance caused by acetylcholine and sodium nitroprusside in normotensives and hypertensives. The response to acetylcholine, but not that to nitroprusside was impaired in hypertensive patients. * p<0.05. (From Linder et al (1990), by permission).
Taddei et al. (1993) have demonstrated that essential hypertension may be associated to an increased production of a cyclooxygenase-dependent endothelium-derived vasoconstrictor substance. In contrast, renovascular and hyperaldosteronism hypertensive patients reveal no role for this substance (Taddi et al., 1993). This group has also shown that acetylcholine-mediated forarm vasodilatation is reduced in normotensive offsprings of essential hypertensive patients, thus demonstrating that endothelial disfunction can precede the appearance of hypertension (Taddi et al., 1992). Vallance et al. (1994) have demonstrated the existence of an inverse relationship between blood pressure and the drop in blood flow in the brachial artery in response to a NO inhibitor (in relation to the responses to norepinephrine) (Calver et al., 1994). Thus, the higher the blood pressure, the lower the production of NO is. Smooth muscle relaxation appears to be maintained in hypertensive subjects (Panza et al., 1993b; Taddi et al., 1993), but not every study agrees with this assumption (Preik et al., 1994). Although some animal studies show beneficial effects of Larginine administration in lowering blood pressure (Chen and Sanders, 1991), in humans hypertensives no decreased availability of substrate for NO has been proven (Panza et al., 1993a). There has been no success either in finding a role for oxidative stress in essential hypertension in humans (García et al., 1995). Unfortunately, no study has been carried out so far focusing of analysis of NO release in specific types of hypertension. It would be interesting to find out whether the concepts on the role of NO that are being established in animal models of hypertension, are valid as well in the different types of hypertension in humans.
HYPERTENSION
259
REFERENCES Amer, M.S., Gomoll, A.W. and Perhach, J.L. Jr. (1974) Ferguson HC, McKinney GR. Aberrations of cyclic nucleotide metabolism in the hearts and vessels of hypertensive rats. Proc. Natl, Acad. Sci. USA, 71, 4930– 4934. Angus, J.A., Dyke, A.C., Jennings, G.L., Korner, P.I., Sudhir, K., Ward, I.E. and Wright, C.E. (1992) Release of endothelium-derived relaxing factor from resistance arteries in hypertension. Kidney International, 41, S73–S78. Anversa, P., Peng, Li, Malhotra, A., Zhang, X., Herman, M.V. and Capasso, J. (1993) Effects of hypertension and coronary constriction on cardiac function, morphology, and contractile proteins in rats. Am. J. Physiol, 265, 713–725. Arnal, J.-R, Battle, T., Ménard, J. and Michel, J.-B. (1993) The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat. J.Hypertens., 11, 945– 950. Awolesi, M.A., Sessa, W.C. and Sumpio, B.E. (1995) Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. J.Clin. Invest., 96, 1449–1454. Benjamin, N., Copland, M. and Smith, L.M. (1995) Reduced nitric oxide synthesis in essential hypertension. Endothelium, 3, 94. Biondi, M.L., Bolterman, RJ. and Romero, J.C. (1992) Zonal changes of guanidine 3',5'-cyclic monophosphate related to endothelium-derived relaxing factor in dog renal medulla. Renal Physiol. Biochem., 15, 1–7. Blot, S., Arnal, J.F., Xu, Y., Gray, F. and Michel, J.-B. (1994) Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats. Stroke, 25, 1666–1673. Buga, G.M., Gold, M.E., Fukuto, J.M. and Ignarro L. (1991) Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension, 17, 187–193. Busse, R. and Mülsch, A. (1990) Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEES letts., 265, 133–136. Cadwgan, T.M. and Benjamin N. (1993) Evidence for altered platelet nitric oxide synthesis in essential hypertension. J. Hypertens., 11, 417–20. Calver, A., Collier, J., Moncada, S. and Vallance, P. (1992) Effect of local intra-arterial NG-mpnomethyl-Larginine in patients with hypertension, the nitric oxide dilator mechanism appears abnormal. J. Hypertens., 10, 1025–1031. Calver, A., Collier, J., Vallance, P. (1994) Forearm blood flow responses to a nitric oxide synthase inhibitor in patients with treated essential hypertension. Cardiovascular Res., 28, 1720–1725. Chen, PY. and Sanders, P.W. (1991) L Arginine abrogates salt sensitive hypertension in Dahl/Rapp rats. J. Clin. Invest., 88, 1559–1567. Chen, P.Y. and Sanders, P.W. (1993) Role of nitric oxide synthesis in salt sensitive hypertension in Dahl/Rapp rats. Hypertension, 22, 812–818. Cohen, M.L. and Berkowitz, B.A. (1976) Decreased vascular relaxation in hypertension. J. Pharmacol. Exp. Ther., 196, 396–406. Cowley, A.W., Mattson, D.L., Lu, S. and Roman, RJ. (1995) The renal medulla and hypertension. Hypertension, 25, 663–663. Cuevas, P., Garcfa-Calvo, M., Carceller, F., Reimers, D., Zaao, M., Cuevas, B., Muñoz-Willery, L, MartínezCoso, V., Lamas, S. and Giménez-Gallego, G. (1996) Correction of hypertension by normalization of endothelial levels of fobroblast growth factor and nitric oxide synthase in spontaneously hypertensive rats. Proc. Natl. Acad. Sci. USA, 93, 11996–12001. Diederich, D., Yang, Z., Bühler, F.R. and Lüscher, T.F. (1990) Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxigenase pathway. Am. J. Physiol., 258, H445-H451 Dohi, Y, Criscione, L. and Lüscher, T.F. (1991) Renovascular hypertension impairs formation of endotheliumderived relaxing factors and sensitivity to endothelin-1 in resistance arteries. Br. J. Pharmacol., 104, 349– 354. Dubey, R.K. and Lüscher, T.F. (1993) Nitric oxide inhibits angiotensin II-induced migration of vascular smooth muscle cells Hypertension, 22, 412. Dubey, R.K., Boegehold, M.A., Gillespie, D.G. and Rosselli, M. (1996) Increased nitric oxide activity in early renovascular hypertension. Am.J.Physiol., 270, R118-R124. Fenoy, F.J., Ferrer, P., Carbonell, L. and Salom, M.G. (1995) Role of nitric oxide on papillary blood flow and pressure natriuresis. Hypertension, 25, 408–414.
260
EDUARDO NAVA AND THOMAS F.LÜSCHER
García, C.E., Kilcoyne, C.M., Cardillo, C., Cannon, R.O., Quyyumi, A.A. and Panza, J.A. (1995) Effect of copper-zinc superoxide dismutase on endothelium-dependent vasodilation in patients with essential hypertension . Hypertension, 26, 863–868. Gil-Longo, J., Fernández-Grandal, D., Ålvarez, M., Sieira, M. and Orallo, F. (1996) Study of in vivo and in vitro resting vasodilator nitric oxide tone in normotensive and genetically hypertensive rats. Eur. J. Pharmacol, 310, 175–183. Hayakawa, H., Hirata, Y, Suzuki, E., Kimura, K., Kikuchi, K., Nagano, T., Hirobe, M. and Omata, M. (1994) Long term administration of L-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate salt hypertensive rats. Hypertension, 23, 752–756. Hayakawa, H., Hirata, Y, Suzuki, E., Sugimoto, T., Matsuoka, H., Kikuchi, K., Nagano, T., Hirobe, M., and Sugimoto, T. (1993) Mechanisms for altered endothelium-dependent vasorelaxation in isolated kidneys from experimental hypertensive rats. Am.J.Physiol., 264, H1535-H1541. Higashi, Y, Oshima, T., Watanabe, M., Matsuura, H. and Kajiyama, G. (1996) Renal response to L-arginine in saltsensitive patients with essential hypertension. Hypertension, 27, 643–648. Huang, PL., Huang, Z., Mashimo, H., Bloch, K.D., Moskowitz, M.A., Bevan, J.A. and Fishman, M.C. (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature, 337, 239–242. Ikeda, Y, Saito, K., Kim, J.I. and Yokoyama, M. (1995) Nitric oxide synthase isoform activities in kidney of Dahl saltsensitive rats. Hypertension, 26, 1030–1034. Kato, T., Kassab, S., Wilkins, F.C., Kirchner, K.A., Keiser, J. and Granger, J.P. (1995) Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension, 25, 883–887. Kelm, M., Feelisch, M., Deussen, A., Strauer, B.E. and Scharader, J. (1991) Release of endothelium derived nitric oxide in relation to pressure and flow. Cardiovasc. Res., 25, 831–836. Kelm, M, Feelisch, M, Krebber, T., Deussen, A., Motz, W. and Strauer, B.E. (1995) Role of nitric oxide in the regulation of coronary vascular tone in hearts from hypertensive rats. Hypertension, 25, 186–193. Koller, A. and Huang, A. (1994) Impaired nitric oxide-mediated flow-induced dilatation in arterioles of spontaneously hypertensive rats. Circ. Res., 74, 416–421. Koller, A. and Huang, A. (1995) Shear stress-mediated dilation is attenuated in skeletal muscle arterioles of hypertensive rats. Hypertension, 25, 758–763. Konishi, M. and Su, C. (1983) Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension, 5, 881–886. Kurtz, T.W., St. Lezin, E.M. and Pravence, M. (1994) Genetic models of hypertension. In Textbook of hypertension, edited by J.D.Swales, pp. 441–76. London: Blackwell Scientific Publications. Lacolley, P.J., Lewis, S.J. and Brody, M.J. (1991) L-NG-Nitro arginine produces an exaggerated hypertension in anesthetized SHR. Eur.J.Pharmacol, 197, 239–240. Laurant, P., Demolombe, B. and Berthelot, A. (1995) Dietary L-Arginine attenuates blood pressure in mineralocorticoid salt hypertensive rats. Clin. Exper. Hypertension, 17, 1009–1024. Li, F. and Joshua, I.G. (1993) Decreased arteriolar endothelium-derived relaxing factor production during the development of genetic hypertension. Clin. Exp. Hypertens., 15, 511–526. Li, J. and Bukoski, R.D. (1993) Endothelium-dependent relaxation of hypertensive resistance arteries is not impaired under all conditions. Circ. Res., 72, 290–296. Linder, L., Kiowski, W., Bühler, F.R. and Lüscher, T.F. (1990) Indirect evidence for the release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation, 81, 1762–1767. Lindop, G.B.M. (1994) Textbook of Hypertension, edited by Swales, J.D., pp. 663–669. London: Blackwell Scientific Publications. Lockette, W., Otsuka, Y. and Carretero, O.A. (1986) The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension, 8, 61–66. Lu, S., Mattson, D.L. and Cowley, A.W. (1994) Renal medullary captopril delivery lowers blood pressure in spontaneously hypertensive rats. Hypertension, 23, 337–345.
HYPERTENSION
261
Lüscher, T.F. and Vanhoutte, P.M. (1986) Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension, 8, 344–348. Lüscher, T.F. and Vanhoutte, P.M. (1988) Mechanisms of altered endothelium-dependent responses in hypertensive blood vessels. In: Relaxing and Contracting Factors, ed., Vanhoutte, P.M., pp. 495–509. Clifton, N.J.: Humana Press. Lüscher, T.F, Raij, L. and Vanhoutte. P.M. (1987) Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension., 9, 157–163. Malinski, T., Kapturczak, M., Dayharsh, J. and Bohr, D. (1993) Nitric oxide synthase activity in genetic hypertension. Biochem. Biophys. Res. Commun., 194, 654–658. Moncada, S. and Higgs A. (1993) Mechanisms of disease. The L-arginine-nitric oxide pathway. N. Eng. J. Med., 329, 2002–2012. Nakamura, T. and Prewitt, R.L. (1992) Alteration of endothelial function in arterioles of renal hypertensive rats at two levels of vascular tone. J. Hypertens., 10, 621–627. Nakazono, K., Watanabe, N., Matsuno, K., Sasaki, J. and Sato, T. (1991) Does superoxide underlie the pathogenesis of hypertension?. Proc. Natl. Acad. Sci. USA, 88, 10045–10048. Nava, E., Leone, A.M., Wiklund, N.P. and Moncada, S. (1994) Detection of release of nitric oxide by vasoactive substances in the anaesthesized rat. In, The Biology of Nitric Oxide, Eds: M.Feelisch, R.Busse and S. Moncada, pp. 179–181, London: Portland Press. Nava, E., Llinás, M.T., González, J.D. and Salazar, F.J. (1996a) Nitric oxide synthase activity in renal cortex and medulla of normotensive and spontaneously hypertensive rats. Am. J. Hypertension, In press. Nava, E., Moreau, P. and Lüscher, T.F. (1995a) Basal production of nitric oxide is increased, but inefficacious in spontaneous hypertension. Circulation, 92, 1–347. Nava, E., Noll, G. and Lüscher, T.F. (1995b) Increased activity of constitutive nitric oxide synthase in hearts from spontaneously hypertensive rats . Circulation, 91, 2310–2313. Nava, E., Salazar, J., Martímez de Velasco, J., Martínez-Murillo, R., Fernández, A.P., Serrano, J. and Rodrigo, J. (1996b) Distribution of neuronal nitric oxide synthase immunoreactivity in normal and hypertensive rat kidneys. J. Am. Soc. Nephrol, 1, 1540. Nava, E., Wiklund, N.P. and Salazar, F.J. (1996c) Changes in nitric oxide release in vivo in response to vasoactive substances. Br J Pharmacol. 119, 1211–1216. Otsuka, Y, Dipiero, A., Hirt, E., Brennaman, B. and Lockette, W. (1988) Vascular relaxation and cGMP in hypertension. Am. J.Physiol, 254, H163-H169. Palmer, R.M.J., Bridge, L., Foxwell, N.A. and Moncada, S. (1992) The role of nitric oxide in endothelial damage and its inhibition by glucocorticoids. Br. J.Pharmacol, 105, 11–12. Panza, J.A., Casino, PR., Badar, D.M. and Quyyumi, A.A. (1993a) Effect of increased availability of endotheliumderived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation, 87, 1475–1481. Panza, J.A., Casino, PR., Kilcoyne, C.M. and Quyyumi, A.A. (1993b) Role of endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation, 87, 1468–1474. Panza, J.A., Quyyumi, A.A., Brush, I.E. and Epstein, S.E. (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Eng. J. Med., 323, 22–27. Papapetropoulos, A., Marczin, N., Snead, M.D., Cheng, C., Milici, A. and Catravas, J.D. (1994) Smooth muscle cell responsiveness to nitrovasodilators in hypertensive and normotensive rats. Hypertension, 23, 476– 484. Preik, M., Kelm, M., Köster, A., Heinzelmann, Notz, W. and Strauer, B.E. (1994) Reduced nitric oxidedependent vasodilation following application of organic nitrates in patients with essential hypertension. In: The Biology of Nitric Oxide, eds., M.Feelisch, R.Busse and S.Moncada, pp. 179–181. London: Portland Press. Pucci, M.L., Miller, K.B., Dick, L.B., Guan, H., Lin, L. and Nasjletti, A. (1994) Vascular responsiveness to nitric oxide synthesis inhibition in hypertensive rats. Hypertension, 23, 744–751. Rees, D., Ben-Ishay, D. and Moncada, S. (1996) Nitric oxide and the regulation of blood pressure in the hypertensionprone and hypertension-resistant Sabra rat. Hypertension, 28, 367–371.
262
EDUARDO NAVA AND THOMAS F.LÜSCHER
Rees, D.D., Palmer, R.M.J. and Moncada, S. (1989) Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA, 86, 3375–3378. Rees, D.D., Palmer, R.M.J., Schulz, R., Hodson, H.F. and Moncada, S. (1991) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J.Pharmacol., 101, 746–752. Salazar, F.J., Alberola, A., Pinilla, J.M., Romero, J.C. and Quesada, T. (1993) Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension, 22, 49–55. Sawada, Y, Sakamaki, T., Nakamura, T., Sato, K., Ono, Z. and Murata, K. (1994) Release of nitric oxide in response to acetylcholine is unaltered in spontaneously hypertensive rats.J. Hypertens., 12, 745–750. Schleiffer, R., Pernot, F, Van Overloop, B. and Gairard, A. (1991) In vivo involvement of endothelium-derived nitric oxide in spontaneously hypertensive rats: effects of NG-nitro-L-arginine methyl ester. J. Hypertension, 9, S192–S193. Schmidt, H.H.H.W., Zernikow, B., Baeblich, S. and Böhme, E. (1990) Basal and stimulated formation and release of Larginine-derived nitrogen oxides from cultured endothelial cells. J. PharmacoL Exp. Ther., 254, 591–597. Sessa, W.C., Pritchard, K., Seyedi, N., Wang, J. and Hintze, T.H. (1994) Chronic exercise in dogs increses coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ. Res., 74, 349–353. Shirasaki, Y, Kolm, P., Nickols, G.A. and Lee, T.J.-F. (1988) Endothelial regulation of cyclic GMP and vascular responses in hypertension. J.PharmacoL Exp. Ther., 245, 53–58. Sigmon, D.H. and Beierwaltes, W.H. (1994) Nitric oxide influences blood flow distribution in renovascular hypertension. Hypertension, 23, 134–139. Spector, S., Fleisch, J.H., Maling, H.M. and Brodie, B.B. (1996) Vascular smooth muscle reactivity in normotensive and hypertensive rats. Science, 166, 1300–1301. Taddei, S., Virdis, A., Mattei, P. and Salvetti, A. (1993) Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension, 21, 929–933. Taddei, S., Virdis, A., Mattei, P., Arzilli, F. and Salvetti, A. (1992) Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J. Cardiovasc. Pharmacol., 20, S193–S195. Takase, H., Moreau, P., Küng, C.F., Nava, E. and Lüscher, T.F. (1996) Antihypertensive therapy improves endotheliumdependent relaxation of resistance arteries in nitric oxide deficient hypertension: Effect of verapamil and trandolapril. Hypertension, 27, 25–31. Tesfamariam, B. and Halpern, W. (1988) Endothelium-dependent and endothelium-independent vasodilation in resistance arteries from hypertensive rats. Hypertension, 11, 440–44. Tschudi, M.R., Mesaros, S., Lüscher, T.F. and Malinski, T. (1996) Direct in situ measurement of nitric oxide in mesenteric resistance vessels. Increased decomposition by superoxide in hypertension. Hypertension, 27, 32–35. Vallance, P., Collier, J. and Moncada, S. (1989) Effects of endothelium derived nitric oxide on peripheral arteriolar tone in man. Lancet, ii, 997–1000. Voorde, J.V. and Leusen, I. (1986) Endothelium dependent and independent relaxation of aortic rings from hypertensive rats. Am. J.Physiol., 250, H711-H717 Weiner, C.R, Lizasoain, I., Baylis, S.A., Knowles, R.G., Charles, I.C. and Moncada, S. (1994) Induction of calciumdependent nitric oxide synthase by sex hormones. Proc. Natl. Acad. Sci. USA, 91, 5212–5216. Yamazaki, J., Fujita, N. and Nagao, T. (1991) NG-monomethyl-L-arginine-induced pressore response at developmental and established stages in spontaneouly hypertensive rats. J.Pharmacol Exp. Then, 259, 52–57.
15 Pulmonary Hypertension Jocelyn Dupuis1, David Langleben2 and Duncan J.Stewart3 1Montreal
Heart Institute, 2Sir Mortimer B. Davis Jewish General Hospital, McGill University, 3Terrence Donnelly Heart Centre, St.Michael's Hospital, University of Toronto, Canada
Unlike systemic vascular beds, the pulmonary circulation must accommodate the entire cardiac output, and yet maintain a much lower arterial pressure. This is accomplished by virtue of a very low normal pulmonary vascular resistance (PVR) in physiological conditions. However, elevation of PVR occurs as a consequence of a wide variety of pulmonary, cardiac and systemic disorders (secondary pulmonary hypertension (SPH)) or as a primary disease (primary pulmonary hypertension (PPH)). The role of abnormalities of the L-arginine/NO pathway in the pathogenesis of PH is uncertain. The evidence both supporting and refuting an important contribution is reviewed. In animal models of PH, the evidence suggests a significant impairment of endothelium-dependent dilation, particularly in the larger conduit pulmonary arteries. The evidence is less compelling that reduced NO synthesis or activity is responsible for vasoconstriction and remodeling of smaller resistance vessels. Similarly, the human data is controversial. Although clearly more studies are needed, it might be reasonable to conclude that the clinical experience to date is generally compatible with the more extensive literature from animal studies. Regardless of whether decreased NO activity plays a pathogenic role in PH, there is a good rationale supporting therapeutic strategies to increase pulmonary vascular NO in the treatment of this disorder, and various therapeutic approaches are reviewed. Keywords: Nitric oxide, pulmonary hypertension, endothelial dysfunction, hypoxia, monocrotaline, nitric oxide synthase.
264
JOCELYN DUPUIS ET AL
INTRODUCTION The human pulmonary circulation is in a series circuit with the systemic circulation, so that the entire cardiac output (approximately 5 L/min in resting humans) also passes through the lungs. Given the large cross-sectional area of the lung capillary bed, and that the pulmonary venous drainage system into the left atrium of the heart also normally operates at a low pressure (0–12 mm Hg), the lung circulation has a low vascular resistance and is able to accommodate blood flow at a low driving (pulmonary arterial) pressure, as compared to the systemic circulation. Moreover, in the resting state, some of the capillary bed is minimally recruited, allowing the pulmonary blood flow to rise dramatically during exercise, with only slight rises in pulmonary arterial pressure. A precapillary arteriolar segment regulates the pulmonary vascular resistance with exquisite homeostatic control, and responds to a variety of factors, including oxygen tension, pH, flow, and circulating and neurohormonal mediators. Pulmonary hypertension remains an important clinical problem. It is defined as an elevated pressure in the pulmonary circulation, often with decreased pulmonary blood flow. The right ventricle, designed to pump at a low pressure, must generate the increased pressure to force blood through the lungs, and it may ultimately fail, resulting in the demise of the patient. Depending on the etiology, the increased pulmonary vascular resistance may be due to vasoconstriction, thickening or structural remodeling of blood vessel walls by cellular proliferation or alterations in extracellular matrix, thrombosis and obliteration of vessels, or a combination of these events. The end result is a reduction in the cross-sectional area of the vessel lumen. The causes of pulmonary hypertension may be broadly divided into “precapillary” and “postcapillary” (Reeves and Groves, 1984). Furthermore, after a careful search to exclude secondary diseases, primary pulmonary hypertension may be diagnosed. Diseases which result in increased pulmonary venous pressure, including left heart failure and mitral valve disease, are the commonest “postcapillary” causes, and represent commonest cause of pulmonary hypertension in humans. The other four major “secondary” causes of pulmonary hypertension include lung disease (obstructive, restrictive, interstitial andhypoxic), chronic thromboemboli, autoimmune or collagen-vascular diseases (such as scleroderma, the CREST syndrome, polymyositis, and mixed connective tissue disease variants), and congenital heart disease with left-to-right shunts. Each of these etiologies offers paradigms for understanding some of the common or differing aspects of the pathophysiologic mechanisms active in pulmonary hypertension. Physical entrapment or compression of vessels may be combined with vasoconstriction from hypoxia (COPD or interstitial disease). Plugging of large, midsized or small arteries is seen in thromboembolic pulmonary hypertension. The collagen vascular diseases cause intimai sclerosis of pulmonary microvessels, as well as causing pulmonary fibrosis. They may also predispose to increased pulmonary vasoconstriction (akin to Raynaud’s phenomenon of the extremities). Longstanding left-to-right intracardiac shunts, with persistent high flow and high shear stress in the pulmonary bed, induce endothelial injury and vascular remodeling that narrows the bed, ultimately resulting in an Eisenmenger physiology. Primary pulmonary hypertension is still an enigma (Rubin, 1997). It presents mainly between the ages of 20 to 40 years, and has a femaleimale ratio of approximately 2:1, with an incidence is 1–2 per million. The most frequent histologie abnormality of the lung circulation is termed “plexogenic pulmonary arteriopathy”. Structural remodeling of pulmonary microvessels, by medial thickening, intimai proliferation and formation of plexiform lesions, progressively increases pulmonary vascular resistance (Voelkel et al., 1997). Vasospasm may be present to varying degrees. Until recently, the clinical course was relentlessly downhill, leading to death. A minority (15–25%) of patients respond well to high-dose calcium channel blockers (Rich et al., 1992), and recent studies have shown dramatic survival benefit from chronic intravenous infusions of prostacycline for patients who are in functional classes III and IV (Barst et al., 1996). Addition
PULMONARY HYPERTENSION
265
of warfarin anti-coagulation also improves survival, presumably by reducing the occurrence of thrombosisin-situ in pulmonary microvessels (Fuster et al., 1984; Rich et al., 1992). Primary pulmonary hypertension has been reported in families and a gene has been localized to chromosome 2 (Nichols et al., 1997). Other risk factors for primary pulmonary hypertension include HIV infection, cirrhosis of the liver, and intake of anorexic agents (Abenhaim et al., 1996). Endothelial dysfunction is a feature common to most types of pulmonary hypertension, and it contributes to the vascular abnormalities seen in these disorders. The pulmonary endothelium has important metabolic activity for many vasoactive and cytokine mediators circulating in the blood, including angiotensin I, bradykinins, 5-hydroxytryptamine (serotonin), catecholamines and other neurohormones. This activity is altered in primary pulmonary hypertension and many types of secondary pulmonary hypertension, and may contribute to the vasoconstriction and cellular proliferation seen in these disorders (Catravas et al., 1992). Reduced production of prostacycline and increased production of endothelin–1 have been described in primary pulmonary hypertension (Giaid et al., 1993; Stewart et al., 1991; Christman et al., 1992). As is discussed below, reduced endothelial-mediated vasorelaxation, implying decreased nitric oxide production, has been reported in primary and secondary pulmonary hypertension. Anorexic agents may alter pulmonary endothelial handling of 5hydroxytryptamine and catecholamines, resulting in high local levels of these vasoconstrictors and smooth-muscle mitogens. The endothelium is an essential element in the homeostasis of thrombosis and fibrinolysis. It normally maintains the balance in favor of anticoagulation and fibrinolysis, thereby promoting vascular patency. Increased thrombotic and decreased fibrinolytic activity has been reported in primary pulmonary hypertension (Voelkel et al., 1997). This thrombus formation and fibrin deposition will itself narrow the vascular lumen, and it may also act as a nidus for cellular ingrowth. The endothelium has a crucial role in the control of inflammation and in regulating growth of other cells (smooth muscle, fibroblast, pericyte) in the vessel wall. It produces cell adhesion molecules which mediate the attachment of inflammatory cells and platelets and, when activated, it produces cytokines, including interleukins and platelet activating factor, which amplify inflammation and alter cell growth. The endothelium also introduces molecules into the extracellular matrix of the vessel wall (proteoglycans, collagens, elastins), which contribute to the control of cell growth and to vascular elastance and compliance. There is at present no good animal model of primary pulmonary hypertension or plexogenic pulmonary arteriopathy. Our understanding of the formation of plexiform lesions is limited. Animal models of secondary pulmonary hypertension have been developed, and two are discussed here. Monocrotaline, a pyrrolizidine alkaloid, will induce pulmonary hypertension when it is converted to active pyrroles in species with the necessary hepatic microsomal enzymes. The pyrroles then travel through the venous system to the next downstream organ, the lung. Endothelial permeability and dysfunction are early findings, with subsequent activation of many secondary mediator cascades that ultimately lead to vascular remodeling and thrombosis. The monocrotaline model may most appropriately be considered a model of the human Acute Respiratory Distress Syndrome (ARDS), which has a variety of triggers, including trauma, burns and sepsis, and which involves early important endothelial injury and dysfunction. Pulmonary vascular remodeling and pulmonary hypertension develop with progressive ARDS. Hypoxia-induced pulmonary hypertension can be reproduced in many species, but sensitivity to hypoxia varies between species and strains (Weir and Archer, 1957). Acute hypoxia is a potent vasoconstrictor of the pulmonary circulation. This effect may be mediated by closure of potassium channels on smooth muscle cells. In vivo, acute hypoxic vasoconstriction is at least in part moderated by release of nitric oxide from the endothelium. Chronic hypoxia causes ongoing vasoconstriction, but it also induces muscularization of large and small pulmonary arteries, and polycythemia (Jones et al., 1991). With return to normoxia, the vascular remodeling regresses more slowly than the constriction and polycythemia resolve. Use of these animal models allows
266
JOCELYN DUPUIS ET AL
the study of various aspects of hypoxia, and they are relevant to chronic lung diseases and to high-altitude exposure. NITRIC OXIDE PRODUCTION BY THE PULMONARY CIRCULATION: ROLE IN CONTROL OF PULMONARY VASCULAR RESISTANCE Endothelium-dependent dilation of pulmonary arteries, like that of systemic vessels, was recognized in the seminal report of Furchgott and Zawadzski (Furchgott and Zawadzski, 1980), and has since been confirmed by many other groups (Gruetter and Lemke, 1986; Cherry et al., 1982; Chand and Altura, 1981). In a manner analogous to that of the systemic vasculature, the pulmonary vascular endothelium produces nitric oxide (NO) by converting L-arginine to L-citrulline through the action of the endothelial constitutive NOsynthase (NOS III). NO and NO breakdown products (NOX) can be measured in the effluent of isolated saline-perfused lungs, demonstrating that there is substantial basal production of NO by the pulmonary vasculature (Wang et al., 1995; Spriestersbach et al., 1995; Nelin et al., 1996). This production is increased by the receptor-independent stimulator of endothelial NO production, A-23187 (Spriestersbach et al., 1995), while it is reduced by inhibitors of NO-synthase, L-NMMA and L-NAME (Wang et al., 1995; Spriestersbach et al., 1995; Nelin et al., 1996). Again, as in systemic vessels, the effect of NO on pulmonary smooth muscle cells is mediated by the stimulation of soluble guanylate cyclase (sGC) and the increased production of cyclic 3',5'-guanosine monophosphate (cGMP) (Ignarro et al., 1987a; Ignarro et al., 1987b). Cyclic GMP levels are two-fold higher in the presence versus the absence of the pulmonary endothelium and an inhibitor of sGC, methylene blue, reduces these levels while increasing pulmonary vascular tone (Ignarro et al., 1987b). Inhibition of phosphodiesterases increases the levels of cGMP in the pulmonary effluent and potentiates the response to NO-induced pulmonary vasodilation (Thusu et al., 1995; Ichinose et al., 1995; Cohen et al., 1996). NO is also present in the exhaled air (Gustafsson et al., 1991; Cremona et al., 1995), although the source of exhaled NO gas is largely naso-pharyngeal in origin (Phillips et al., 1996; Kimberly et al, 1996; Dillon et al., 1996; Lundberg et al., 1995). However, experimental evidence suggests that pulmonary vascular production also contributes to NO in exhaled air in isolated porcine lungs (Nelin et al, 1996; Cremona et al., 1995), and this is increased by acetylcholine and reduced by L-NAME (Nelin et al., 1996; Cremona et al., 1995). As well, exhaled NO is reduced by perfusion of isolated lungs by blood (Cremona et al., 1995), presumably due to the binding of vascular-derived NO to hemoglobin. In contrast to the systemic vasculature, endothelial NO release is not diminished by aging in the rat pulmonary artery (2). This difference between the aorta and the pulmonary artery may at least in part reflect the lower pressures to which the latter is exposed throughout life. The site of action of NO in the pulmonary circulation has been studied using the double occlusion method in isolated perfused lung preparations (Roos et al., 1994; Rimar and Gillis, 1995; Lindeborg et al., 1995; Hakim, 1994; Ferrario et al., 1996). Both in response to the endogenous release of endothelial NO by acetylcholine as well the pharmacological generation of NO by sodium nitroprusside, preferential dilation occurs at the level of small precapillary arteries, and to a lesser degree in small veins and larger pulmonary arteries (Roos et al., 1994; Ferrario et al., 1996). Pulsatile flow during hypoxia is associated with an increase in EDRF production by precapillary pulmonary arteries (Hakim, 1994), suggesting a shear-stress induced increase in NO release at this level of the circulation, again analogous to systemic vessels (Griffith et al., 1987). Inhaled NO also causes dilation of small pulmonary arteries and veins (Roos et al., 1994; Rimar and Gillis, 1995; Lindeborg et al., 1995), whereas, as expected, it does not affect the tone of the larger upstream capacitance vessels (Roos et al., 1994). This preferential effect of NO on small resistence pulmonary vessels needs to be kept in mind in the interpretation of in vitro studies of pulmonary vascular
PULMONARY HYPERTENSION
267
reactivity which often use larger capacitance vessels. Thus, some of the apparent discrepancies in data derived from models of experimental pulmonary hyper tension examining vascular reactivity of isolated pulmonary conduit vessels versus studies in isolated intact lungs or in vivo may be explained by the greater contribution of the small precapillary arteries to changes in pulmonary vascular resistance and therefore pulmonary pressures. Role of NO in Maintaining Normal Pulmonary Pressures The pulmonary circulation is characterized by a very low vascular resistance and it is attractive to speculate that a high basal release of NO by the endothelium of pulmonary resistance vessels contributes significantly to low baseline pulmonary vascular tone. Many studies have addressed this issue by measuring pulmonary vascular tone and blood flow after the inhibition of endogenous NO production using various NOS antagonists, however, often with conflicting results. Some investigators have reported little or no increase in pulmonary vascular tone after NOS inhibition (Wanstall et al., 1995; Russ and Walker, 1993; Lindeborg et al., 1995; Hasunuma et al., 1991; Hakim, 1994; Ferrario et al., 1996; Barnard et al., 1993), whereas others have shown more substantial effects (Rodman et al., 1990; Nelin et al., 1996; Madden et al., 1995; Isaacson et al., 1994; Cremona et al., 1995; Cooper et al., 1996; Blitzer et al., 1996). In general, the modulation of basal vascular tone by NO is accentuated in situations of increased pulmonary vascular tone induced by hypoxia or by pharmacological stimulation with vasoconstrictor substances, such as angiotensin II, endothelin-1 or the thrombaxne A2 mimetic U-46619 (Wanstall et al., 1995; Russ and Walker, 1993; Roos et al., 1994; Rimar and Gillis, 1995; Persson et al., 1994; Liu et al., 1991a,b; Hasunuma et al., 1991; Ferrario et al., 1996; Adnot et al., 1991). In isolated rat lungs, increases in flow associated with the simultaneous elevation of arterial and venous pressures (so that the transpulmonary gradient is maintained constant) were inhibited by L-NAME (Barnard et al., 1993), consistent with a role of NO in buffering increases in pulmonary perfusion pressure. However, against such a role is the observation that chronic inhibition of NO production by L-NAME for three weeks in normal rats reduced cardiac output and increased systemic arterial pressure, without affecting pulmonary pressure (Hampl et al., 1996; Hampl et al., 1993). In the same experiments, the perfusion pressure-flow relationship of isolated lungs was only mildly shifted upwards by long-term L-NAME, much less than that of animals subjected to chronic hypoxia. Moreover, chronic hypoxia, but not L-NAME administration, caused hypertensive pulmonary remodeling whereas long-term supplementation with the NO precursor, L-arginine did not prevent these changes in the hypoxic animals (Hampl et al., 1996). The modest role of NO in the maintenance of normal pulmonary hemodynamics was further underscored by recent studies of targeted disruption of the endogenous NOS III gene in mice (Steudel et al., 1997). These mice exhibited only mild increases in pulmonary arterial pressure, associated with increased pulmonary vascular resistance measured in vivo, but no noticeable morphological abnormalities of the pulmonary vasculature. In conclusion, despite the evidence that there is substantial basal NO production by the normal pulmonary circulation, the current weight of evidence would support only a modest contribution in the maintenance of the normally low basal pulmonary vascular resistance. Rather, it appears that NO may play a more significant role in attenuating increases in pulmonary vascular tone in response to pharmacological of pathophysiological stimuli that result in pulmonary hypertension.
268
JOCELYN DUPUIS ET AL
Role Of NO In Acute Hypoxic Pulmonary Vasoconstriction Acute hypoxia causes pulmonary vasoconstriction resulting in increased pulmonary arterial pressures and is often used as a constrictor stimulus in the evaluation of pulmonary vascular reactivity. Acute hypoxic pulmonary vasoconstriction is also of considerable clinical importance because of the numerous pathological conditions which produce hypoxia, including respiratory distress syndromes in newborns and adults, pulmonary edema, pulmonary embolism, and pneumonia, just to name a few. A number of studies have suggested that hypoxic vasoconstriction is dependent on the presence of an intact endothelium (Rubanyi and Vanhoutte, 1988; Rodman et al., 1997; Hoshino et al., 1988; Holden and McCall, 1984), consistent with a contribution of reduced NO production (or activity) to hypoxic pulmonary hypertension. In isolated rat pulmonary arteries, the inhibition of EDRF production mimics effect of hypoxia (Rodman et al., 1990), and hypoxic vessels contain lower levels of cGMR Moreover, these hypoxic vessels exhibited reduced responsiveness to acetylcholine, whereas relaxation in response to authentic NO or 8-bromo-cGMP was preserved. In contradistinction to these findings in isolated vessels, there is general consensus that in intact lungs in vitro or in vivo, withdrawal of NO does not contribute vasoconstriction in response to acute hypoxia, but rather its release may attenuate the increase in pulmonary vascular tone (Sprague et al., 1992; Robertson et al., 1990; Persson et al., 1990; Nelin et al., 1996; Nelin and Dawson, 1993; Blitzer et al., 1996; Archer et al., 1989). Indeed, acute hypoxia is associated with an increase, not a decrease, in NO release into the perfusate of isolated rat lungs (Wang et al., 1995). The mechanism of increased NO production is unknown but could be related to the increase in shear stress caused by the hypoxic constriction (Hakim, 1994; Barnard et al., 1993). Moreover, the pharmacological stimulation of NO release by acetylcholine, bradykinin or A-23187 (McMurtry, 1985; Archer et al., 1990), as well as the administration of authentic NO itself (Frostell et al., 1993; Archer et al., 1990), reduces hypoxic vasoconstriction, pointing to a potential therapeutic role for NO in the treatment of pulmonary hypertension in this condition. The L-arginine-NO Pathway In Experimental Models Of Pulmonary Hypertension Rats exposed to hypoxia for a period of three weeks or more develop pulmonary hypertension with structural remodeling of the pulmonary arteries in the form of concentric hypertrophy. This model is particularly relevant to pulmonary hypertension which develops in patients with chronic obstructive pulmonary disease (normobaric hypoxia) and to the less frequent condition of high altitude pulmonary hypertension (hypobaric hypoxia). The model of hypoxic pulmonary hypertension in rats has, therefore, been extensively utilized to study the potential pathophysiological role of NO in pulmonary hypertension. While there is general agreement that the L-arginine-NO pathway plays an important role in the modulation of pulmonary vascular tone in response to chronic hypoxia, there is more controversy surrounding nature of this modulation. Some investigators have reported reduced NO production or activity (Rodman et al., 1990; Maruyama and Maruyama, 1994; Eddahibi et al., 1992; Carville et al., 1993; Adnot et al., 1991), whereas others have demonstrated preserved and even enhanced NO activity (Wanstall et al., 1995; Russ and Walker, 1993; Resta and Walker, 1994; Oka et al., 1993; Isaacson et al., 1994; Hampl et al., 1993; Barer et al., 1993). Several hypotheses have been advanced in an effort to reconcile these apparent discrepancies, including differences in species, experimental conditions, duration of hypoxia, and data from intact lungs versus isolated pulmonary vessels. For example, many of the studies demonstrating reduced NO activity were performed using isolated pulmonary conduit arteries (Rodman et al., 1990; Maruyama and Maruyama, 1994; Eddahibi et al., 1992; Carville et al., 1993), and thus may not faithfully predict the behaviour of the small arteries that determine the resistance of the intact pulmonary vascular bed. In isolated lungs, a reduction in NO activity was described in one report (Adnot et al., 1991), however, this has not been
PULMONARY HYPERTENSION
269
reproduced in the majority of studies (Resta and Walker, 1996; Russ and Walker, 1993; Resta and Walker, 1994; Oka et al, 1993; Hampl et al., 1993; Barer et al., 1993) in which NO activity has been found to be preserved or increased during long-term exposure to hypoxia, serving to attenuate increases in pulmonary vascular tone. As well, increased levels of NOX (NO, NO2, and NO3) have been recovered from the pulmonary effluent of chronically hypoxic rats (Isaacson et al., 1994). This was associated with increased NOS activity as determined by conversion of 3H-Larginine to 3H-L-citrulline (Shaul et al., 1995) in the lung homogenates, and increased expression of NOS III mRNA and protein (Xue and Johns, 1996; Shaul et al., 1995). Others have confirmed the upregulation of NOS III expression in the rat chronic hypoxia model of pulmonary hypertension (Le Cras et al., 1996; Xue et al., 1994), and increased expression of NOS III protein has been shown by immunostaining to be tightly correlated with the development of vascular hypertrohy in hypoxic pulmonary hypertension (Xue and Johns, 1996). Monocrotaline (MCT) is an alkaloid derivative which in rats is metabolized by the liver to dehydromonocrotaline, a substance highly toxic to pulmonary vascular endothelium. Rats injected with MCT develop pulmonary hypertension due predominantly to increased precapillary vascular resistance, right ventricular hypertrophy and medial hypertrophy of pulmonary arteries that are well established after three weeks. Large hilar pulmonary arteries from MCT-treated animals demonstrate impaired endotheliumdependent dilation to ADP, A23187 and acetylcholine (Mathew et al., 1995), which was not reversed by Larginine or superoxide dismutase suggesting that neither a deficiency of the substrate for NOS, nor inactivation of NO by free radicals, contributed to the apparent reduction in NO activity. Isolated pulmonary intralobar arteries (~700 µm in diameter) exhibited preserved but reduced relaxation in response to acetylcholine (Madden et al., 1994). This decrease in endothelium-dependent dilation was interpreted as being due to reduced arterial distensibility secondary to vascular remodeling rather than a decrease in the release or activity of NO (Madden et al., 1994). This is consistent with the observation in the same model, that the inhibition of NO synthesis by L-NAME caused a greater decrease in pulmonary artery diameter in vessels from MCT-treated compared with those from normal rats (Madden et al., 1995). Moreover, in intact isolated lungs from MCT-treated rats perfused at constant flow and preconstricted by hypoxia, there was an increase in responsiveness to acetlycholine (Archer et al., 1990) suggesting an increase in receptor-mediated stimulation of NO production in this model of pulmonary hypertension. Recently, it has also been shown that immunoreactive NOS III was increased in pulmonary arterial endothelium of lungs from MCT-treated animals compared to control rats (Resta et al., 1997), whereas there was no change in NOS III expression in pulmonary veins. Therefore, it is hard on the face of the evidence reviewed here to conclude that a decrease in endothelial NO production or activity underlies pulmonary hypertension in the animal models most thoroughly investigated. Rather, it is possible that in these animal models of pulmonary hypertension, the NO-Larginine pathway may in fact be upregulated perhaps as a mechanism of compensation, serving to buffer increases in pulmonary vascular resistance and attenuate the degree of elevation in pulmonary arterial pressures. Thus, although a defect in the NO system may not be a primary cause of pulmonary hypertension in these models, it could be argued that in more advanced states of pulmonary hypertension there is a relative deficit of NO activity since clearly there is failure of this compensatory mechanism. It follows that various means of increasing NO production or activity could represent potentially useful therapeutic strategies for the treatment of pulmonary hypertension.
270
JOCELYN DUPUIS ET AL
The L-arginine-NO Pathway in Human Pulmonary Hypertension The first report of endothelium-dependent dilation of human pulmonary arteries appeared in 1987 (Greenberg et al., 1987). Relatively normal segments of pulmonary arteries obtained from patients undergoing surgery for removal of malignant tumors exhibited relaxation to acetylcholine that was abolished by removal of the endothelium (Greenberg et al., 1987). In normal humans, the systemic administration of the inhibitor of NO synthesis, L-NMMA (300 mg i.v.) produced increases in systemic and pulmonary vascular resistance, resulting in a modest increase in pulmonary arterial pressures (Stamler et al., 1994; Blitzer et al., 1996). Although, in part, the increases in pulmonary vascular resistance might have occurred passively as a consequence of the decrease in cardiac output caused by the increased afterload, the increase in pulmonary artery pressure stongly supports a contribution of NO to basal pulmonary vascular tone. Another recent study was designed to exclude the passive influence of changes in systemic hemodynamics on the pulmonary circulation by direct infusion of L-NMMA and acetylcholine into a branch of the pulmonary artery, measuring changes in pulmonary blood flow using a doppler flow wire (Cooper et al., 1996). Infusion of acetylcholine produced a dose-dependent increase in pulmonary blood flow while LNMMA caused a reduction, demonstrating that normal basal pulmonary vascular tone is influenced by a continuous local release of NO by the pulmonary vasculature (Cooper et al., 1996). The acute hypoxic increase in pulmonary arterial pressures in humans, as in animals, is also attenuated by endothelium-derived NO, again consistent with role for this vasodilator mediator as a counter-regulatory mechanism (Blitzer et al., 1996). In healthy subjects, infusion of the NO substrate, L-arginine, did not significantly modify pulmonary hemodynamics (Mehta et al., 1995). However, in a small group of patients with various forms of pulmonary hypertension, L-arginine infusion for 30 minutes caused a 15.8±3.6% reduction in pulmonary arterial pressure and a 27.6±5.8% reduction in pulmonary vascular resistance (Mehta et al., 1995). In subgroup analysis it was noted that patients with secondary causes of pulmonary hypertension (nearly all of which had heart failure), were particularly responsive to L-arginine infusion while those with primary or scleroderma pulmonary hypertension showed little response. The same authors demonstrated that the infusion of L-arginine was accompanied by an increase in circulating levels of L-citrulline, the immediate product of L-arginine metabolism by NOS (Mehta et al., 1995), and by an increase in exhaled NO (Mehta et al., 1996). Peak levels of L-citrulline, but not L-ornithine (the direct metabolite of L-arginine by the hepatic urea cycle) correlated with the reduction in pulmonary pressures, however, somewhat counterintuitively the basal L-arginine levels correlated inversely rather than directly with pulmonary hemodynamic responsiveness (Mehta et al., 1995). None-the-less, it appears that L-arginine has potent short-term vasodilating effects in some patients with pulmonary hypertension that is mediated at least in part through increased endogenous production of NO. Although pulmonary hypertension in humans does not appear to be related to a systemic decrease in L-arginine availability, reduced cellular transport of Larginine (Durante et al., 1996; Bogle et al., 1996) or endogenous inhibitors of NO synthesis (Vallance et al., 1992) may be contributing factors. As well, it is possible that, as a result of an upregulation of NOS activity as part of a compensatory mechanism, any limitation in NO availability is aggravated by increased L-arginine utilization. Isolated pulmonary vascular rings taken from patients with chronic obstructive pulmonary disease exhibited reduced basal and receptor mediated endothelium-dependent dilation (Dinh-Xuan et al., 1991), but preserved responses to endothelium-independent, NO donor compound, sodium nitroprusside. The magnitude of impairment in endothelium-dependent dilation correlated with the severity of intimai hypertrophy and the degree of hypoxia, based on measurements of oxygen partial pressure in arterial blood (Dinh-Xuan et al., 1991), suggesting a link between endothelial dysfunction and disease severity. Similarly, the same group has shown that pulmonary arteries from patients with Eisenmenger’s syndrome also have
PULMONARY HYPERTENSION
271
reduced response to acetylcholine, even exhibiting paradoxical vasoconstriction at higher concentrations (Dinh Xuan et al., 1990). Consistent with these functional observations in larger pulmonary arteries, it has been reported that there is reduced expression of NOS III protein by immunostaining and mRNA by in situ hybridization in lungs from patients with pulmonary hypertension of various etiologies (Giaid and Saleh, 1995) in proportion to the severity of hypertensive morphological vascular abnormalities. In particular, the most severe cases, i.e. those associated with plexiform lesions, exhibited very little NOS III expression (Giaid and Saleh, 1995). However, as with animal models of pulmonary hypertension, there is not yet general agreement concerning the pathophysiological role of reduced NO activity in human pulmonary hypertension. Another study in a similar group of patients with pulmonary hypertension (Xue and Johns, 1995), reported an increase in NOS III immunoreactivity in pulmonary vascular endothelium, rather than a decrease, even in patients with severe primary pulmonary hypertension. Clearly, more studies in humans with pulmonary hypertension are required to resolve this controversy. It is perhaps worthwhile to note, as reviewed in the previous sections, that in animals studies a pattern is emerging supporting increases in NO synthesis in pulmonary hypertension in the smaller precapillary resistance vessels likely as a mechanism of compensation, whereas endothelium-dependent dilation in larger conduit pulmonary arteries appears to be reduced, possibly secondary to the effects of increased pulmonary arterial pressure and pulsatility. The limited data available to date from clinical studies is not necessarily incompatible with a similar interpretation. THERAPEUTIC CONSIDERATIONS From the above discussion we can conclude that the L-arginine-NO pathway likely plays a critical role in pulmonary hypertension; either in the case of a primary impairment in endothelial NO production or activity, or a relative deficiency, in which case the NO system acts as a failed mechanism of compensation. In any event, strategies to increase pulmonary vascular NO activity should be beneficial in the treatment of this condition. The simplest approach is the systemic administration of NO-donor compounds such as sodium nitroprusside or nitroglycerin. The obvious limitation in the therapeutic utility of these compounds is their profound effects on systemic arterial pressures. Patients with severe pulmonary hypertension are often in a delicate balance of hemodynamic compensation, which can be easily upset by systemic vasodilation, sometimes with fatal consequences. Alternate pharmacological approaches have been tested in experimental models, including the delivery of inhibitors of phospodiesterase via the tracheobronchial tree to elevate pulmonary cGMP (Ichinose et al., 1995), or the direct inhalation of analogues of cGMP (Lawson et al., 1995). In addition, the infusion of L-arginine, as discussed above, has been applied therapeutically to a limited number of clinical situations, including persistent pulmonary hypertension of the new born (McCaffrey et al., 1995) and pulmonary hypertension complicating heart failure. Newer NO donor compounds have also been tested in experimental models of pulmonary hypertension (Vanderford et al., 1994), but their potential clinical utility remains to be explored. The ideal pharmacological agent will deliver NO only to the pulmonary circulation. Being a gas, it is highly feasible to deliver NO by inhalation. It is beyond the scope of this manuscript to review the extensive literature which has developed recently on the therapeutic utility of inhaled NO. A more detailed analysis can be found in several recent reviews of the topic (Adnot and Raffestin, 1996). This treatment modality is now being commonly used in the management of pulmonary hypertension in several clinical situations including, persistent pulmonary hypertension of the newborn (Kinsella and Abman, 1993; Kinsella et al., 1992; Roberts et al., 1992; Abman, 1995; Lönnqvist et al., 1994), pulmonary hypertension following cardiac surgery (Shah et al., 1995; Ivy et al., 1996; Breuer et al., 1995; Beghetti et al., 1995; Journois et al.,
272
JOCELYN DUPUIS ET AL
1994; Rich et al., 1993; Haydar et al., 1992), respiratory distress syndrome (Pappert et al., 1995; Gerlach et al., 1993), among others (Channick et al., 1994; Weitzberg et al., 1993; Scherrer et al., 1996; Williamson et al., 1996). This approach has also been applied to the screening of pulmonary hypertension (Adatia et al., 1995; Sitbon et al., 1995) to establish vasodilator reserve either in evaluation of patients with primary disease (Sitbon et al., 1995), or in patients awaiting heart transplantation for heart failure (Adatia et al., 1995). Its therapeutic utility in patients with pulmonary hypertension of nonreversible causes, such as in primary pulmonary hypertension, is in question since the withdrawal of inhaled NO can precipitate a rebound increase in pulmonary vascular resistance (Lavoie et al., 1996; Miller et al., 1995), leading to destabilization of the delicate hemodynamic balance and fatalities have been reported (Partanen and Nieminen, 1995). However, inhaled NO has been successfully used as a bridge to transplantation in such cases (Snell et al., 1995). In the case of primary pulmonary hypertension in particular, the therapeutic challenge is to provide increases in NO activity selectively in the pulmonary circulation for prolonged periods, possibly for life. Strategies have been developed for delivery of long-term inhaled NO to patients with primary pulmonary hypertension in an ambulatory setting (Channick et al., 1996), but role in the treatment of the devastating condition remains to be established. In future, a gene therapy approach might offer the advantage of continuous overproduction of NO in the lung, at least for the period of transgene expression. Adenoviralmediated transfer of endothelial NOS through the tracheobronchial tree has been shown to reduce hypoxic vasoconstriction in rats (Janssens et al., 1996), without affecting systemic arterial pressure. However, adenoviral-mediated gene transfer may have limited therapeutic utility clinically due to the inflammatory response induced by viral proteins and relatively short duration of transgene expression (Lemarchand et al., 1993). Newer adenoviral constructs may overcome these limitations, or nonviral approaches to gene transfer in the lung may provide alternate approaches in the development of more clinically relevant gene transfer strategies for the treatment of pulmonary hypertension. REFERENCES Abenhaim, L., Moride, Y, Brenot, F. et al. (1996) Appetite suppressant drugs and the risk of primary pulmonary hypertension. N. Engl. J. Med., 335, 609–616. Abman, S.H. (1995) Inhaled nitric oxide therapy of severe neonatal pulmonary hypertension. Acta Anaesthesiol. Scand., 39 (Suppl. 105), 65–68. Adatia, L, Perry, S., Landzberg, M., Moore, P., Thompson, J.E. and Wessel, D.L. (1995) Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J. Am. Coll. Cardiol, 25, 1656–1664. Adnot, S., Raffestin, B., Eddahibi, S., Braquet, P. and Chabrier, P.-E. (1991) Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J.Clin. Invest., 87, 155– 162. Adnot, S. and Raffestin, B. (1996) Pulmonary hypertension: NO therapy? Thorax, 51, 762–764. Archer, S.L., Tolins, J.P., Raij, L. and Weir, E.K. (1989) Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. Biochem. Biophys. Res. Commun., 164, 1198–1205. Archer, S.L., Rist, K., Nelson, O.P., DeMaster, E.G., Cowan, N.J. and Weir, E.K. (1990) Comparison of the hemodynamic effects of nitric oxide and endothelium-dependent vasodilators in intact lungs. J. Appl. Physiol, 68, 735–747. Barer, G., Emery, C., Stewart, A., Bee, D. and Howard, P. (1993) Endothelial control of the pulmonary circulation in normal and hypoxic rats. J. Physiol, 463, 1–16. Barnard, J.W., Wilson, P.S., Moore, T.M., Thompson, W.J. and Taylor, A.E. (1993) Effect of nitric oxide and cyclooxygenase products on vascular resistance in dog and rat lungs. J. Appl Physiol, 74, 2940–2948.
PULMONARY HYPERTENSION
273
Barst, R.J., Rubin, L.J., Long, W.A. et al., (1996) A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N.Engl. J.Med., 334, 296–301. Beghetti, M., Habre, W., Friedli, B. and Berner, M. (1995) Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br. Heart J., 73, 65–68. Blitzer, M.L., Loh, E., Roddy, M.A., Stamler, J.S. and Creager, M.A. (1996) Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans. J. Am. Coll Cardiol, 28, 591–596. Bogle, R.G., Baydoun, A.R., Pearson, J.D. and Mann, G.E. (1996) Regulation of L-arginine transport and nitric oxide release in supervised porcine aortic endothelial cells. J.PhysioL (Lond.), 490, 229–241. Breuer, J., Sieverding, L. and Apitz, J. (1995) Postoperative therapy with low-dose nitric oxide inhalation in an infant with cardiogenic pulmonary hypertension. ACP, 5, 147–151. Carville, C., Raffestin, B., Eddahibi, S., Blouquit, Y. and Adnot, S. (1993) Loss of endothelium-dependent relaxation in proximal pulmonary arteries from rats exposed to chronic hypoxia: Effects of in vivo and in vitro supplementation with L-arginine. J.Cardiovasc. Pharmacol, 22, 889–896. Catravas, J.D., Toivonen, H.J., Orfanos, S.E. and Chen, X. (1992) Endothelial function in pulmonary vascular disease. In: The diagnosis and treatment of pulmonary hypertension, edited by Weir, E.K., Archer, S.L. and Reeves, J.T., pp. 95–109. Mount Kisco: Futura. Chand, N. and Altura, B.M. (1981) Acetylcholine and bradykinin relax intrapulmonary arteries by acting on endothelial cells. Science, 213, 1376–1379. Channick, R.N., Hoch, R.C., Newhart, J.W., Johnson, F.W. and Smith, C.M. (1994) Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis. Am. J.Respir. Crit. Care Med., 149, 811–814. Channick, R.N., Newhart, J.W., Johnson, F.W, Williams, P.J., Auger, W.R., Fedullo, P.P. and Moser, K.M. (1996) Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension—An ambulatory delivery system and initial clinical tests. Chest, 109, 1545–1549. Cherry, P.D., Furchgott, R.R, Zawadzski, J.V. and Jothianandan, D. (1982) Role of endothelial cells in relaxation of isolated arteries to bradykinin. Proc. Natl. Acad. Sci. USA, 79, 2106–2110. Christman, B.W., McPherson, C.D., Newman, J.H., King, G.A., Bernard, G.R., Groves, B.M. and Loyd, I.E. (1992) An imbalance between excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension . N.Engl. J.Med., 327, 70–75. Cohen, A.H., Hanson, K., Morris, K., Fouty, B., McMurtry, I.F., Clarke, W. and Rodman, D.M. (1996) Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest, 97, 172–179. Cooper, C.J., Landzberg, M.J., Andersen, T.J., Charbonneau, F., Creager, M.A., Ganz, P. and Selwyn, A.P. (1996) Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation, 93, 266–271. Cremona, G., Higenbottam, T., Takao, M., Hall, L. and Bower, E.A. (1995) Exhaled nitric oxide in isolated pig lungs. J.Appl Physiol, 78, 59–63. Dillon, W.C., Hampl, V., Shultz, P.J., Rubins, J.B. and Archer, S.L. (1996) Origins of breath nitric oxide in humans. Chest, 110, 930–938. Dinh Xuan, A.T., Higenbottam, T.W., Clelland, C, Pepke-Zaba, J., Cremona, G. and Wallwork, J. (1990) Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger’s syndrome. Br. J.Pharmacol., 99, 9–10. Dinh-Xuan, A.T., Higenbottam, T.W., Clelland, C.A., Pepke-Zaba, J., Cremona, G., Butt, A.Y., Large, S.R., Wells, F.C. and Wallwork, J. (1991) Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N.Engl. J.Med., 324, 1539–1547. Durante, W., Liao, L., Iftikhar, L, O’Brien, WE. and Schafer, A.L (1996) Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium. Circ. Res., 78, 1075– 1082. Eddahibi, S., Adnot, S., Carville, C., Blouquit, Y. and Raffestin, B. (1992) L-Arginine restores endotheliumdependent relaxation in pulmonary circulation of chronically hypoxic rats. Am. J.Physiol. Lung Cell. Mol. Physiol, 263, L194– L200.
274
JOCELYN DUPUIS ET AL
Ferrario, L., Amin, H.M., Sugimori, K., Camporesi, E.M. and Hakim, T.S. (1996) Site of action of endogenous nitric oxide on pulmonary vasculature in rats. Pflugers Arch., 432, 523–527. Frostell, C.G., Blomqvist, H., Hedenstierna, G., Lundberg, J. and Zapol, W.M. (1993) Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology, 78, 427–35. Furchgott, R.F. and Zawadzski, J.V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle to acetylcholine. Nature, 288, 373–376. Fuster, V., Steele, P.M., Edwards, W.D., Gersh, B.J., McGoon, M.D. and Frye, R.L. (1984) Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation, 70, 580–587. Gerlach, H., Rossaint, R., Pappert, D. and Falke, K.J. (1993) Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur. J.Clin. Invest., 23, 499–502. Giaid, A., Yanagisawa, M., Langleben, D., Michel, R., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W.P. and Stewart, D.J. (1993) Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N.Engl. J.Med., 328, 1732–1739. Giaid, A. and Saleh, D. (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N.Engl. J.Med., 333, 214–221. Greenberg, B., Rhoden, K. and Barnes, P.J. (1987) Endothelium-dependent relaxation of human pulmonary arteries. Am. J.Physiol, 252, H434-H438. Griffith, T.M., Edwards, D.H., Davies, R.L.I., Harrison, TJ. and Evans, K.T. (1987) EDRF coordinates the behaviour of vascular resistance vessels. Nature, 329, 442–445. Gruetter, C.A. and Lemke, S.M. (1986) Bradykinin-induced endothelium-dependent relaxation of bovine intrapulmonary artery and vein. Biochem. Biophys. Res. Commun., 122, 363–367. Gustafsson, L.E., Leone, A.M., Persson, M.G., Wiklund, N.P. and Moncada, S. (1991) Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun., 181, 852–857. Hakim, T.S. (1994) Flow-induced release of EDRF in the pulmonary vasculature: Site of release and action. Am. J.Physiol. Heart Circ. Physiol, 267, H363-H369. Hampl, V., Archer, S.L., Nelson, D.P. and Weir, E.K. (1993) Chronic EDRF inhibition and hypoxia: Effects on pulmonary circulation and systemic blood pressure. J. Appl. Physiol, 75, 1748–1757. Hampl, V., Tristani-Firouzi, M, Nelson, D.R and Archer, S.L. (1996) Chronic infusion of nitric oxide in experimental pulmonary hypertension: pulmonary pressure-flow analysis. Eur. Respir. J., 9, 1475–1481. Hasunuma, K., Yamaguchi, T., Rodman, D.M., O’Brien, R.F. and McMurtry, I.F. (1991) Effects of inhibitors of EDRF and EDHF on vasoreactivity of perfused rat lungs. Am.J.Physiol. Lung Cell. Mol. Physiol, 260, L97–L104. Haydar, A., Malhere, T., Mauriat, P., Journois, D., Pouard, P., Denis, N., Lefèbvre, D., Safran, D. and Vouhé, P. (1992) Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects. Lancet, 340, 1545. Holden, W.E. and McCall, E. (1984) Hypoxia-induced contractions of porcine pulmonary artery strips depend on intact endothelium. Exp. Lung Res., 7, 101–112. Hoshino, Y., Obara, H., Kusunoki, M., Fujii, Y. and Iwai, S. (1988) Hypoxic contractile response in isolated human pulmonary artery: role of calcium ion. J.Appl. Physiol., 65, 2468–2474. Ichinose, K, Adrie, C, Hurford, W.E. and Zapol, W.M. (1995) Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J. Appl. Physiol, 78, 1288–1295. Ignarro, L.J., Byrns, R.E., Buga, G.M. and Wood, K.S. (1987a) Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacological and chemical properties identical to those of nitric oxide. Circ. Res., 61, 866–879. Ignarro, L.J., Byrns, R.E. and Wood, K.S. (1987b) Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ. Res., 60, 82–92. Isaacson, T.C., Hampl, V., Weir, E.K., Nelson, D.P. and Archer, S.L. (1994) Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J. Appl. Physiol., 76, 933–940.
PULMONARY HYPERTENSION
275
Ivy, D.D., Kinsella, J.P., Wolfe, R.R. and Abman, S.H. (1996) Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease. Am. J.Cardiol, 11, 102–105. Janssens, S.P., Bloch, K.D., Nong, Z.X., Gerard, R.D., Zoldhelyi, P. and Collen, D. (1996) Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J. Clin. Invest., 98, 317–324. Jones, R., Langleben, D. and Reid, L.M. (1991) Patterns and mechanisms of remodelling of the pulmonary circulation in acute and subacute lung injury. In: The pulmonary circulation and acute lung injury, edited by Said, S.L, pp. 179–242. Mount Kisco: Futura. Journois, D., Pouard, P., Mauriat, P., Malhère, T., Vouhé, P. and Safran, D. (1994) Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J.Thorac.Cardiovasc. Surg., 107, 1129–1135. Kimberly, B., Nejadnik, B., Giraud, G.D. and Holden, W.E. (1996) Nasal contribution to exhaled nitric oxide at rest and during breathholding in humans. Am. J.Respir. Crit. Care Med., 153, 829–836. Kinsella, J.P., Neish, S.R., Shaffer, E. and Abman, S.H. (1992) Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet, 340, 819–820. Kinsella, J.P. and Abman, S.H. (1993) Inhalational nitric oxide therapy for persistent pulmonary hypertension of the newborn. Pediatrics, 91, 997–998. Lavoie, A., Hall, J.B., Olson, D.M. and Wylam, M.E. (1996) Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am.J.Respir. Crit. Care Med., 153, 1985–1987. Lawson, C.A., Smerling, A.J., Naka, Y, Burkhoff, D., Dickstein, M.L., Stern, D.M. and Pinsky, D.J. (1995) Selective reduction of PVR by inhalation of a cGMP analogue in a porcine model of pulmonary hypertension. Am. J.Physiol. Heart Circ. Physiol., 268, H2056–H2062. Le Cras, T.D., Xue, C., Rengasamy, A. and Johns, R.A. (1996) Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am. J. Physiol. Lung Cell. Mol. Physiol., 270, L164-L170. Lemarchand, P., Jones, M., Yamada, I. and Crystal, R.G. (1993) In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ. Res., 12, 1132– 1138. Lindeborg, D.M., Kavanagh, B.P., Van Meurs, K. and Pearl, R.G. (1995) Inhaled nitric oxide does not alter the longitudinal distribution of pulmonary vascular resistance. J. Appl Physiol, 78, 341–348. Liu, S.F., Crawley, D.E., Barnes, P.J. and Evans, B.J. (1991a) Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats. Am. Rev. Respir. Dis., 143, 32–37. Liu, S.F., Crawley, D.E., Evans, T.W. and Barnes, P.J. (1991b) Endogenous nitric oxide modulates adrenergic neural vasoconstriction in guinea-pig pulmonary artery. Br. J.Pharmacol, 104, 565–569. Lönnqvist, P.A., Winberg, P., Lundell, B., Selldén, H. and Olsson, G.L. (1994) Inhaled nitric oxide in neonates and children with pulmonary hypertension. Acta Paediatr., 83, 1132–1136. Lundberg, J.O.N., Lundberg, J.M., Settergren, G., Alving, K. and Weitzberg, E. (1995) Nitric oxide, produced in the upper airways, may act in an ‘aerocrine’ fashion to enhance pulmonary oxygen uptake in humans. Acta Physiol Scand., 155, 467–68. Madden, J.A., Keller, P.A., Effros, R.M., Seavitte, C, Choy, J.S. and Hacker, A.D. (1994) Responses to pressure and vasoactive agents by isolated pulmonary arteries from monocrotaline treated rats. J. Appl. Physiol., 76, 1589–1593. Madden, J.A., Keller, P.A., Choy, J.S., Alvarez, T.A. and Hacker, A.D. (1995) L-arginine-related responses to pressure and vasoactive agents in monocrotaline-treated rat pulmonary arteries. J.Appl. Physiol, 79, 589– 593. Maruyama, J. and Maruyama, K. (1994) Impaired nitric oxide-dependent responses and their recovery in hypertensive pulmonary arteries of rats. Am.J.Physiol. Heart Circ. Physiol, 266, H2476-H2488. Mathew, R., Zeballos, G.A., Tun, H. and Gewitz, M.H. (1995) Role of nitric oxide and endothelin-1 in monocrotalineinduced pulmonary hypertension in rats. Cardiovascular Research, 30, 739–746. McCaffrey, M.J., Bose, C.L., Reiter, P.D. and Stiles, A.D. (1995) Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate, 67, 240–243. McMurtry, I.E. (1985) BAY K8644 potentiates and A23187 inhibits hypoxic vasoconstriction in rat lungs. Am. J. Physiol, 249, H741–H746.
276
JOCELYN DUPUIS ET AL
Mehta, S., Stewart, D.J., Langleben, D. and Levy, R.D. (1995) Short-term pulmonary vasodilation with Larginine in pulmonary hypertension. Circulation, 92, 1539–1545. Mehta, S., Stewart, D.J. and Levy, R.D. (1996) The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest, 109, 1550–1555. Miller, O.I., Tang, S.F., Keech, A. and Celermajer, D.S. (1995) Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet, 346, 51–52. Nelin, L.D., Thomas, C.J. and Dawson, C.A. (1996) Effect of hypoxia on nitric oxide production in neonatal pig lung. Am.J.Physiol Heart Circ. Physiol, 271, H8-H14. Nelin, L.D. and Dawson, C.A. (1993) The effect of N-omega-nitro-L-arginine methylester on hypoxic vasoconstriction in the neonatal pig lung. Pediatr. Res., 34, 349–353. Nichols, W.C., Koller, D.L., Slovis, B. et al. (1997) Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–31. Nature Genet., 15, 277–280. Oka, M., Hasunuma, K., Webb, S.A., Stelzner, T.J., Rodman, D.M. and McMurtry, I.E. (1993) EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am.J.Physiol Lung Cell Mol Physiol, 264, L587– L597. Pappert, D., Busch, T., Gerlach, H., Lewandowski, K., Radermacher, P. and Rossaint, R. (1995) Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology, 82, 1507–1511. Partanen, J. and Nieminen, M.S. (1995) Death of a young woman suffering from primary pulmonary hypertension during inhaled nitric oxide therapy. Arch. Intern. Med., 155, 875–876. Persson, M.G., Gustafsson, L.E., Wiklund, N.P., Moncada, S. and Hedqvist, P. (1990) Endogenous nitric oxide as a probable modulator of pulmonary circulation and hypoxic presser response in vivo. Acta Physiol Scand., 140, 449–57. Persson, M.G., Agvald, P. and Gustafsson, L.E. (1994) Detection of nitric oxide in exhaled air during administration of nitroglycerin in vivo. Br.J.Pharmacol, 111, 825–828. Phillips, C.R., Giraud, G.D. and Holden, W.E. (1996) Exhaled nitric oxide during exercise: Site of release and modulation by ventilation and blood flow. J. Appl Physiol, 80, 1865–1871. Reeves, J.T. and Groves, B.M. (1984) Approach to the patient with pulmonary hypertension. In: Pulmonary hypertension, edited by Weir, E.K. and Reeves, J.T., pp. 1–40. Mount Kisco: Futura Publishing Co. Resta, T.C., Gonzales, R.J., Dail, W.G., Sanders, T.C. and Walker, B.R. (1997) Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am.J.Physiol, 272, H806-H813. Resta, T.C. and Walker, B.R. (1994) Orally administered L-arginine does not alter right ventricular hypertrophy in chronically hypoxic rats. Am.J.Physiol Regul Integr. Comp. Physiol, 266, R559–R563. Resta, T.C. and Walker, B.R. (1996) Chronic hypoxia selectively augments endothelium-dependent pulmonary arterial vasodilation. Am.J.Physiol Heart Circ. Physiol, 270, H888–H896. Rich, G.F., Murphy, G.D., Jr., Roos, C.M. and Johns, R.A. (1993) Inhaled nitric oxide: Selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology, 78, 1028–1035. Rich, S., Kaufman, E. and Levy, PS. (1992) The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. New Engl. J.Med, 327, 76–81. Rimar, S. and Gillis, C.N. (1995) Site of pulmonary vasodilation by inhaled nitric oxide in the perfused lung. J. AppL Physiol., 78, 1745–1749. Roberts, J.D., Polaner, D.M., Lang, P. and Zapol, W.M. (1992) Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet, 340, 818–819. Robertson, B.E., Warren, J.B. and Nye, PC. (1990) Inhibition of nitric oxide synthesis potentiates hypoxic vasoconstriction in isolated rat lungs. Exp. Physiol., 75, 255–257. Rodman, D.M., Yamaguchi, T., Hasunuma, K., O’Brien, R.R and McMurtry, I.F. (1990) Effects of hypoxia on endothelium-dependent relaxation of rat pulmonary artery. Am. J.Physiol. Lung Cell. Mol. Physiol., 258, L207–L214. Rodman, D.M., Yamaguchi, T., Hasunuma, R.F., O’Brien, R.F. and McMurtry, I.F. (1997) Hypoxic contraction of isolated rat pulmonary artery. J. Pharmacol. Exp. Ther., 248, 952–959.
PULMONARY HYPERTENSION
277
Roos, C.M., Rich, G.F., Uncles, D.R., Daugherty, M.O. and Frank, D.U. (1994) Sites of vasodilation by inhaled nitric oxide vs. sodium nitroprusside in endothelin-constricted isolated rat lungs. J.AppL Physiol., 77, 51–57. Rubanyi, G.M. and Vanhoutte, P.M. (1988) Calcium and activation of the release of endothelium-derived relaxing factor. Ann. NY Acad. Sci, 522, 226–233. Rubin, LJ. (1997) Primary Pulmonary Hypertension. N.Engl. J.Med., 336, 111–117. Russ, R.D. and Walker, B.R. (1993) Maintained endothelium-dependent pulmonary vasodilation following chronic hypoxia in the rat. J. Appl Physiol., 74, 339–344. Scherrer, U., Vollenweider, L., Delabays, A., Savcic, M., Eichenberger, U., Kleger, G.R., Fikrle, A., Ballmer, P.E., Nicod, P. and Bärtsch, P. (1996) Inhaled nitric oxide for high-altitude pulmonary edema. N.Engl. J.Med., 334, 624–629. Shah, A.S., Smerling, A.J., Quaegebeur, J.M. and Michler, R.E. (1995) Nitric oxide treatment for pulmonary hypertension after neonatal cardiac operation. Ann. Thorac. Surg., 60, 1791–1793. Shaul, P.W., North, A.J., Brannon, T.S., Ujiie, K., Wells, L.B., Nisen, P.A., Lowenstein, C.J., Snyder, S.H. and Star, R.A. (1995) Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am.J.Respir. Cell Mol. Biol, 13, 167–174. Sitbon, O., Brenot, F, Denjean, A., Bergeron, A., Parent, F, Azarian, R., Herve, P., Raffestin, B. and Simonneau, G. (1995) Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: A dose-response study and comparison with prostacyclin. Am.J.Respir. Crit. Care Med., 151, 384–389. Snell, G.I., Salamonsen, R.F, Bergin, P., Esmore, D.S., Khan, S. and Williams, T.J. (1995) Inhaled nitric oxide used as a bridge to heart-lung transplantation in a patient with end-stage pulmonary hypertension. Am. J.Respir. Crit. Care Med., .151, 1263–1266. Sprague, R.S., Thiemermann, C. and Vane, J.R. (1992) Endogenous endothelium-derived relaxing factor opposes hypoxic pulmonary vasoconstriction and supports blood flow to hypoxic alveoli in anesthetized rabbits. Proc. Natl. Acad. Sci USA, 89, 8711–8715. Spriestersbach, R., Grimminger, F, Weissmann, N., Walmrath, D. and Seeger, W. (1995) On-line measurement of nitric oxide generation in buffer-perfused rabbit lungs. J.Appl Physiol., 78, 1502–1508. Stamler, J.S., Loh, E., Roddy, M.A., Currie, K.E. and Creager, M.A. (1994) Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation, 89, 2035–2040. Steudel, W., Ichinose, F, Huang, PL., Hurford, WE., Jones, R.C., Bevan, J.A., Fishman, M.C. and Zapol, W.M. (1997) Pulmonary vasoconstriction and hypertension in mice with targeted disruption of endothelial nitric oxide synthase (NOS 3) gene. Circ. Res., 81, 34–1. Stewart, D.J., Levy, R.D., Cernacek, P. and Langleben, D. (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med., 114, 464–469. Thusu, K.G., Morin, F.C., III, Russell, J.A. and Steinhorn, R.H. (1995) The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitre oxide. Am.J.Respir. Crit. Care Med., 152, 1605–1610. Vallance, P., Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J.Cardiovasc. Pharmacol., 20 Suppl. 12, S60-S62. Vanderford, P.A., Wong, J., Chang, R., Keefer, L.K., Soifer, S.J. and Fineman, J.R. (1994) Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs.J.Cardiovasc. Pharmacol., 23, 113–119. Voelkel, N.F, Tuder, R.M. and Weir, E.K. (1997) Pathophysiology of primary pulmonary hypertension:from physiology to molecular mechanisms. In: Primary pulmonary hypertension, edited by Rubin, L.J. and Rich, S., pp. 83–133. New York: Marcel Dekker. Wang, D., Hsu, K., Hwang, C.-P. and Chen, H.I. (1995) Measurement of nitric oxide release in the isolated perfused rat lung. Biochem. Biophys. Res. Commun., 208, 1016–1020. Wanstall, J.C., Hughes, I.E. and O’Donnell, S.R. (1995) Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br.J.Pharmacol, 114, 109–114. Weir, E.K. and Archer, S.L. (1957) The mechanism of acute hypoxic vasoconstriction. FASEB J., 9, 183–189.
278
JOCELYN DUPUIS ET AL
Weitzberg, E., Rudehill, A. and Lundberg, J.M. (1993) Nitric oxide inhalation attenuates pulmonary hypertension and improves gas exchange in endotoxin shock. Eur.J.Pharmacol., 233, 85–94. Williamson, D.J., Hayward, C., Rogers, P., Wallman, L.L., Sturgess, A.D., Penny, R. and Macdonald, P.S. (1996) Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation, 94, 477–482. Xue, C., Rengasamy, A., Le Cras, T.D., Koberna, P.A., Dailey, G.C. and Johns, R.A. (1994) Distribution of NOS in normoxic vs. hypoxic rat lung: Upregulation of NOS by chronic hypoxia. Am.J.Physiol. Lung Cell. Mol. Physiol., 267, L667–L678. Xue, C. and Johns, R.A. (1995) Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N.Engl J. Med., 333, 1642 Xue, C. and Johns, R.A. (1996) Upregulation of nitric oxide synthase correlates temporally with onset of pulmonary vascular remodeling in the hypoxic rat. Hypertension, 28, 743–753.
16 Atherosclerosis: Role of NO John P.Cooke and Philip S.Tsao Division of Cardiovascular Medicine, Stanford University, Stanford, CA, USA
INTRODUCTION The most common cause of morbidity and mortality in Europe and the United States is atherosclerosis, a clinical entity that most physicians will deal with frequently in their practice. Atherosclerosis is a complex process that is thought to be initiated by a “response to injury” of the endothelium (Ross, 1997). The specific injuries that precipitate atherogenesis are not known, although risk factors have been identified. These include hypercholesterolemia, hypertension, diabetes mellitus, and tobacco use. Another important risk factor is a family history of premature atherosclerosis (i.e., first-degree relatives who have incurred myocardial infarction or stroke under the age of 60). This risk factor likely represents predisposing genetic factors that have not yet been elucidated. In addition to these traditional risk factors, there is accumulating evidence that elevated plasma levels of lipoprotein(a) and homocysteine also accelerate the process of atherosclerosis. Finally, obesity, type A personality, and sedentary lifestyle predispose to adverse vascular events (e.g., myocardial infarction). Elevated levels of serum cholesterol seem to be necessary for the progression of atherosclerosis. In countries where dietary intake of cholesterol and serum cholesterol levels are low, myocardial infarctions are much less common than in countries where individuals consume a Western diet and have higher cholesterol levels. It is the low-density lipoprotein (LDL) fraction of serum cholesterol that is positively correlated with adverse vascular events. Elevated levels of LDL cholesterol (particularly oxidized LDL) perturb the cell membrane, alter permeability and secretion, and are associated with the expression of intercellular adhesion molecules, cytokines, and growth factors. Recent evidence suggests that specific glycoprotein adhesion molecules
280
JOHN P.COOKE AND PHILIP S.TSAO
(e.g., vascular cell adhesion molecule-1, or VCAM-1) and chemokines (e.g., monocyte chemotactic protein-1, or MCP-1) elaborated by endothelial cells may participate in monocyte adhesion and infiltration in vessels exposed to high levels of serum cholesterol (Cybusky and Gimbrone, 1991; Berliner et al., 1995). The expression of these adhesion molecules and chemokines may explain the observation that within several days of a high cholesterol diet, monocytes adhere to the endothelium, particularly at intercellular junctions (Ross, 1997). The monocytes migrate into the subendothelium, where they begin to accumulate lipid and become foam cells. This is the earliest event in the formation of the fatty streak. These activated monocytes (macrophages) release mitogens and chemoattractants that recruit additional macrophages as well as vascular smooth muscle cells into the lesion. As foam cells accumulate in the subendothelial space they distort the overlying endothelium, and eventually may even rupture through the endothelial surface. In these areas of endothelial ulceration, platelets adhere to the vessel wall, releasing epidermal growth factor, platelet-derived growth factor, and other mitogens and cytokines that contribute to smooth muscle migration and proliferation. These factors induce smooth muscle cells in the vessel wall to proliferate and migrate into the area of the lesion. These vascular smooth muscle cells undergo a change in phenotype from a “contractile” cell to a “secretory” cell. Secretory vascular smooth muscle cells elaborate extracellular matrix (i.e., elastin), which transforms the lesion into a fibrous plaque. The smooth muscle cells may also become engorged with lipid to form foam cells. The lesion grows with the recruitment of more cells, the elaboration of extracellular matrix, and the accumulation of lipid until it is transformed from a fibrous plaque to a complex plaque. The complex plaque typically is characterized by a fibrous cap which overlies a necrotic core. The necrotic core is composed of cell debris and cholesterol, and contains a high concentration of the thrombogenic tissue factor, secreted by macrophages. In later stage lesions, calcification may occur. Calcifying vascular cells in the vessel wall can transform into osteoblast-like cells and secrete bone proteins such as osteopontin (Parhami et al., 1997). Microscopic examination of these areas reveals histology very similar to bone tissue. Oxidized lipoprotein stimulates the elaboration of bone protein by these vascular cells. Intriguingly, oxidized lipoprotein reduces bone formation by osteoblasts (Parhami et al., 1997). This recent finding may account for the clinical observation that some patients with atherosclerosis (typically elderly women) appear (by X-ray) to have nearly as much calcium in their aorta as in their spine—one speculates as to which structure is holding them upright! By virtue of its bulk the complex plaque may limit blood flow. With moderate-sized lesions (i.e., occupying 50% of the cross-sectional area of the lumen), ischemia occurs only when the tissue supplied by the vessel requires more blood (e.g., exercise-induced myocardial ischemia, manifested by exertional angina). As the lesion becomes larger (i.e., 80–90% of the cross-sectional area), it may limit basal blood flow, causing ischemia at rest (e.g., rest angina). The complicated plaque is the major cause of acute cardiovascular events (e.g., unstable angina, myocardial infarction, embolie stroke, acute arterial occlusion). Hemorrhage into the plaque (secondary to spontaneous rupture of vasa vasorum supplying the lesion) can cause rapid expansion of the plaque and even luminal obstruction. Ulceration or rupture of the fibrous plaque (i.e., due to hemodynamic force or balloon angioplasty) exposes the highly thrombogenic necrotic core, leading to local thrombosis and/or distal embolization.
Correspondence: John P.Cooke, MD, PhD, Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305–5246, USA
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
281
Plaque rupture is the most common cause of myocardial infarctions and stroke. Rupture of the complex plaque exposes the flowing blood to the highly thrombogenic constituents of the plaque (the foam cells, which elaborate tissue factor). Microscopic examination of the ruptured plaque generally reveals that the rupture has occurred at the shoulder of the lesion. In this area the fibrous cap can be seen to be thinned. Immunohistochemical studies reveal an intense concentration of macrophages in the area, which are elaborating copious amounts of metalloproteinases (Knox et al., 1997). These macrophages appear to be undermining the fibrous cap, weakening it and predisposing to its rupture under the stress of hemodynamic forces. It is not known what may be the trigger for this inflammation and destruction of the fibrous cap. However, an infectious etiology must be considered. A viral role in atherogenesis was proposed over two decades ago (Fabricant et al., 1973, 1978), and more recently there is accumulating evidence, albeit circumstantial, that infectious agents may trigger inflammatory processes that contribute to the pathophysiology of atherosclerosis. Seroepidemiological links have been made between cytomegalovirus infections and atherosclerosis in patients undergoing vascular surgery or in those with transplant coronary artery disease (Adam et al., 1987; Gratton et al., 1989; MacDonald et al., 1989). There is also histopathological evidence of the presence of cytomegalovirus or herpes simplex virus in atherosclerotic lesions in human vessels (Gyorkey et al., 1984; Benditt et al., 1983; Hajjar et al., 1987) Moreover, an avian herpes virus (Marek’s disease virus) can induce atherosclerosis in chickens, which can be prevented by immunization (Minick et al., 1079). Trials of antibiotics in patients with atherosclerosis are under way, in an attempt to test the hypothesis that infection plays a role in the progression of atherogenesis. The fibrous cap, weakened by the degradative action of the macrophages, ruptures under the stress of hemodynamic forces. With rupture of the plaque, thrombus forms in the fissures of the lesion. The thrombus often extends into, and may occlude, the lumen. Plaque rupture and thrombus formation is the most common cause of heart attack and stroke. Furthermore, as the thrombus organizes it can contribute to growth of the lesion and increase the symptoms of the patient. CLINICAL PRESENTATIONS OF ATHEROSCLEROSIS Atherosclerosis causes symptoms as the lesion impinges on the lumen of the vessel. Usually this reduction of lumen diameter takes decades to develop, and symptoms gradually increase over time as the lesion becomes flow-limiting (when it occupies about 50% of lumen diameter). Coronary atherosclerosis causes angina, typically described as a retrosternal pressure with exertion. Symptoms of coronary disease may appear at rest when the lesion becomes greater than 70% of lumen diameter. Carotid artery disease may cause transient ischemie attacks (amaurosis fugax; transient paresthesis, paraplegia, or dysphasia) or stroke. Disease in the leg arteries causes intermittent claudication (cramping pain with walking, relieved by standing still). Renal artery stenosis may cause hypertension and renal insufficiency. Mesenteric artery stenosis causes post-prandial pain and weight loss. When lesions in the conduit vessel become subocclusive (e.g., occupying greater than 80% of the crosssectional area), basal blood flow may be limited. Under these conditions, alterations may also occur at the level of the microvasculature (European Working Group on Critical Leg Ischemia, 1991). Because of reduced blood flow (and reduced shear stress), platelets and leukocytes may be more likely to adhere to the endothelium (as adherence is inversely dependent upon the level of shear stress). Neutrophils become activated and begin to generate superoxide anion. In this milieu of oxidative stress the endothelium begins to express adhesion molecules and chemokines, which further promotes interaction of circulating blood elements with the endothelium. Platelets release serotonin and thromboxane All, which induce vasoconstriction and further stimulate platelet adherence and aggregation. The beneficial effects of some
282
JOHN P.COOKE AND PHILIP S.TSAO
pharmaceuticals (such as prostaglandin El analogues, naftidrofuryl, and pentoxifylline) may be due in part to their ability to disrupt this cycle of platelet and leukocyte interaction with the vessel wall. When atherosclerotic arterial occlusive disease of a vessel progresses to the point that symptoms cannot be medically controlled, interventional techniques, such as catheter balloon angioplasty or atherectomy, endarterectomy, or venous bypass grafting, are indi cated. Acute failure of these procedures is due generally to thrombosis precipitated by gross endothelial denudation and exposure of the thrombogenic constituents of the plaque. Hemorrhage into the vessel wall due to plaque rupture or dissection also contributes to early closure. Long-term success of these catheter-based procedures is limited by a different pathophysiologic process known as myointimal hyperplasia (Cooke and Candipan, 1994). This process is characterized by migration of vascular smooth cells from the media to the intima where they proliferate and transform into secretory cells, synthesizing extracellular matrix that contributes to the lesion. This process is precipitated by endothelial denudation, platelet-vessel wall interactions, and the release of growth factors such as plateletderived growth factor and fibroblast growth factor from platelets and injured vascular smooth muscle cells. Inflammatory cells also contribute, releasing cytokines (such as interleukin1) and other paracrine substances that stimulate migration and proliferation. In addition to myointimal hyperplasia, which causes intimai thickening and narrowing of the lumen, another process called vascular remodeling participates in renarrowing of the vessel. Vascular remodeling is not well understood, but can be observed as a reduction of the outer diameter of the vessel, possibly secondary to adventitial fibrosis. The combination of myointimal hyperplasia and negative remodeling may cause symptomatic restenosis in over 30% of patients within 6 months of balloon angioplasty or atherectomy, and contributes to most late failures of bypass grafts. ROLE OF THE ENDOTHELIUM Atherosclerosis begins with an alteration in the adhesiveness of the endothelium for circulating monocytes. In our laboratory, the focus is on this role of the endothelium in the initiation of atherogenesis. Specifically, we have directed our attention to an endogenous anti-atherogenic molecule that is derived from the endothelium. Most recently, we have found that the production of this factor can be modulated; a reduction in its synthesis accelerates atherosclerosis, whereas an increase in its synthesis suppresses and can even reverse atherosclerosis. This endothelium-derived relaxing factor is now known to be nitric oxide (NO). NO is derived from the metabolism of L-arginine to L-citrulline and NO by the enzyme NO synthase (Moncada and Higgs, 1995). NO is the most potent endogenous vasodilator known, and it exerts its actions in the same way as do exogenous nitrovasodilators such as nitroglycerine. NO released from the endothelium diffuses to the subjacent vascular smooth muscle and activates soluble guanylate cyclase within the vascular smooth muscle, leading to the production of cyclic guanosine monophosphate (cGMP). This cyclic nucleotide is the second messenger for the action of endothelium-derived NO as well as exogenous nitrovasodilators, and it activates cGMP-dependent kinases and phosphatases that mediate vascular smooth muscle relaxation. NO is not only a potent vasodilator but also has important effects on circulating blood elements. NO inhibits platelet adherence and aggregation (Cohen, 1995). Together, the endothelial products NO and prostacyclin confer a resistance to platelet-vessel wall interaction. NO exerts its effect on platelet reactivity in part by stimulating intra-platelet production of cGMP which subsequently phosphorylates proteins which regulate platelet activation and adherence. Platelets themselves contain small amounts of NO synthase and are capable of generating NO which may act as a brake on their activation. NO also inhibits adherence of leukocytes to the endothelium (Kubes et al., 1991). This salutary effect of NO was first discovered using models of ischemia-reperfusion. When the coronary artery of an experimental
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
283
animal is ligated, this induces ischemia of the myocardium subserved by that vessel. When the ligature is released, the ensuing reperfusion is associated with further injury to the myocardium which is in part due to the adherence and infiltration of neutrophils, and the concomitant release of oxygen-derived free radicals. The adherence of leukocytes and subsequent reperfusion injury can be markedly inhibited by the simultaneous perfusion of the coronary artery by exogenous NO donors (Johnson et al., 1990). NO AND MODULATION OF MONOCYTE ADHERENCE Other investigators have looked at the interaction of monocytes with endothelial cells. The ability of monocytes to bind to endothelial cells in vitro is inhibited by exogenous NO in a dose-dependent manner (Bath et al., 1991). These investigations suggest that NO is a potent modulator of leukocyte-vessel wall interactions. The mechanism by which NO inhibits monocyte adherence and infiltration is under investigation in our laboratory and others. NO has both acute and chronic effects on monocyte adhesion. Within minutes of exposure to exogenous NO, endothelial cells become more resistant to monocyte adherence (Tsao et al., 1995). Because of the rapid time course, this effect of NO must be due to inhibition of signalling pathways involved in adhesion— perhaps by a cGMP-dependent mechanism. More chronic exposure to NO suppresses gene expression of adhesion molecules (such as VCAM-1), and chemokines (such as MCP-1) involved in monocyte adhesion and infiltration (Zeiher et al., 1995; Tsao et al., 1996, 1997). By contrast, inhibition of NO synthesis increases the expression of endothelial proteins required for monocyte adhesion (Tsao et al., 1996). NO appears to exert its effects on gene expression by blocking the activation of specific transcriptional proteins (such as nuclear factor KB) (Figure 16–1) (Zeiher et al., 1995; Tsao et al., 1996, 1997). Accumulating evidence supports the hypothesis that NO exerts its effect on monocyte adherence and chemotaxis in part by modulating the activity of redox-responsive transcriptional pathways (Tsao et al., 1997; Marui et al., 1993; DeCaterina et al., 1995). We have observed that vascular smooth muscle cells exposed to oxidized lipoprotein or cytokines begin to elaborate superoxide anion. This generation of reactive oxygen species is associated with transcription of MCP-1 mRNA and increased chemotactic activity for monocytoid cells (Tsao et al., 1997). These effects are all suppressed by the NO-donor, DETANO. These observations indicate that NO reduces transcription of MCP-1; it is also possible that NO may reduce the half-life of MCP-1 mRNA although this was not directly examined in this study. NO may act by reducing intracellular oxidative stress. There are several possible mechanisms by which NO may reduce oxidative stress. NO can scavenge superoxide anion, although the product of this reaction, peroxynitrate anion, is itself a highly reactive free radical (Ischiropoulos, 1992; Lin, 1995). However, it is possible that peroxynitrate anion could subsequently nitrosylate sulfhydryl groups to form S-nitrosothiols (Radi et al., 1991). This class of molecules is known to induce vasodilation, inhibit platelet aggregation, and interfere with leukocyte adherence to the vessel wall (Stamler et al., 1992, 1989). Another mechanism by which NO may ameliorate oxidative stress is by terminating the autocatalytic chain of lipid peroxidation that is initiated by oxidized LDL or intracellular generation of oxygen-derived free radicals. Indeed, exogenous NO inhibits copper-induced oxidation of LDL cholesterol, causing a lag in the formation of conjugated dienes (Hogg et al., 1993). Finally, NO may directly suppress the generation of oxygen-derived free radicals by nitrosylating, and thereby inactivating oxidative enzymes. This hypothesis is supported by the observation that the generation of superoxide anion by stimulated neutrophils is reduced by their exposure to exogenous NO (Clancy et al., 1992). This is due to the inactivation of NADPH oxygenase, a multimeric enzyme, with cytosolic and particulate components. The particulate component is vulnerable to nitrosylation by NO (either at its heme moiety or sulfhydryl group), which prevents its
284
JOHN P.COOKE AND PHILIP S.TSAO
Figure 16±1. Atherosclerotic risk factors such as hypercholesterolemia, hypertension, tobacco, and diabetes mellitus lead to increased free radical production and decreased nitric oxide activity in endothelial cells. This endothelial dysfunction not only has acute effects on vascular tone, but also chronic effects on vessel structure. Increased superoxide anion leads to activation of NFicB via phosphorylation and degradation of the inhibitor protein IKB a. NFicB is then free to translocate into the nucleus to initiate transcription of proatherogenic genes such as VCAM-1 and MCP-1. Nitric oxide can inhibit these processes by inhibiting superoxide production, directly scavenging superoxide anions, as well as increasing the transcription and activity of iKBoc. Moreover, since NO is a paracrine factor, it can have important inhibitory effects on circulating leukocytes and underlying smooth muscle cells.
association with the cytosolic component, and reconstitution of the active enzyme. A similar phenomenon may occur in endothelial cells. This would explain the observation of Niu and colleagues (1994), who reported that antagonism of endogenous NO production increases oxidative stress in HUVECs, as demonstrated using redox-sensitive fluorophores. Furthermore, Pagano and colleagues (1993) have shown that exogenous NO donors inhibit the generation of superoxide anion by the endothelium of rabbit thoracic aortae treated ex vivo with antagonists of superoxide dismutase. It is well established that hypercholesterolemia reduces the activity of endothelium-derived NO (Heistad et al., 1984; McLenahan et al., 1991). In parallel, the endothelium begins to generate superoxide anion (McLenahan et al., 1991). This alteration in endothelial redox state triggers the oxidant-sensitive transcriptional cascade that results in the activation of genes encoding molecules that regulate endothelial adhesiveness (Ohara et al., 1991). The cytokine-induced activation of VCAM-1 and MCSF in cultured endothelial cells is suppressed by antioxidants or NO donors (Tsao et al., 1997; Marui et al., 1993). This effect of NO appears to be due in
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
285
part to stabilization and/or increased expression of IicBa, which complexes with NFicB to inhibit its transcriptional activity (Marui et al., 1993). Our data are consistent with this model of an oxidant-responsive NFKB-mediated pathway that is modulated by NO. Recently, Zeiher and colleagues (1995) have also provided evidence that NO inhibits MCP-1 expression in cytokine-stimulated HUVECs, in a cGMP-independent fashion. To summarize, there is accumulating in vitro and in vivo evidence that NO suppresses the expression of monocyte adhesion molecules and chemokines. NO appears to exert its effects by reducing intracellular oxidative stress, thereby defusing oxidant-triggered transcription. Therapeutic strategies to enhance vascular NO activity may therefore inhibit the progression of atherosclerosis as well as restore normal vasoreactivity. EFFECTS ON VASCULAR GROWTH NO also regulates the growth of vascular smooth muscle cells. In vitro, NO-donors inhibit the proliferation of vascular smooth muscle cells; this effect is mimicked by exogenous administration of 8-bromo-cGMP, a stable analog of the second messenger of NO action (Garg and Hassid, 1990). Other agents such as atrial natriuretic peptide which increase the intracellular levels of cGMP inhibit proliferation of vascular smooth muscle cells in culture. Does NO inhibit the proliferation of vascular smooth muscle cells in vivo? Some initial studies indicate that NO does indeed play an important role in controlling vascular growth. In a number of disease states where the release of NO is reduced or abolished, such as restenosis, hypercholesterolemia, and hypertension, there is an increase in the proliferation of vascular smooth muscle cells within the media and the intima. In experimental animal models, augmentation of endogenous NO synthesis (as with administration of the NO precursor L-arginine), inhibits “restenosis” (myointimal hyperplasia) after balloon angioplasty (Candipan, 1996). In one study, after subjecting the carotid artery to balloon angioplasty, we successfully transfected the vessel with a plasmid construct containing the gene encoding NO synthase. This gene transfer had the effect of enhancing NO synthesis locally and inhibiting myointimal hyperplasia (von der Ley en et al., 1995). More recently, we have shown that the intramural administration of a single dose of L-arginine, at the time of balloon angioplasty, can markedly inhibit myointimal hyperplasia 2–4 weeks later (Schwarzacher et al., 1997). This effect of L-arginine is associated with increased local production of NO, probably due to utilization of L-arginine by induced NO synthase in vascular smooth muscle cells in the injured area. ENDOTHELIAL DYSFUNCTION: ROLE IN VASCULAR DISEASE Proliferation of vascular smooth muscle cells, as well as monocyte adherence and infiltration, platelet adherence, and aggregation, are key processes involved in atherogenesis. Because endothelium-derived NO inhibits each of these processes, we have proposed that NO is an endogenous anti-atherogenic molecule (Cooke and Tsao, 1993). Therefore an endothelial injury or alteration which results in a reduction in NO activity could promote atherogenesis. Indeed, a number of disorders that are associated with atherosclerosis, are also associated with an impairment in the ability of the endothelium to elaborate NO (Cooke and Dzau, 1993). In animal models, and in humans, hypercholesterolemia, hypertension, homocysteinemia, diabetes mellitus, and exposure to tobacco are each associated with impaired NO-dependent vasodilation. This endothelial impairment occurs well before any structural changes of atherogenesis are detected. Indeed when otherwise normal vessels are exposed in vitro to oxidized lipoproteins, an impairment in NO-
286
JOHN P.COOKE AND PHILIP S.TSAO
dependent vasodilation can be detected within minutes. This reduction in NO activity is due to a reduced synthesis and/or an increased degradation of the molecule. If a reduction in NO activity promotes atherogenesis, a restoration of NO activity might be expected to retard progression of the disease. In support of this hypothesis, a wide variety of interventions that inhibit the progression of atherosclerosis, are also associated with improvements in NO-dependent vasodilation, including antilipid agents, antioxidants, estrogen, angiotensin-converting enzyme inhibitors, and L-arginine (Cooke et al., 1992). This of course does not imply causality, and the improvement in endothelial function could be a secondary phenomenon. However, we have accumulated evidence that indicates a direct role for endothelium-derived NO as an anti-atherogenic molecule. We reasoned that if we could increase the synthesis of NO by the vessel wall, a number of key processes in atherosclerosis would be inhibited and progression of the disease halted. To test this hypothesis NZW rabbits were placed on normal or high cholesterol diet; some of the animals on the high cholesterol diet also received supplemental dietary arginine or methionine to increase the intake of these amino acids six-fold (Cooke et al., 1992; Wang et al., 1994). After 10 weeks the thoracic aortae and coronary arteries were harvested for studies of vascular reactivity and histomorphometry. The supplemental dietary arginine did not alter the lipid profile nor any hemodynamic parameters in the hypercholesterolemic animals; the only difference between the hypercholesterolemic groups was that plasma arginine was doubled in the hypercholesterolemic animals receiving dietary arginine supplementation. At 10 weeks, the thoracic aortae and coronary arteries were harvested for studies of vascular reactivity and histomorphometry. As expected, NO-dependent vasodilation to acetylcholine was inhibited in the hypercholesterolemic animals receiving vehicle. By contrast hypercholesterolemic animals receiving L-arginine had an improvement in NOdependent vasodilation. The improvement of NO-dependent vasodilation in hypercholesterolemic animals receiving L-arginine was associated with a striking effect on vascular structure. A significant reduction was observed in the surface area of the thoracic aorta involved by lesions in the hypercholesterolemic animals receiving arginine (Figure 16–2) (Cooke et al., 1992). In the left main coronary artery the differences were even more striking; no lesions at all were observed in the hypercholesterolemic animals receiving L-arginine (Wang et al., 1994). The mechanism by which dietary arginine inhibits atherogenesis is being elucidated in our laboratory. It appears to be due in part to an inhibition of monocyte-endothelial cell interaction in the hypercholesterolemic animals. After only 2 weeks of a high cholesterol diet, we find that the thoracic aorta of hypercholesterolemic animals has increased adhesiveness for monocytes (Tsao et al., 1994). Compared with the thoracic aortae from normal animals, those from hypercholesterolemic rabbits manifest a three-fold increase in the number of adherent cells. The increase in cell binding is attenuated in thoracic aortae from hypercholesterolemic animals receiving dietary arginine supplements (Tsao et al., 1994). This is associated with an increase in the release of NO from these tissues (Tsao et al., 1994), as well as a reduced vascular expression of MCP-1 (Tsao et al., 1997). To provide further evidence that NO regulates monocyteendothelial cell interaction, some animals were exposed to nitro-arginine, an antagonist of NO synthase. The number of adherent cells was dramatically increased in normocholesterolemic animals receiving nitroarginine (Tsao et al., 1994). The increased adhesiveness of the endothelium in the nitro-arginine treated animals was associated with an increased vascular expression of MCP-1 (Tsao et al., 1997). Thus, reductions in NO activity by hypercholesterolemia, or inhibition of NO synthesis, is associated with increased monocyte-endothelial cell binding, possibly due to the increased expression of specific chemokines and adhesion molecules.
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
287
Figure 16±2. Photomicrographs of thoracic aortae from New Zealand White rabbits fed a high cholesterol diet in the absence (top panel) or the addition (bottom panel) of dietary arginine.
288
JOHN P.COOKE AND PHILIP S.TSAO
NO AND APOPTOSIS More recently we have found that administration of arginine can also restore NO activity in hypercholesterolemic rabbits with established lesions. This improvement in NO activity is associated with regression of pre-existing lesions (Candipan et al., 1996). Preliminary studies indicate that the enhancement of vascular NO activity causes regression by inducing apoptosis of macrophages within the lesion. Apoptosis has been reported to occur in vascular cells of human atherosclerotic plaque (Isner et al., 1995; Geng and Libby, 1995). Factors involved in the initiation and regulation of apoptosis in atherosclerosis have not been fully elucidated, but immunohistochemical studies provide evidence for several proteins known to participate in apoptosis, including p53 (Bennett et al, 1995). Among the myriad pathways that may be involved, there is accumulating evidence to implicate L-arginine/NO synthase. Cytokine-mediated activation of iNOS induces apoptosis of macrophages in vitro (Messmer et al., 1995). The effect of iNOS activation is augmented by additional L-arginine, and attenuated by antagonists of NO synthase. To determine if modulation of vascular NO activity could induce apoptosis of macrophages in the intimai lesion, we performed the following study. Male New Zealand White rabbits were fed a 0.5% cholesterol diet for 10 weeks and subsequently placed on 2.5% L-arginine HC1 in the drinking water, and the cholesterol diet continued for two weeks, at which time the aortae were harvested for histological studies. We observed by Hoechst staining that L-arginine treatment increased the number of apoptotic cells (largely macrophages) in the intimai lesions by three-fold. In subsequent studies, aortae were harvested for ex vivo studies. Aortic segments were incubated in cell culture medium for 4 to 24 hours with modulators of NO synthase pathway. The tissues were then collected for histological studies, and the conditioned medium collected for measurement of nitrogen oxides by chemiluminescence. Addition of sodium nitroprusside to the medium caused a time-dependent increase in apoptosis of vascular cells (largely macrophages) in the intimai lesion. L-arginine (10−3 M) had an identical effect on apoptosis, which was associated with an increase in NOX released into the medium. These effects were not mimicked by D-arginine, and they were antagonized by the NO synthase inhibitor, L-nitroarginine (10−4 M). The effect of L-arginine was not influenced by an antagonist of cGMP-dependent protein kinase, nor was the effect mimicked by the agonist of protein kinase G or 8-Br-cyclic GMR These results indicated that supplemental L-arginine induces apoptosis of macrophages in intimai lesions by its metabolism to nitric oxide, which acts via a cyclic-GMP independent pathway. Furthermore, these studies explain our previous observation that supplementation of dietary arginine induces regression of atheroma in this animal model. It is likely that iNOS expressed by cells within the lesion is responsible for the effect of L-arginine. Indeed, previous immunohistochemical studies have detected iNOS in the intimai macrophages and vascular smooth muscle cells of human atherosclerotic plaque (Ohara et al., 1993). These are activated cells which also produce superoxide anion. In this milieu, the product of iNOS is quickly transformed into peroxynitrite anion, a highly reactive free radical (Ischiropoulos et al., 1992). Peroxynitrite anion is cytotoxic and induces apoptosis (Lin et al., 1995). Peroxynitrite anion can also affect cell function by nitrosylating tyrosine residues that are involved in the signal transduction of transmembrane receptors. Using monoclonal antibodies directed against nitrotyrosine, evidence of peroxynitrite formation has been observed in human atherosclerotic plaque (Beckman et al, 1993). This is relevant to the present study, since peroxynitrite anion is likely the NO species mediating the effects observed in this study. Previous studies have suggested that apoptosis induced by iNOS activity may be mediated in part by mechanisms independent of cGMP (Pollman et al., 1996). Consistent with this observation is our finding that the various manipulations of the cGMP pathway did not influence apoptosis in the lesions of this animal model.
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
289
The activation of iNOS may have complex effects on the evolution of atherosclerotic plaque. By inducing cell death, iNOS activation may contribute to the development of the “necrotic core” of complex lesions. One might also speculate that iNOS may be involved in the characteristic atrophy of the media beneath atheroma or the dissolution of the fibrous cap by activated macrophages. Peroxynitrite anion produced by these activated macrophages could induce apoptosis of vascular smooth muscle. Furthermore, peroxynitrite anion may reduce collagen formation by vascular cells, and activate metalloproteinases which degrade extracellular matrix (Rajagopalan et al., 1996). These actions of peroxynitrite anion would contribute to plaque instability and have led some to explore antagonism of iNOS as a potential therapeutic avenue. However, it is likely that such a strategy would have unintended consequences. Antagonism of iNOS activity could promote platelet aggregation, leukocyte adherence, vasoconstriction, and proliferation of vascular smooth muscle cells and macrophages. We speculate that iNOS may be in fact a countervailing force in the accretion of atherosclerotic plaque. Furthermore, by reducing proliferation and by promoting apoptosis of macrophages in the lesion, iNOS activation may lead to plaque stabilization and even regression, as suggested by our observations. It is worthy of emphasis that both macrophages and vascular smooth muscle cells contribute to the intimai lesion in the balloon-injured hypercholesterolemic rabbits, but we observed that it was largely the macrophages that were undergoing apoptosis. ADMA: A NEW RISK FACTOR FOR ATHEROSCLEROSIS? The mechanism by which hypercholesterolemia impairs the L-arginine/NO pathway is probably multifactorial, and dependent upon the stage of atherosclerosis. Most studies have reported that the defect in hypercholesterolemia and therosclerosis is reversed by exogenous L-arginine (Cooke et al., 1991; Drexler et al., 1991; Creager et al., 1992). Recently, asymmetric dimethylarginine (ADMA) has been characterized to be an endogenous, competitive inhibitor of NO synthase (Vallance et al., 1992). ADMA has been shown to be synthesized by human endothelial cells (Pickling et al., 1993). The plasma level of ADMA is elevated in hypercholesterolemic rabbits (Bode-Böger et al., 1996; Böger et al., 1997a) as well as in hypercholesterolemic (Böger et al., unpublished observation) and atherosclerotic humans (Böger et al., 1997b) concomitantly with impaired endothelial NO elaboration. We have examined the effect of ADMA upon cultured endothelial cells. Incubation of endothelial cells with ADMA (at concentrations that are observed in hypercholesterolemic humans) inhibited NO production. This effect was associated with increased endothelial superoxide radical elaboration and NFkBB activation, resulting in enhanced MCP-1 expression and endothelial adhesiveness for monocytes. These effects of ADMA were reversed by L-arginine. Vascular NO activity is decreased in hypercholesterolemia and atherosclerosis, leading to impaired endothelium-dependent vasodilation (Creager et al., 1990), increased platelet aggregability (Wolf et al., 1997), and monocyte adhesiveness for the endothelium (Theilmeier et al., 1997). This impaired NO activity may contribute to the development and progression of atherosclerosis. Indeed, in animal models of hypercholesterolemia, pharmacological inhibition of NO synthase promotes atherosclerosis (Tsao et al., 1994b; Cayatte et al., 1994; Naruse et al., 1994). On the other hand, as previously mentioned, enhancement of endogenous NO formation with L-arginine supplementation improves endothelial function, inhibits platelet activation and monocyte adhesiveness for the endothelium, and slows progression of lesions or even induces regression (Cooke et al., 1992; Böger et al., 1995; Candipan et al., 1996; Tsao et al., 1994b; Creager et al., 1990; Tsao et al., 1994a). The mechanism(s) leading to the impaired NO activity in hypercholesterolemia and atherosclerosis has remained unclear. Increased degradation and/or reduced synthesis of NO may be involved. The mechanism
290
JOHN P.COOKE AND PHILIP S.TSAO
Figure 16±3. Asymmetric dimethylarginine (ADMA) can competitvely inhibit the production of NO from NOS. ADMA is normally converted by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) to L-citrulline, which is then recycled back to L-arginine. ADMA can also decrease the uptake of L-arginine via the cationic transporters.
by which L-arginine exerts its beneficial effects is likely through enhanced production of endotheliumderived NO. However, it is not yet completely understood how exogenous L-arginine increase NO elaboration in hypercholesterolemia, given the low Km of the purified endothelial NO synthase (2.9 µM (Pollock et al., 1991)) and the relatively high physiological plasma concentrations of L-arginine (60–100 µmol/L), which are unchanged in hypercholesterolemia (Laghi-Pasini et al., 1992). We suggest that this “L-arginine paradox” is likely due to the presence of endogenous competitive NOS inhibitors like ADMA (Figure 16–3) (Böger et al., 1997a). In 1992, Vallance et al., (1992) observed that ADMA, but not SDMA, competitively inhibits NO synthesis. ADMA plasma levels, which are 1.0±.0.1 mmol/L in healthy humans, are elevated to 2.2±.0.2 mmol/L in hypercholesterolemic individuals (Cooke et al., unpublished observation). In elderly patients with peripheral arterial disease and generalized atherosclerosis, ADMA levels range from 2.5 to 3.5 mmol/L, corresponding to the severity of the vascular disease (Böger et al., 1997b). Increased ADMA levels are associated with reduced NO elaboration in hypercholesterolemic subjects (Laghi-Pasini et al., 1992) and in atherosclerotic patients (Böger et al., 1997b), as judged by reduced urinary nitrate excretion and impaired endothelium-dependent, NO-mediated forearm vasodilation. We have found that intracellular ADMA levels within endothelial cells are considerably higher than those in conditioned media from human endothelial cells. The same may be true for ADMA levels in endothelial cells in vivo in respect to human plasma. Our observation that endothelial cells are a source of ADMA corroborates the previous finding by Fickling et al (1993) that human endothelial cells release ADMA and
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
291
SDMA. ADMA competitively inhibits endothelial NO synthesis in an autocrine manner. This observation is in line with previous findings that exogenous ADMA concentrations between 1 and 10 µM affect the activity of the NO synthase in rat mesentery tissue (Kurose et al., 1995) in rat brain (Faraci et al., 1995), and in cultured macrophages (Fickling et al., 1993). Faraci et al., (1995) calculated an IC50 value for the inhibition of NO production in rat cerebellar homogenate by ADMA of 1.8 ± .1 µM, and Fickling et al., (1993) reported that 2 and 10 µM ADMA inhibited nitrite production in LPS-simulated J774 macrophages by 17 and 33% respectively. Taken together with our recent observations, these data suggest that ADMA may be a potential autocrine regulator of endothelial NO synthase. The source of ADMA in endothelial cells is currently unclear. Dimethylarginines are likely the result of degradation of methylated proteins (McDermott, 1976; MacAllister et al., 1996). The specific enzyme Sadenosylmethionine: protein arginine N-methyl-transferase (protein methylase I) has been shown to methylate internal arginine residues in a variety of polypeptides, yielding NG-monomethyl-L-arginine, NG,NG-dimethyl-L-arginine, and NG, NG-dimethyl-L-arginine upon proteolysis (Rawal et al., 1995). The metabolism of ADMA, but not SDMA, occurs via hydrolytic degradation to citrulline by the enzyme dimethylarginine dimethylaminohydrolase (DDAH) (MacAllister et al., 1994). Inhibition of DDAH causes a gradual vasoconstriction of vascular segments, which is reversed by L-arginine (MacAllister et al., 1996). This latter finding also suggests that regulation of intracellular ADMA levels affects NO synthase activity. Intriguingly, recent data from our laboratory indicate that low-density lipoprotein increases endothelial cell ADMA elaboration. Although the mechanism by which LDL may affect ADMA formation or metabolism is currently unknown, this finding suggests that elevated ADMA levels may mediate some of the effects of LDL on the endothelium in an autocrine manner. Most importantly, within the concentration range we found in cultured endothelial cells (5–0 µM), ADMA can induce some of the pathophysiological changes of the endothelium that occur in hypercholesterolemia. Inhibition of endothelial NO synthase activity is associated with a concentration-dependent increase of endothelial adhesiveness for human THP-1 monocytoid cells. This effect of ADMA and L-NMMA mimics the increase in adhesiveness observed when endothelial cells are pre-incubated with nLDL; in both cases, adhesion is diminished by co-incubating endothelial cells with L-arginine. Supplementation of cholesterol-fed rabbits with L-arginine has previously been shown to reduce aortic endothelial asgesiveness for monocytes (Tsao et al., 1994bb). The cumulative data strongly suggest that NO is an endogenous anti-atherogenic molecule. Therefore impairment of NO activity (by hypercholesterolemia, diabetes mellitus, hypertension, homocysteinemia, or tobacco use), likely plays a role in the initiation of atherosclerosis. Preliminary studies indicate that many disorders associated with endothelial dysfunction and/or atherogenesis are also associated with elevated levels of ADMA. SUMMARY Vascular disease begins with an alteration in the endothelium which is characterized by an increase in intracellular oxidative stress, and the activation of oxidant-response genes regulating the expression of adhesion molecules and chemokines. These changes promote interaction of the endothelium with circulating blood elements. Monocyte infiltration and foam cell formation ensue, followed by further endothelial dysfunction and damage which precipitates platelet adherence and proliferation of vascular smooth muscle. These key processes in atherogenesis are opposed by nitric oxide. NO suppresses the expression and signaling of adhesion molecules involved in monocyte adhesion to the vessel wall, and inhibits platelet adherence and vascular smooth muscle cell proliferation. The NO synthase pathway is perturbed by hypercholesterolemia and other metabolic disorders that predispose to atherosclerosis. It is likely that basic
292
JOHN P.COOKE AND PHILIP S.TSAO
insights regarding the mechanisms of endothelial dysfunction will lead to new therapeutic strategies to halt the progression, or induce regression, of atherosclerosis. REFERENCES Adam, E., Melnick, J.L., Probesfield, J.L., Petrie, B.L., Burek, J., Kailey, K.R., McCollum, C.H. and DeBakey, M.E. (1987) High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet, 2, 291–293. Aji, W., Ravalli, S., Szabolcs, M. et al. (1997) L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation, 95, 430–437. Bath, P.M.W., Hassall, D.G., Gladwin, A.-M. et al. (1991) Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro . Arterioscler. Thromb., 11, 254– 260. Beckman, J.S., Ye, Y.Z., Anderson, P.O. et al. (1993) Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Benditt, E.P., Barrett, T., McDougall, J.K. (1983) Viruses in the etiology of atherosclerosis. Proc. Natl. Acad. Sci. USA, 80, 6386–6389. Bennett, M.D., Evan, G.I. and Schwarz, S.M. (1995) Apoptosis of rat vascular smooth muscle cells is regulated by p53dependent and—independent pathways. Circ. Res., 77, 266–273. Berliner, J.A., Navab, M., Fogelman, A.M. et al. (1995) Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation, 91, 2488–2496. Bode-Böger, S.M., Böger, R.H., Kienke, S., Junker, W. and Frölich, J.C. (1996) Elevated L-arginine/ dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem. Biophys. Re. Comm., 219, 598–603. Böger, R.H., Bode-Böger, S.M., Brandes, R.P. et al. (1997a) Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits—comparison with lovastatin. Circulation, 96, in press. Böger, R.H., Bode-Böger, S.M., Mügge, A. et al. (1995) Supplementation of hypercholesterolaemic rabbits with Larginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis, 111, 273–284. Böger, R.H., Bode-Böger, S.M., Thiele, W. et al. (1997b) Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation, 95, 2068–2074. Candipan, R.C., Wang, B., Buitrago, R. et al. (1996) Regression or progression: Dependency upon vascular nitric oxide. Arterioscler. Thromb. Vase. Biol, 16, 44–50. Cayatte, A.J., Palacino, J.J., Horten, K. and Cohen, R.A. (1994) Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Throm., 14, 753–759. Clancy, R.M., Leszczynska, P., Piziak, J. and Abramson, S.B. (1992) Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on NADPH oxidase. J. Clin. Invest., 90, 1116–1121. Cohen, R.A. (1995) The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis., XXXVIII(2) (Sept./Oct.), 105–128. Cooke, J.P. and Candipan, R. (1994) Vascular biology of restenosis: Insights for therapeutic strategies.J. Intervent. Cardiol, 6, 25–35. Cooke, J.P. and Tsao, PS. (1993) Cytoprotective effects of nitric oxide. Circulation, 88, 2151–2154. Cooke, J.P, Andon, N.A., Girerd, X.J., Hirsch, A.T. and Creager, M.A. (1991) Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation, 83, 1057–1062. Cooke, J.P. and Dzau, VJ. (1997) Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular disease (editorial). Circulation, 96, 379–382. Cooke, J.P, Singer, A.H., Tsao, P. et al. (1992) Anti-atherogenic effects of L-arginine in the hypercholesterolemic rabbit. J. Clin. Invest., 90, 1168–1172.
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
293
Creager, M.A., Cooke, J.P, Mendelsohn, M.E. et al. (1990) Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans . J.Clin. Invest., 86, 228–234. Creager, M.A., Gallagher, S.J., Girerd, X.J. et al. (1992) L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J.Clin. Invest., 90, 1248–1253. Cybulsky, M.I. and Gimbrone, M.A. Jr. (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science, 251, 788–791. DeCaterina, R., Libby, P., Peng, H.-B., Thannickal, V.J., Rajavashisth, T.B., Gimbrone, M.A., Jr., Shin, W.S. and Liao, J.K. (1995) Nitric oxide decreases cytokine-induced endothelial activation. J. din. Invest., 96, 60–68. Drexler, H., Zeiher, A.M., Mainzer, K. and Just, H. (1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet, 338, 1546–1550. European Working Group on Critical Leg Ischemia (1991) Second European consensus document on chronic critical leg ischemia. Circulation, 84(suppl. 4), IV–l–IV–26. Fabricant, C.G., Fabricant, J., Litrenta, M.M. and Minick, D.R. (1978) Virus-induced atherosclerosis. J. Exp. Med., 148, 335–340. Fabricant, C.G., Knook, L. and Gillespie, J.G. (1973) Virus-induced cholesterol crystals. Science, 181, 566– 567. Faraci, P.M., Brian, I.E. and Heistad, D.D. (1995) Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am. J.Physiol, 269, H1522-H1527. Fickling, S.A., Leone, A.M., Nussey, S.S., Vallance, P. and Whitley, G.SJ. (1993) Synthesis of NG, NG dimethylarginine by human endothelial cells. Endothelium, 1, 137–140. Garg, U.C. and Hassid, A. (1990) Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/C 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem. Biophys. Res. Comm., 171, 474–479. Garg, U.C., Hassid, A. et al. (1989) Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit nitrogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest., 83, 1774–1777. Geng, Y.J. and Libby, P. (1995) Evidence for apoptosis in advanced human atheroma, colocalization with interleukinlep-converting enzyme. Am.J.Path., 147, 251–266. Gratton, M.T., Moreno-Cabral, C.E., Starnes, VA., Oyer, P.E., Stinson, E.B. and Shumway, N.B. (1989) Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA, 261, 3561–3566. Gyorkey, F, Melnick, J.L., Guinn, G.A., Gyorkey, P. and DeBakey, M.E. (1984) Herpes viridae in the endothelial and smooth muscle cells of the proximal aorta of atherosclerotic patients. Exp. Mol Pathol, 40, 328– 339. Hajjar, D.P., Pomerantz, K.B., Falcone, D.J., Weksler, B.B. and Grant, A.J. (1987) Herpes simplex virus infection in human arterial cells: Implications in atherosclerosis. J.Clin. Invest., 80, 1317–1321. Heistad, D.D., Armstrong, M.L.I., Marcus, M.L., Piegors, D.J. and Mark, A.L. (1984) Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ. Res., 43, 711–718. Hogg, N., Kalyanaramer, B., Joseph, J., Struck, A. and Parthasarathy, S. (1993) Inhibition of low-density lipoprotein oxidation by nitric oxide. Potential role in atherogenesis. FEBS Letters, 334, 170–174. Ischiropoulos, H., Zhu, L. and Beckman, J.S. (1992) Peroxynitrite formation from macrophage-derived nitric oxide. Arch. Biochem. Biophys., 298, 446–51. Isner, J.M., Kearney, M., Bortman, S. and Passeri, J. (1995) Apoptosis in human atherosclerosis and restenosis. Circulation, 91, 2703–2711. Johnson, G. III, Tsao, PS. et al. (1990) Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. /. Pharmacol Exp. Therap., 252, 35–41. Knox, J.B., Sukhova, G.K., Whittemore, A.D. and Libby, P. (1997) Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic disease. Circulation, 95, 205–212. Kubes, P., Suzuki, M. et al (1991) Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA , 88, 4651–685. Kurose, I., Wolf, R., Grisham, M.B. and Granger, D.N. (1995) Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am.J.Physiol., 268 H2224-H2231. Laghi-Pasini, F, Frigerio, C., De Giorgi, L. et al. (1992) L-arginine plasma concentrations in Hyperchoesterolemia. Lancet, 340, 549.
294
JOHN P.COOKE AND PHILIP S.TSAO
Lin, K.T., Xuie, J.Y., Nomen, M. et al. (1995) Peroxynitrite-induced apoptosis in HL-60 cells. J.Biol. Chem., 270, 16487–16490. MacAllister, R.J., Pickling, S.A., Whitley, G.SJ. and Vallance, P. (1994) Metabolism of methylarginines by human vasculature: Implications for the regulation of nitric oxide synthesis. Br.J.Pharmacol., 112, 43– 48. MacAllister, R.J., Parry, H., Kimoto, M. et al. (1996) Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br.J.Pharmacol, 119, 1533–1540. MacDonald, K., Rector, T.S., Braunlan, E.A., Coubo, S.H. and Olivori, M.T. (1989) Association of coronary artery disease in cardiac transplant recipients with cytomagalovirus infection. Am.J.Pathol, 64, 359– 362. Marui, N., Offerman, M.K. and Swerlick, R. et al. (1993) Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanisms in human vascular endothelial cells. J.Clin. Invest., 92, 1866–1872. McDermott, J.R. (1976) Studies on the catabolism of NG0-methylarginine, NG, NG-dimethylarginine and NG, NG’dimethylarginine in the rabbit. Biochem. J., 154, 179–184. McLenahan, J.M., William, J.K., Fish, R.D., Ganz, P. and Selwyn, A.P. (1991) Loss of flow-mediated endotheliumdependent dilation occurs early in the development of atherosclerosis. Circulation, 84, 1273–1278. Messmer, U.K., Lapetina, E.G. and Brüne, B. (1995) Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds. Mol. Pharmacol, 47, 757–756. Minick, C.R., Fabricant, C.G., Fabricant, J. and Litrenta, M.M. (1979) Atherosclerosis induced by infection with herpes virus. Am.J.Pathol, 96, 673–706. Moncada, S. and Higgs, E.A. (1995) Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB, J., 9, 1319–1330. Naruse, K., Shimizu, K., Muramatsu, M. et al. (1994) Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. Arterioscler. Thromb., 14, 746–752. Niu, X.-F, Smith, C.W. and Kubes, P. (1994) Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ. Res., 74, 1133–1140. Ohara, Y., Petersen, T.E. and Harrison, D.G. (1993) Hypercholesterolemia increases endothelial superoxide anion production. J.Clin. Invest., 91, 2546–2551. Pagano, P.J., Tornheim, K. and Cohen, R.A. (1993) Superoxide anion production by rabbit thoracic aorta: effect of endothelium-derived nitric oxide. Am.J.Physiol, 265, H707–712. Parhami, F., Morrow, A.D., Balucan, J. et al. (1997) Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vase. Biol., 17, 680–687. Peng, H.B., Libby, P. and Liao, J.K. (1995) Induction and stabilization of 1 kappa B alpha by nitric oxide mediates inhibition of NF-KB. J. Biol. Chem., 270, 14214–14219. Pollman, M.J., Yamada, T., Horiuchi, M. and Gibbons, G.H. (1996) Vasoactive substances regulate vascular smooth muscle cell apoptosis, countervailing influences of nitric oxide and angiotensin II. Circ. Res., 79, 748–756. Pollock, J.S., Försterman, U., Mitchell, J.A. et al. (1991) Purification and characterization of particulate endotheliumderived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc. Natl. Acad. USA, 88, 10480–10484. Radi, R., Beckman, J.S., Bush, K.M. and Freeman, B.A. (1991) Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J.Biol. Chem., 266, 4244–4250. Rajagopalan, S., Meng, X.P., Ramasamy, S. et al. (1996) Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J.Clin. Invest., 98, 2572–2579. Rawal, N., Rajpurohit, R., Lischwe, M.A. et al. (1995) Structural specificity of substrate for S-adenosylmethionine: protein arginine N-methyltransferases. Biochem. Biophys. Acta, 1248, 11–18. Ross, R. (1997) Cellular and molecular studies of atherosclerosis. Atherosclerosis, 131 (suppl), S3–4. Schwarzacher, S.P., Lim, T.T., Wang, B.Y. et al. (1997) Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation, 95, 1863–1869.
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
295
Stamler, J.S., Mendelsohn, M.E., Amarante, P., Smick, D., Andon, N., Davies, P.P., Cooke, J.R and Loscalzo, J. (1989) N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. Circ. Res., 65, 789–95. Stamler, J.S., Simon, D.I., Osborne, J.A., Mullins, M.E., Jaraki, O., Michel, T., Singel, D.J. and Loscalzo, J. (1992) Snitrosylation of proteins with nitric oxide: Synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. USA, 89, 444–48. Theilmeier, G., Chan, J., Zalpour, C. et al. (1997) Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler. Thromb. Vase. Biol., (in press). Tsao, P., McEvoy, L.M., Drexler, H., Butcher, E.G. and Cooke, J.P. (1994b) Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation, 89, 2176–2182. Tsao, PS., Buitrago, R., Chan, J.R. and Cooke, J.P. (1996) Fluid flow inhibits endothelial adhesiveness: Nitric oxide and transcriptional regulation of VCAM-1. Circulation, 94, 1682–1689. Tsao, P.S., Lewis, N.R, Alpert, S. and Cooke, J.R (1995) Exposure to shear stress alters endothelial adhesiveness: Role of nitric oxide. Circulation, 92, 3513–3519. Tsao, P.S., Theilmeier, G., Singer, A.H. et al. (1994a) L-arginine attentuates platelet reactivity in Hypercholesterolemic rabbits. Arterioscler. Thromb., 14, 1529–1533. Tsao, P.S., Wang, B.Y., Buitrago, R. et al (1997) Nitric oxide regulates monocyte chemotactic protein-1. Circulation, 96, 934–940. Vallance, R, Leone, A., Calver, A., Collier, J. and Moncada, S. (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J.Cardiovasc. PharmacoL, 20(Suppl. 12), S60–S62. von der Ley en, H., Gibbons, G.H. et al. (1995) Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl Acad. Scl USA, 92, 1137–1141. Wang, B., Singer, A., Tsao, R et al. (1994) Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J.Am. Coll. Cardiol, 23, 452–58. Wolf, A., Zalpour, C., Theilmeier, G. et al (1997) Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J.Am. Coll Cardiol, 29, 479–185. Zeiher, A.M., Fisslthaler, B. et al. (1995) Nitric oxide modulates expression of monocyte chemoattractant protein-a in cultured human endothelial cells. Circ. Res., 76, 980–986.
17 Nitric Oxide in Myocardial and Splanchnic Ischemia/ Reperfusion Allan M.Lefer and Rosario Scalia Department of Physiology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
INTRODUCTION Abrupt shutting off blood flow (i.e., ischemia) to a vascular bed followed by reperfusion (i.e., reestablishment of blood flow) results in a severe form of injury to the tissue perfused by that vascular bed. This phenomenon is known as “reperfusion injury”. Reperfusion injury occurs in a variety of vascular beds, including the coronary (Van Benthuysen et al., 1987), mesenteric (Lefer et al., 1991), renal (Lieberthal et al., 1989), cerebral (Rosenblum et al., 1992), and skeletal muscle (Korthuis et al., 1988) circulations. One of the earliest important events after reperfusion of an ischemic bed is a significant degree of endothelial dysfunction characterized by the loss of endothelium-derived relaxing factor (EDRF) (Tsao et al., 1990), now known to be nitric oxide (NO) (Moncada et al., 1990). This reduction in NO formation and release is observed both in response to challenge with endothelium-dependent vasodilators (e.g., acetylcholine, A23187), so-called agonist-mediated NO release, as well as in response to NO synthase inhibitors [e.g., NGnitro-L-arginine methyl ester (L-NAME), NG-monomethyl-L-arginine (L-NMMA)], which unmask the basal release of NO (Moncada et al., 1990). A significant and sustained endothelial dysfunction has been observed in myocardial ischemiareperfusion (Tsao et al., 1990) and in splanchnic ischemia-reperfusion (Carey et al., 1992). This may contribute significantly to the reperfusion injury of the underlying tissue, because NO is known to induce vasorelaxation (Furchgott and Zawadzki, 1980), inhibit platelet aggregation (Radomski et al., 1991), quench superoxide radicals (Rubanyi et al., 1986; Gryglewski et al., 1986), and attenuate adherence of polymorphonuclear (PMN) leukocytes to the endothelium (McCall et al., 1988; Kubes et al., 1991). The endothelial dysfunction occurring in ischemia/reperfusion, is characterized by an abrupt decrease in activity
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
297
of nitric oxide released from the affected endothelium. This marked decrease in NO activity is an important event signalling early pathophysiologic changes and serves as the hallmark of the first phase of reperfusion injury, termed the “endothelial trigger”. This endothelial trigger sets up the cascade of pathophysiological events manifest in reperfusion injury leading to a second major event resulting in tissue injury (Lefer and Lefer, 1993). This second major event, directly dependent on the endothelial dysfunction is known as the “neutrophil amplification” step. This relationship was originally coined by Bulkley (1989) in reference to splanchnic ischemia/reperfusion but clearly pertains to myocardial ischemia/reperfusion and to that of other regional vascular beds (e.g., renal, cerebral) (Lieberthal et al., 1989). It also occurs in total body ischemia/ reperfusion such as that occurring in hemorrhage/reinfusion (Wang, 1993) and in endotoxemia/sepsis (Siegfried et al., 1992; Wang et al., 1995). This chapter will focus on the role of nitric oxide in myocardial ischemia-reperfusion (MI/R) and splanchnic ar tery occlusion reperfusion (SAO/ R) injury, since most of the NO related data have been obtained in these two forms of ischemia/reperfusion (I/R). NO AND THE ENDOTHELIUM IN ISCHEMIA/REPERFUSION A. Time Course of NO Changes in Ischemia/Reperfusion A variety of well designed experiments have been conducted in order to characterize the time course of loss of endothelial derived nitric oxide (EDNO) in ischemia/reperfusion. The first complete study of this type was reported by Tsao et al. (1990) who studied MI/ R in cats. Cats were subjected to 90 minutes of complete occlusion of the left anterior descending (LAD) coronary artery followed by either no reperfusion (i.e., 0 min) or reperfusion of 2.5, 5, 10, 20, 60, 180 and 270 minutes. LAD coronary artery rings were challenged with two endothelium-dependent vasodilators: acetylcholine (ACh), a receptor mediated endothelium-dependent dilator, and A23187, a non-receptor mediated endothelium-dependent dilator. Responses to these agents were compared to an endothelium-independent dilator, acidified sodium nitrite (NaNO2). These responses were also compared to vasorelaxant responses obtained with the same three vasodilators in the non-ischemic control left circumflex coronary artery. Figure 17–1 illustrates the vasorelaxant responses of these LAD coronary artery rings to ACh and NaNO2 at key time points. Surprisingly, total occlusion of the LAD for 90 minutes without reperfusion did not diminish the vasorelaxant response to either ACh or NaNO2. However, 90 minutes of ischemia followed by only 2.5 minutes of reperfusion resulted in a marked attenuation of the vasorelaxation response of ACh (also to A23187) but not to NaNO2. This pattern is characteristic of endothelial dysfunction and is due to reduced NO release by the affected endothelium. Over the ensuing post-reperfusion time (i.e., 5 to 270 minutes) the vasorelaxation response to ACh diminished even more, but at no time was there an attenuation in the vasorelaxant response to NaNO2. Although not shown in Figure 17–1, the responses to A23187 paralleled those to ACh at all times. Thus, endothelial dysfunction originated in the first 2.5 minutes of reperfusion, and was exacerbated and sustained over the entire 4.5 hour post-reperfusion observation period. Moreover, intravenous infusion of recombinant human superoxide dismutase (hSOD) just prior to reperfusion prevented most of the endothelial dysfunction occurring after reperfusion (Tsao et al., 1990). Thus, endothelial dysfunction was manifest in terms of agonist mediated NO release by the endothelium (i.e.,
1Supported
N.I.H.
in part by Research Grant No. GM-45434 from the National Institute of General Medical Science of the
298
ALLAN M.LEFER AND ROSARIO SCALIA
pulsed, release). However, the endothelium usually releases NO continuously in low concentrations (i.e., basal release). Basal release is more difficult to quantify, but can be done by measuring the degree of vasocontraction of vascular rings to a nitric oxide synthase (NOS) inhibitor (e.g., L-NMMA, L-NAME). Using this technique, Ma et al. (1993) showed that the vasocontraction of cat LAD coronary arteries to LNAME was markedly diminished 5 min post-reperfusion following 90 min of ischemia. The response was exacerbated at all post-reperfusion times over the 270 min observation period just as in the case of reduced ACh and A23187 responses. Thus, the endothelial dysfunction occurring following reperfusion of an ischemic coronary vasculature is manifest both in agonist-mediated (i.e., pulsed release of NO) as well as in basal release of NO (i.e., low level continuous release of NO). Additional important information on the mechanism of the endothelial dysfunction was provided by Tsao and Lefer (1990). This study was performed in isolated rat hearts perfused with Krebs-Henseleit buffer rather than with blood. Hearts were subjected to global ischemia (i.e., total cessation of coronary flow for 20 min) followed by reperfusion for periods of 2.5 to 45 minutes with Krebs-Henseleit solution gassed with either 95%O2+5%CO2 or with 95%N2+5%CO2. In addition, superoxide radical release was determined by chemiluminescent methods. As expected, there was a profound endothelial dysfunction 2.5 minutes following reperfusion characterized by markedly attenuated vasorelaxation of the coronary microcirculation (i.e., a smaller decrease in coronary perfusion pressure) to ACh but not to nitroglycerin (NTG). This endothelial dysfunction gradually worsened over the remainder of the 45 min post-reperfusion period. Moreover, there was a large pulse of superoxide radical released by the ischemic-reperfused vasculature within the first minute following reperfusion which lasted for about 1 to 2 minutes. The burst of superoxide radical production preceded the endothelial dysfunction, and in the absence of blood cells in the perfusate could be traced to the endothelium itself. Moreover, infusion of hSOD, but not the hydroxyl radical scavenger MPG, given at the time of reperfusion, abolished both the pulse of superoxide release, and the endothelial dysfunction. However, the most surprising finding in this study is shown in Figure 17–2. The interesting result in this study was that reperfusion with 95%N2+5%CO2 abolished the superoxide release and the endothelial dysfunction clearly pointing to reoxygenation (i.e., re-introduction of oxygen) as the cause of the endothelial dysfunction. In additional studies, it was determined that myocardial ischemia/ reperfusion in the intact rat results in much the same degree of coronary microvascular endothelial dysfunction (Tsao and Lefer, 1991). Moreover, studies on the recovery of normal endothelial function revealed that the endothelial dysfunction persisted for six to seven weeks following ischemia/reperfusion (Tsao and Lefer, 1991) probably as a function of the slow generation of new endothelial cells. This time course of the onset of endothelial dysfunction observed in MI/R in cats and rats is not unique to the coronary circulation, but is very similar to that occurring in the mesenteric vasculature. Thus, splanchnic artery occlusion/reperfusion (SAO/R) also results in a profound endothelial dysfunction in the superior mesenteric artery (SMA) of the rat (Lefer and Ma, 1991, 1993). Moreover, the endothelial dysfunction occurs as early as 2.5 min post-reperfusion and progresses to its maximal state by 60 min post-reperfusion (Lefer and Ma, 1993). Endothelial dysfunction has been observed in cats subjected to SAO/R (Carey et al., 1992; Karasawa et al., 1991) and thus is not species specific. In summary, a severe form of endothelial dysfunction occurs within 2.5 min of reperfusion of the ischemic coronary or mesenteric circulation. The endothelial dysfunction is characterized by a markedly diminished release of NO assessed either by agonist stimulation or by basal release. There is some question of whether the dysfunction occurs in all segments of the ischemic-reperfused vasculature (i.e., large vessels, microvessels) (Quillen et al., 1990). The antecedent event most likely to bring about the endothelial dysfunction is rapid reoxygenation of the previously ischemic vasculature resulting in a burst of superoxide radicals which inactivate NO and may actually injure the NO biosynthetic process. Recent evidence
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
299
Figure 17±1. Representative force recording of coronary artery rings isolated from cats subjected to either ischemia alone or ischemia followed by reperfusion. At the arrow, 20 nM U–4619 was given to add tone to the rings. Before reperfusion (time 0) the response to the endothelium-dependent vasodilator ACh (100 pM to 100 nM) was normal and comparable to that induced by the endothelium-independent vasodilator NaNO2 (100 nM to 100 µM). However, after reperfusion, the ACh-induced relaxation was significantly attenuated with maximal decrement observed after 270 min of reperfusion. All NaNO2 responses showed normal relaxation. This pattern of response is indicative of endothelial dysfunction.
300
ALLAN M.LEFER AND ROSARIO SCALIA
Figure 17±2. Effects of oxygenation on ischemia and reperfusion-induced endothelial dysfunction of the rat coronary circulation. In isolated rat hearts perfused with Krebs-Henseleit solution, reperfusion with 95% N2+5% CO2 prevents the endothelial dysfunction typical of reperfusion injury when reperfused with 95% O2+5% CO2. In these conditions, reoxygenation of ischemic tissues is a critical step for the production of superoxide radicals which are responsible of endothelial damage. Control hearts were not subjected to ischemia/reperfusion, but were time matched controls perfused at 20 ml/min for 65 minutes. All values are means ± SEM for 6–12 rings.
suggests that a critical deficit in tetrahydrobiopterin (TB4) may be a key factor in the endothelial dysfunction (Tiefenbacher et al., 1996). B. Role of NO in Endothelial Adhesion Molecules In recent years, considerable evidence has been gathered which points toward the conclusion that NO attenuates leukocyte-endothelium interaction (i.e., inhibits adherence of leukocytes to the endothelium). One of the earliest findings in this regard is that NO inhibits formyl-methionyl-leucyl-phenylalanine (fMLP) induced PMN aggregation (McCall et al., 1988). Three years later, Kubes et al. (1991) showed that superfusion with L-NMMA, a NOS inhibitor, over the cat mesenteric microvasculature resulted in a profound increase in adherence of leukocytes to the venular endothelium. This enhanced adhesiveness could be overcome by addition of a monoclonal antibody directed against the leukocyte 2-integrin CD18, the major neutrophil adhesion molecule responsible for firm cellular adhesion. Additional evidence has been obtained in the coronary vasculature. In a series of studies employing nitric oxide donors, Siegfried and coworkers (Siegfried et al., 1992a, 1992b; Johnson et al., 1990) showed that a variety of different types of NO donors (e.g., sydnonimine, cysteine, nitrate) attenuated release of superoxide radical by cat neutrophils resulting in a NO-sparing effect on the coronary endothelium and on the mesenteric vascular endothelium (Carey et al., 1992). This has been subsequently confirmed in human neutrophils for superoxide (Clancy et al., 1992; Moilanen et al., 1993) and for hydrogen peroxide (Forslund
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
301
and Sundqvist, 1995). Although these data strongly pointed toward a marked anti-neu trophil effect of NO, they fell short of associating the leukocyte-endothelial interaction with specific cell adhesion molecules. More recently, efforts were made to ascertain which cell adhesion molecules were down-regulated by nitric oxide. A recent study (Lefer et al., 1993) employing human aortic endothelial cells (HAECs) in culture found that NO donors or the NO precursor, L-arginine decreased basal ICAM-1 surface expression. This has been followed up by DeCaterinia et al. (1995) who showed that NO donors can also down-regulate the mRNA and protein for ICAM-1 and VCAM-1 in cultured human endothelial cells. Down-regulation of these important endothelial cell adhesion molecules was related to suppression of the transcription factor NF B and can also be initiated by oxidized low density lipoproteins (oxo-LDL) (Liao et al., 1995). More recently, Armstead et al. (1997) reported that NO donors or L-arginine down-regulated the mRNA and protein expression of P-selectin in human cultured iliac artery and vein endothelial cells. Moreover, LNAME upregulated P-selectin expression in these same cell types. These studies carried out in cultured human endothelial cells under carefully controlled conditions are important in understanding the cell signalling mechanisms responsible for the regulatory effects of NO on cell adhesion molecules. However, they do not yield information on whether these relationships pertain to the intact animal under physiologically relevant conditions. To answer these questions, studies have been conducted in vivo employing intravital microscopy (See the section on microcirculatory changes in NO and leukocyteendothelium interaction). NEUTROPHILS AND NO IN ENDOTHELIAL DYSFUNCTION AND TISSUE NECROSIS As mentioned above, endothelial dysfunction is the hallmark of the early events following reperfusion of a previously ischemic vasculature. This applies to both the coronary and the mesenteric circulation. The key event in this endothelial dysfunction is a loss of endothelial derived nitric oxide (EDNO). One of the major triggers of endothelial dysfunction is a large early burst of superoxide radicals. This early superoxide burst is thought to originate from the hypoxic-reoxygenated endothelium itself (Zweier et al., 1987). This “endothelial trigger” sets up the microvasculature for the consequences of endothelial dysfunction, since superoxide is known to quench NO and thus inactivate EDNO (Rubanyi and Vanhoutte, 1986; Gryglewski et al., 1986). One of the probable sources of the endothelial superoxide is the xanthine-oxidase system (Bulkley, 1989). This endothelial production of superoxide is an important event in the early endothelial dysfunction, occurring in the first minute of reperfusion (Tsao et al., 1990; Tsao and Lefer, 1990; Lefer et al., 1990). However, this early loss of NO is not sufficient by itself to produce marked tissue injury. In the isolated perfused cat heart, rendered globally ischemic and then reperfused with and without neutrophils, about 25% of the endothelial dysfunction occurs in the absence of neutrophils and 75% of the dysfunction occurs upon perfusion with activated PMNs (Tsao et al., 1992). These results are summarized in Figure 17–3 in which coronary artery rings were isolated from isolated cat hearts, perfused either with buffer (no PMNs) or with PMNs activated by fMLP. These hearts were made ischemic (i.e., perfused at 15% of control coronary flow for 90 minutes) followed by reperfusion at control flows for 20 minutes. These data are consistent with the findings of Tsao and Lefer (1990) showing that PMNs play a key role in propagating the endothelial dysfunction and in contributing to the cell injury of the underlying parenchymal cells (i.e., cardiac myocytes in the case of myocardial ischemia/reperfusion, and liver and intestinal cells in the case of splanchnic ischemia/reperfusion). Another aspect of the interaction of PMNs with the NO generated by the endothelium in ischemia/ reperfusion is the interesting effect the oxidative burst of neutrophils has on residual NO from the
302
ALLAN M.LEFER AND ROSARIO SCALIA
Figure 17±3. Role of neutrophils in cat coronary endothelial dysfunction. Cat hearts were perfused under control (nonischemic) conditions or reduced ischemia for 90 min at 15% of control flows, and reperfused for 20 minutes. Coronary artery rings were then isolated and studied. Addition of inactivated neutrophils to isolated cat coronary artery rings did not interfere with acetylcholine (ACh)-induced relaxation. Concomitant incubation of cat coronary rings with fMLPactivated neutrophils significantly impaired the endothelial-mediated dilator response to ACh, but not to NaNO2. All values are means ± SEM, numbers of experiments are indicated at the bottom of the bars.
dysfunctional endothelium. This large secondary burst of superoxide from activated PMNs blocks any further release of NO from the endothelium, and results in a vasospasm-like contraction of coronary arteries (Ma et al., 1991; Ohlstein and Nichols, 1989). Results obtained in both cat (Ma et al., 1991) and rabbit (Ohlstein and Nichols, 1989) coronary arteries clearly show that activated PMNs induce a marked and sustained vasoconstriction in isolated arterial segments. The basis for this constriction, somewhat analogous to a coronary vasospasm, is that the PMNs activated by fMLP or LTB4, release an oxidative burst of superoxide radicals which antagonize the basal release of NO by the endothelium. This vasospasm doesn’t occur in an artery denuded of endothelium or when the PMNs are not activated, indicating that the vasocontraction is clearly due to the superoxide released by activated PMNs acting on endothelium derived NO. This vasocon striction can be washed out, and the arteries tested for their ability to relax to endothelium-dependent dilators (e.g., acetylcholine). Figure 17–4 shows responses to key agents delineating the key principles involved in this phenomenon. Addition of inactivated PMNs (Control) does not interfere with the acetylcholine (ACh) induced vasorelaxation (i.e., NO-dependent relaxation). However activation of the PMNs with fMLP markedly reduced the ACh induced relaxation (i.e., from 93% to 18%). If human superoxide dismutase (hSOD) is added to the PMNs which scavengers superoxide anions released from the activated PMNs, then the NO is spared, and a marked vasorelaxation to ACh occurs. This protection does
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
303
not occur in the presence of the hydroxyl radical scavenger, mercaptopropionyl glycine (MPG). Not only are activated PMNs necessary for this reaction, but the activated PMNs must adhere to the endothelium in order to attenuate the endothelium-dependent relaxation. If one adds a monoclonal antibody (i.e., R15.7) directed against the common -chain of the leukocyte 2-integrins (i.e., CD18), one can also protect the ACh-induced vasorelaxation, whereas a control isotype antibody (R3.1) is ineffective in this regard (Figure 17–4). This anti-CD 18 antibody also worked effectively in attenuating cardiac necrosis and preserving coronary endothelial function when administered in vivo just before reperfusion of the ischemic myocardium (Ma et al., 1991). Indeed, if one blocks adherence of PMNs to the coronary endothelium with a neutralizing monoclonal antibody directed against either ICAM-1 (Ma et al., 1992) or P-selectin (Weyrich et al., 1993) or an anti-selectin oligosaccharide (Buerke et al., 1994) one preserves vascular endothelial function as well as attenuates myocardial reperfusion. Moreover, critical reductions in basal NO release to the coronary vascular endothelium were shown to promote PMN adhesion to the ischemicreperfused endothelium (Ma et al., 1993). Thus, preservation of endogenous NO in the coronary vascular endothelium is a salient feature of the protection against reperfusion injury in myocardial ischemia/reperfusion. MICROCIRCULATORY CHANGES IN NO AND LEUKOCYTEENDOTHELIUM INTERACTION Due to its strategic anatomic position, between the large conductance vessels and the parenchymal tissue of body organs, the microcirculation is a primary candidate as a target and mediator of cardiovascular diseases and inflammatory states. Recently, particular emphasis has been attributed to the physiology and physiopathology of the microvascular endothelium as a major factor in the regulation of circulatory function. The vascular endothelium contributes to the control of the cardiovascular system by synthesis and release of endothelium-derived nitric oxide (NO) under normal as well as pathophysiologic conditions (Moncada et al., 1990). NO is synthesized by vascular endothelial cells via the action of constitutive NO synthase in the L-arginine and citrulline pathway (Moncada et al., 1990; Ignarro, 1989). Beyond its role as a vasodilator substance, NO exerts a variety of other functions in the vascular endothelial environment. In particular, NO is known to inhibit platelet aggregation, inhibit leukocyte endothelial interaction and maintain capillary vascular integrity (Lefer and Lefer, 1993; Ignarro, 1989). Thus, the occurrence of endothelial dysfunction or decreased NO release during pathophysiological conditions (e.g., ischemia-reperfusion) not only affects vascular tone, but also disrupts many other facets of the normal microcirculatory environment. In this regard, it is well established that impaired endothelial production or release of NO occurs in a variety of models of ischemia-reperfusion of different organs, such as heart (Tsao et al., 1990) and splanchnic viscera (Karasawa et al., 1991). Despite the fact that restoration of blood flow to ischemic areas is essential for tissue salvage, reperfusion of the ischemic tissue also triggers a series of events which enhance and extend ischemic tissue injury (Tsao et al., 1990; Lefer and Lefer, 1993; Parks and Granger, 1986). At the present time, one of the most important factors believed to play a central role in this reperfusion-induced tissue injury is circulating leukocytes (i.e., polymorphonuclear leukocytes). Evidence indicates that leukocyte accumulation in the post-ischemic tissue is in part dependent on early endothelial dysfunction (Tsao et al., 1990). Several investigators have demonstrated that basal release of NO is significantly decreased in the microcirculation very early following ischemia-reperfusion, and this decrease in basal NO release results in a significant increase in PMN adherence to the vascular endothelium (Ma et al., 1993 ; Horgan et al., 1990; Kurtel et al., 1992). These data taken together indicate that ischemia followed by reperfusion results in a
304
ALLAN M.LEFER AND ROSARIO SCALIA
Figure 17±4. Cat coronary artery rings isolated from control cats and incubated with autologous PMNs (1×106). Neutrophil-induced endothelial dysfunction can be attenuated by two different strategies. The addition of hSOD but not the hydroxyl radical scavenger MPG, to co-incubated cat coronary rings with activated neutrophils, restores the response of the endothelium to ACh. Inhibition of activated PMN adherence to the vascular endothelium by a monoclonal antibody against CD18 but not an irrelevant control MAb (R3.1) can also protect the vascular endothelium from neutrophil mediated injury, as confirmed by the preservation of ACh-induced vasorelaxation in isolated coronary rings. All values are means ± SEM; numbers in bars are numbers of rings studied.
rapid endothelial dysfunction associated with a reduced NO release, which promotes leukocyte-endothelial interaction and leukocyte accumulation in the post-ischemic tissue. This interrelationship has been studied also by several investigators (Kubes et al., 1991; Arndt et al., 1993; Kubes et al., 1992) who have been able to mimic increases in leukocyte-endothelium interaction observed following ischemia-reperfusion through the use of nitric oxide synthase inhibitors such as NG monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine methyl ester (L-NAME). Both L-NMMA and L-NAME have been shown to increase leukocyte-endothelium interaction and in particular leukocyte adherence to the microvascular endothelium and leukocyte emigration from the microcirculation (Kubes and Granger, 1992). These effects have been attributed to the loss of endothelial NO, as evidenced by the fact that administration of exogenous NO or L-arginine, the substrate for NO synthase, can override the effects of both L-NMMA and L-NAME (Gauthier et al., 1994; Davenpeck et al., 1994). This inhibition of endothelial NO synthesis, even in the absence of ischemia and reperfusion, results in enhanced leukocyteendothelial interaction. Another important factor involved in leukocyte-endothelial interaction during the inflammatory process initiated by ischemia-reperfusion is the expression of cell adhesion molecules. Identification and characterization of the leukocyte and endothelial cell adhesion molecules that mediate leukocyteendothelial interaction have been crucial in determining the mechanism controlling the trafficking of
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
305
leukocytes in the vasculature and the movement of leukocytes out of the circulation into areas of tissue injury. In fact, an important aspect of enhanced leukocyte-endothelial interaction during ischemiareperfusion is the expression of specific endothelial cell adhesion molecules. P-selectin, a member of the selectin family of adhesion glycoproteins is one of the earliest endothelial adhesion molecules involved in leukocyte recruitment to the site of inflammation. Davenpeck and coworkers (Guathier et al., 1994; Davenpeck et al., 1994a, 1994b) extensively studied the interrelationship between NO and cell adhesion molecules and their relationship to ischemia-reperfusion. These investigators employed intravital microscopy of the rat mesenteric microvasculature to further investigate the interaction between NO and cell adhesion molecules. In one of their first studies, Davenpeck et al. (1994b), demonstrated that ischemiareperfusion of the mesenteric circulation, a condition which has been shown to dramatically reduce endothelial NO, resulted in a rapid increase in leukocyte rolling and adherence to the venular endothelium during the first 30 min following reperfusion. At the same time, a marked increase of P-selectin expression in the venular endothelial surface was found 30 min after reperfusion. These results clearly indicate that the critical reduction in NO release 30 min after reperfusion is correlated with an increased upregulation of Pselectin on the endothelial surface (Davenpeck et al., 1994b). In a follow-up study, Gauthier et al. (1994) showed in the same model of ischemia-reperfusion of the rat mesenteric circulation, infusion of an NO donor markedly attenuated post-reperfusion rolling and adherence of leukocyte to the venular endothelium. This clearly demonstrates that restoration of physiological levels of NO in the systemic circulation during microcirculatory perturbations results in a reduced leukocyte-endothelial cell interaction and amelioration of the associated circulatory shock. In order to further investigate this interrelationship between NO and cell adhesion molecules, Davenpeck et al. (1994a), also showed that exposure of the rat mesenteric microvasculature to NOS inhibitors mimicks the effect of ischemia-reperfusion. The key results from this study are depicted in Figure 17–5. The number of adherent leukocytes in the microvasculature is very low during normal physiological conditions. However, exposure of the rat mesentery to increasing concentrations of L-NAME from 25 to 100 μM resulted in a progressive concentration-dependent increase in leukocyte adherence. Equimolar concentration of Larginine, but not of its stereoisomer D-arginine, was able to overcome the L-NAME-induced leukocyte adherence, thus suggesting the specific NO-mediated mechanism of L-NAME-induced leukocyte adherence. Moreover leukocyte adherence could be markedly reduced by administration of a monoclonal antibody directed against P-selectin. Similar results were obtained with leukocyte rolling. Immunohistochemical localization of P-selectin showed upregulation of this adhesion molecule in the rat mesenteric microvasculature following direct inhibition of nitric oxide synthase by L-NAME (Davenpeck et al., 1994a). These findings, taken together, clearly point to the fact that a dynamic negative feedback relationship exists between nitric oxide release and leukocyte-endothelial cell interaction. Reduced nitric oxide release from the microvascular endothelium, during pathophysiologic conditions, leads to an increased adhesion molecule expression on the endothelial cell surface and enhancing NO exogenously can markedly diminish these processes. This phenomenon plays an important role in the margination and emigration of leukocytes from the blood stream and their accumulation in injured tissues. MOLECULAR MECHANISMS OF NO IN REGULATION OF CELL ADHESION MOLECULE EXPRESSION A critical factor involved in leukocyte-endothelial interaction is the expression of cell adhesion molecules on the microvascular endothelium (Carlos and Harlan, 1994). To date, three major families of cell adhesion
306
ALLAN M.LEFER AND ROSARIO SCALIA
Figure 17±5. L-NAME-induced inhibition of nitric oxide synthase increases leukocyte adherence along the venular endothelium of the rat mesenteric microcirculation utilizing intravital microscopy. This phenomenon was inhibited by equimolar concentration of L-arginine and was also blocked by the systemic administration of an antibody against Pselectin (PB 1.3). Therefore, loss of endogenous nitric oxide release upregulates leukocyte rolling, the prelude to leukocyte adherence. All values are means ± SEM for 6 rats in each group.
molecules which regulate leukocyte-endothelial cell interaction are known to play a role in ischemiareperfusion: a) selectins (i.e., P-selectin, L-selectin, E-selectin (Bevilacqua and Nelson, 1993; Lefer et al., 1994); b) the 2 integrins (e.g., CD11/18) (Springer, 1990), and c) the immunoglobulin superfamily (e.g., ICAM-1, VCAM-1, PECAM-1) (Springer, 1990). The expression of selectins (i.e., P-selectin) and immunoglobulin superfamily members (e.g., ICAM-1 and VCAM-1) on the microvascular endothelium has been recently correlated to impairment of nitric oxide synthesis and release from endothelial cells, during pathological perturbations of the microcirculation (e.g., ischemia-reperfusion and hyperlipidemia). In particular, rapid (i.e., 10–15 min) P-selectin endothelial cell surface expression has been linked to leukocyte accumulation and tissue injury in several in vivo models of acute inflammation generally associated with a reduced release of nitric oxide (Weyrich et al., 1993; Gauthier et al., 1994; Davenpeck et al., 1994a). Furthermore, other investigators have shown, employing intravital microscopy, that the NO synthase inhibitor L-NAME directly induces P-selectin expression, thus facilitating neutrophil rolling and adherence in the rat mesenteric microcirculation in vivo (Davenpecket al., 1994a). P-selectin and ICAM-1 expression on endothelial cells were also found to be upregulated during induction of hypercholesterolemia in cholesterol fed animals (Gauthier et al., 1995). More recently, nitric oxide was also found to be able to reduce cytokine-induced expression of an other physiologically relevant effector molecule characteristic of endothelial activation during atherogenesis (i.e., VCAM-1) (DeCaterina et al., 1995). Despite these numerous data regarding nitric oxide-induced modulation of adhesion molecules on the endothelial cell surface, the precise molecular mechanisms of this cell signalling pathway are still poorly
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
307
understood. Nevertheless, at the present time, only a few mechanisms have been proposed for explaining NO-mediated regulation of adhesion molecules expression. The first mechanism is related to the fact that both endothelial dysfunction (i.e., loss of endothelial NO) and P-selectin expression are believed to be mediated by the generation of oxygen-derived radicals at the time of reperfusion. Virtually all cells generate oxygen derived free radicals through normal physiological pathways such as the mitochondrial electron transport pathway and the NADPH pathway (Grisham and Granger, 1989). Normally, adequate mechanisms exist within the cell to scavenge these radicals and thus prevent injury to the cell. In this connection, endogenous NO is a known scavenger of oxygen derived free radicals and in particular the superoxide radical (Rubanyi et al., 1991). Accordingly, Gaboury et al. (1993) recently demonstrated that superoxide radicals introduced directly into the rat mesenteric microcirculation following generation by hypoxanthine-xanthine oxidase results in P-selectin mediated leukocyte rolling and adherence. Thus reduced endogenous NO synthesis by endothelial cells as a result of superfusion with LNAME could lead to an excess of oxygen-derived free radicals within these cells, stimulating expression of endothelial cell adhesion molecules (Davenpeck et al., 1994a). A similar mechanism may occur outside the endothelial cell as well, since NO also scavenges radicals at the endothelial cell surface (Rubanyi et al., 1991). Also consistent with this hypothesis is the observation that both L-arginine and 8-bromo-cGMP can significantly attenuate the L-NAME induced increase in P-selectin expression (Davenpeck et al., 1994a). More recently, a second line of in vitro studies has focused attention on the potential role of protein kinase C (PKC) as a signalling molecule in these processes. Murohara et al. (1995), examined the hypothesis that L-NAME stimulates P-selectin expression on platelets via PKC activation utilizing flow cytometry. These workers showed it is possible to induce P-selectin surface expression in cat platelets, as well as PKC activity on platelet membranes, following a 10 min incubation with either phorbol-12myristate-13 acetate (i.e., a well known PKC stimulator), thrombin, or L-NAME. Conversely, the specific PKC inhibitor UCN-01 (i.e., 7-hydroxystauroporine) was able to attenuate L-NAME-induced P-selectin expression on isolated platelets (Figure 17–6), thus confirming the role of PKC activation in NO-mediated P-selectin cell surface expression (Murohara et al., 1995). These two purported mechanisms of cell signalling between nitric oxide and cell adhesion molecules could explain some of the molecular mechanisms by which nitric oxide can regulate cell adhesion molecule expression on endothelial cells. Actually, P-selectin, which is constitutively stored in Weibel-Palade bodies of endothelial cells (McEver et al., 1995), is rapidly translocated (i.e., in 10 min) to the endothelial surface upon stimulation with histamine, thrombin, hydrogen peroxide or hypoxia-reoxygenation (Lorant et al., 1991). These temporal relationships are consistent with signalling times for both cyclic GMP and protein kinase C. More complex molecular mechanisms have been recently reported in the case of other endothelial cell adhesion molecules (i.e., E-selectin, ICAM-1 and VCAM-1) in which upregulation of endothelial cells requires de novo synthesis of proteins and therefore requires 2 to 4 hours to induce changes. DeCaterina et al. (1995) have recently shown that, in cytokine-stimulated human saphenous vein endothelial cells, several NO donors inhibit VCAM-1 expression by 35–55%, and also reduce to a lesser extent E-selectin and ICAM-1 level in similar conditions. In the case of VCAM-1, these investigators also showed that nitric oxide inhibits VCAM-1 gene transcription, in part by inhibiting NFKB (DeCaterina et al., 1995). These observations offer new insights into the biology of nitric oxide and the physiological pathways by which, NO can modulate the expression of cell adhesion molecules, thus affecting the pathology of the inflammatory and immune response.
308
ALLAN M.LEFER AND ROSARIO SCALIA
NO, NO DONORS AND PEROXYNITRITE IN ISCHEMIA/ REPERFUSION One of the major endogenous agents which is important in preserving vascular homeostasis is nitric oxide. Nitric oxide is produced in low nanomolar concentrations by the vascular endothelium (Kelm and Schrader, 1990). NO can diffuse to the basilar surface of the endothelial cells and then to vascular smooth muscle cells where it can induce vasorelaxation of the vascular smooth muscle cells. NO can also diffuse to the luminal surface where it interfaces with the blood and exerts some very important physiologic actions including inhibition of platelet aggregation (Radomski et al., 1991), quenching of superoxide radicals (Rubanyi and Vanhoutte, 1986; Gryglewski et al., 1986; Stewart et al., 1988) and attenuation of leukocyte adherence to the endothelium (McCall et al., 1988; Kubes et al., 1991; Gauthier et al., 1994; Davenpecketf et al., 1994a, 1994b; Gaboury et al., 1993). These effects occur at low nanomolar concentrations, below concentrations which are necessary to produce vasodilation (Gauthier et al., 1994; Davenpeck et al., 1994a, 1994b; Gaboury et al., 1986). In ischemia/reperfusion, authentic NO gas dissolved in physiological solutions (e.g., 0.9% NaCl) yielding local NO concentrations of 2 to 10 nM, has been shown to exert protective effects in both myocardial ischemia/reperfusion (Johnson et al., 1991) and in splanchnic ischemia/reperfusion (Aoki et al., 1990). The major effect was an attenuation of tissue injury and improved biochemical sequelae. Figure 17–7 illustrates the effect of authentic NO on myocardial necrosis in cats subjected to MI/R. In the case of myocardial ischemia/reperfusion this was related to reduced neutrophil infiltration into the reperfused myocardium (Johnson et al., 1991). These results were confirmed by the administration of the inorganic NO releasing agent sodium nitrite (NaNO2) at pH 2.0 (Johnson et al., 1990). These were the earliest reports that addition of physiological amounts of NO could exert beneficial effects in severe life-threatening forms of ischemia/ reperfusion. However, these agents require significant improvement in order to be clinically useful. The next advance occurred with the synthesis of third generation organic NO donors. These are organic nitrates that release NO in solution, and are much more potent than classical NO donors (e.g., nitroglycerin, nitroprusside) in addition to inducing much less tolerance than these agents. Also, these newer agents are more stable compounds, and do not release superoxide radicals or cyanide, as do some of the earlier NO donors (e.g., SIN-1). Several of these newer NO donors have been studied in myocardial ischemia/ reperfusion. Thus, C87–3754, a sydnonimine NO donor, but not its non-NO releasing control compound C88–3934, markedly protected the ischemic cat myocardium from necrosis, and preserved the integrity of the coronary vascular endothelium (Siegfried et al., 1992a). These results were followed by a study employing another NO donor, a cysteine analog SPM-5185, and its non-NO donating control compound SPM-5267 in the same cat model of myocardial ischemia/reperfusion (Siegfried et al., 1992b). In this second study, the major mechanism of the cardioprotection was identified as inhibition of neutrophilendothelium interaction and subsequent release of superoxide by activated PMNs (Siegfried et al., 1992b). This was subsequently confirmed using the same NO donor in dogs (Lefer et al., 1993), and another NO donor in isolated rat hearts perfused with PMNs (Pabla et al., 1996). The same principles apply to splanchnic ischemia-reperfusion since the sydnonimine, C87–3754 also protected cats subjected to splanchnic artery occlusion/reperfusion (Carey et al., 1992). This NO donor increased survival and attenuated the formation of a myocardial depressant factor (MDF) (Lefer, 1987) in this lethal form of shock. Moreover, the NO donor preserved the integrity and function of the superior mesenteric arterial endothelium (Carey et al., 1992). In all cases, infusion of the NO donor occurred at a rate which did not exert any detectable effect on arterial blood pressure (i.e., was sub-vasodilator). More recently, the precursor of NO, the amino acid L-arginine has been studied in myocardial ischemiareperfusion (Weyrich et al., 1992; Nakanishi et al., 1992). In the same cat model of myocardial ischemia/ reperfusion as that employed in the NO donor studies, intravenous infusion of L-arginine was also effective
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
309
Figure 17±6. Representative fluorescence histograms of P-selectin cell surface expression on feline platelets, as assessed by flow cytometry. Inhibition of nitric oxide synthase by 1 mM L-NAME significantly increaseds P-selectin expression. This L-NAME mechanism selectively operates on nitric oxide synthase as confirmed by the observation that co-incubation with equimolar concentration of L-arginine, but not D-arginine, can override L-NAME effects. The PKC inhibitor (UCN-01) also inhibited L-NAME-induced P-selectin expression, thus confirming the role of PKC in nitric oxide cell signaling.
310
ALLAN M.LEFER AND ROSARIO SCALIA
Figure 17±7. Effect of authentic NO on myocardial necrosis in cats subjected to MI/R. Nitric oxide significantly reduced the amount of necrotic myocardial tissue, following ischemia-reperfusion of cat coronary circulation for 90 minutes of ischemia and 270 minutes of reperfusion. NO infusion was administered lose to the heart just before reperfusion, and continued for the entire reperfusion period. All values are means ± SEM for 6 cats in each group.
in reducing infarct size as well as attenuating neutrophil infiltration into the ischemic reperfused myocardium and preserving coronary vascular endothelial function (Weyrich et al., 1992). Similar effects were observed in a dog model of myocardial ischemia-reperfusion injury (Nakanishi et al., 1992). Thus, availability of arginine may be important in maintaining endothelial NO in ischemia/reperfusion. Recently, Tiefenbacher et al. (1996) showed that there is also a deficit in tetrahydrobiopterin, (TB4) a critical cofactor in the biosynthesis of NO. Where TB4 is replaced, much of the post-reperfusion endothelial dysfunction is prevented. It should be emphasized that there are many published reports showing that either low doses of NO gas or NO donors or higher doses of L-arginine or TB4 are protective in ischemia/reperfusion (Tsao et al., 1990; Siegfried et al., 1992a, 1992b; Gauthier et al., 1994; Lefer et al., 1993; Pabla et al., 1996). However, there are some dissenting studies in which NO synthase inhibitors (e.g., L-NAME) also have been shown to be protective in myocardial hypoxia-reoxygenation models (Mathies et al., 1992; Schulz and Wambolt, 1995) and in either hypoxic-reoxygenated pigs or isolated perfused rat hearts, suggesting that NO may not be good under all conditions. It is difficult to distinguish among several possible explanations from these findings; including the possibility that (a) L-NAME may be cardiotoxic at high doses due to coronary constrictor or other effects, (b) NO may exert different effects in ischemia/reperfusion from hypoxia/reoxygenation, or (c) there is cardiotoxicity in these models due to formation of peroxynitrite. However, the last potential
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
311
Figure 17±8. Effects of the nitric oxide metabolite peroxynitrite on ischemic-reperfused rat hearts. Infusion of peroxynitrite to (800 nM) ischemic hearts markedly attenuated the neutrophils-induced myocardial injury, as confirmed by improved postischemic LVDP values throughout reperfusion. All values are means ± SEM for 6–7 hearts in each group.
explanation is unlikely, due to recent findings showing physiologically relevant concentrations of peroxynitrite to be cardioprotective (Lefer et al., 1997a). Recently, authentic peroxynitrite (ONOO−) was added to isolated perfused rat hearts to yield a local concentration of 800 nM, a concentration calculated to be comparable to biologically achievable concentrations (Lefer et al., 1997a). In rat hearts subjected to ischemia for 30 minutes and reperfusion for 45 minutes, ONOO− had no detectable effect on left ventricular developed pressure (LVDP), dP/dt max, or coronary flow. When rat hearts were subjected to ischemia/reperfusion and perfused with rat neutrophils (i.e., PMNs), a severe reduction in LVDP, dP/dt max, and coronary flow occurred. However, perfusion with 800 nM ONOO− in ischemic/reperfused rat hearts perfused with PMNs resulted in a marked amelioration of the cardiodepression observed with the pH matched vehicle for ONOO− (Lefer et al., 1997a). Figure 17–8 illustrates the major cardioprotective effect of ONOO− in the isolated perfused rat hearts. Physiological concentrations of ONOO− clearly protected the heart against post-ischemia/reperfusion induced cardiac stunning. These results also correlated closely with reduced MPO activity and fewer PMNs in the ischemic rat hearts reperfused with PMNs (Lefer et al., 1997a). Thus, ONOO− markedly attenuated accumulation of PMNs in the ischemia/reperfused rat heart, and preserved left ventricular contractility in the face of ischemia-reperfusion with neutrophils.
312
ALLAN M.LEFER AND ROSARIO SCALIA
Recently, these studies in isolated perfused hearts have been confirmed in vivo in cats subjected to myocardial ischemia/reperfusion. In these experiments, ONOO− was infused directly into the heart to achieve a local concentration of 400 nM. Under these conditions, ONOO− significantly preserved the reperfused ischemic myocardium by 55% (Lefer et al., 1997b). These ONOO− treated cats also exhibited a significant preservation of coronary endothelial function (i.e., maintained NO release) as well as attenuated PMN infiltration into the ischemic/reperfused myocardium (Lefer et al., 1997b). Thus, physiologically relevant concentrations of ONOO− (i.e., 400–800 nM) act as a cardioprotective agent in ischemia/ reperfusion. Earlier studies demonstrating cytotoxic effects of ONOO− employed concentrations of 500 μM to 1.5 mM ONOO− to produce significant cell death (Szabo et al., 1996). These extremely high concentrations are unlikely to ever occur in vivo, since ONOO− is formed from the equimolar combination of NO and superoxide radical (Pryor and Squadritto, 1995; Beckman et al., 1990) and NO is present in blood at 1–10 nM (Kelm and Schrader, 1990). Even if NO levels increase by a factor of 100 to 1,000, this could only yield maximal ONOO− concentrations of 10 µM. With a half-life of < 1 second, ONOO− would probably never achieve these cytotoxic levels in vivo. In summary, physiological levels of NO are important in preserving endothelial cell integrity and preventing increased leukocyte-endothelium interaction as well as platelet adherence to the endothelium. Physiological concentrations of NO therefore prevent leukocyte infiltration into inflamed areas following reperfusion of an ischemic circulation (e.g., myocardium, splanchnic region). This results in markedly limiting tissue necrosis and protects the function of these ischemic-reperfused organs. These effects of physiologic concentration of NO are very important and lead to cytoprotective effects. These cytoprotective effects need to be studied further to fully elucidate their molecular mechanisms. REFERENCES Aoki, N., Johnson, G. III and Lefer, A.M. (1990) Beneficial effects of two forms of NO administration in feline splanchnic artery occlusion shock. Am.J.Physiol., 258, G275–G281. Armstead, V.E., Minchenko, A.G., Schuhl, R.A., Hayward, R., Nossuli, T.O. and Lefer, A.M. (1997) Regulation of Pselectin expression in human endothelial cells by nitric oxide. Am. J.Physiol, 273, H740–746. Arndt, H., Russell, J.B., Kurose, I., Kubes, P. and Granger, D.N. (1993) Mediators of leukocyte adhesion in rat mesenteric venules elicited by inhibition of nitric oxide synthesis. Gastroenterology, 105, 675–680. Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A. and Freeman, B.A. (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA, 87, 1620–1624. Bevilacqua, M.P. and Nelson, R.M. (1993) Selectins. J. Clin. Invest., 91, 379–387. Buerke, M., Weyrich, A.S., Zheng, Z., Gaeta, F.C.A., Forrest, M.J. and Lefer, A.M. (1994) Sialyl Lewisxcontaining oligosaccharide attenuates myocardial reperfusion injury in cats. J.Clin. Invest., 93, 1140– 1148. Bulkley, G.B. (1989) Mediators of splanchnic organ injury: overview and perspective. In: Splanchnic Ischemia And Multiple Organ Failure, edited by A.Marston, G.B.Bulkley, R.G.Fiddian-Green and U.H.Haglund, pp. 191–193. London: Edward Arnold. Carey, C, Siegfried, M.R., Ma, X-L, Weyrich, A.S. and Lefer, A.M. (1992) Antishock and endothelial protective actions of a NO donor in mesenteric ischemia and reperfusion. Cire. Shock., 38, 209–216. Carlos, T.M. and Harlan, J.M. (1994) Leukocyte-endothelial adhesion molecules. Blood, 84, 2068–2101. Clancy, R.M., Leszczynska-Piziak, J. and Abramson, S.B. (1992) Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action in the NADPH oxidase. J. Clin. Invest., 90, 1116–1121. Davenpeck, K.L., Gauthier, T.W. and Lefer, A.M. (1994) Inhibition of endothelial-derived nitric oxide promotes Pselectin expression and actions in the rat microcirculation. Gastroenterology, 107, 1050–1058.
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
313
Davenpeck, K.L., Gauthier, T.W., Albertine, K.H. and Lefer, A.M. (1994) Role of P-selectin in microvascular leukocyte-endothelial interaction in splanchnic ischemia-reperfusion. Am. J.Physiol., 267, H622-H630. DeCaterina, R., Libby, P., Peng, H.-B., Thannickol, V.J., Rajavashisth, T.B., Gimbrone, M.A.Jr., Shin, W.S. and Liao, J.K. (1995) Nitric oxide decreases cytokine-induced endothelial activation. No selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J.Clin. Invest., 96, 60–68. Forslund, T. and Sundqvist. T. (1995) Nitric oxide reduces hydrogen peroxide production from human polymorphonuclear neutrophils. Eur. J.Clin. Invest., 25, 9–14. Furchgott, R.F. and Zawadzki, J.V. (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373–376. Gaboury, J., Niu, X.F. and Kubes, P. (1986) Nitric oxide inhibits numerous features of most cell-induced inflammation. Circulation, 93, 318–326. Gaboury, J., Woodman, R.C., Granger, D.N., Reinhardt, P. and Kubes, P. (1993) Nitric oxide prevents leukocyte adherence: role of superoxide. Am.J.Physiol., 265, H862–7. Gauthier, T.W., Davenpeck, K.L. and Lefer, A.M. (1994) Nitric oxide attenuates leukocyte-endothelial interaction via Pselectin in splanchnic ischemia-reperfusion. Am. J .Physiol., 267, G562–G568. Gauthier, T.W., Scalia, R., Murohara, T., Guo, J.P. and Lefer, A.M. (1995) Nitric oxide protects against leukocyteendothelium interactions in the early stages of hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 15, 1652–1659. Grisham, M.B. and Granger, D.N. (1989) Metabolic sources of reactive oxygen metabolites during oxidant stress and ischemia with reperfusion. Clin. Chest Med., 10, 71–81. Gryglewski, R.J., Palmer, R.M.J. and Moncada, S. (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature, 320, 454–456. Horgan, M.J., Wright, S.D. and Malik, A.B. (1990) Antibody against leukocyte integrin (CD 18) prevents reperfusioninduced lung vascular injury. Am. J.Physiol., 259, L315–9. Ignarro, L.J. (1989) Endothelium-derived nitric oxide: actions and properties. FASEB J., 3, 31–36. Johnson, G. III, Tsao, P.S. and Lefer, A.M. (1991) Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Critical Care Medicine, 19, 244–252. Johnson, G. III, Tsao, P.S., Mulloy, D. and Lefer, A.M. (1990) Cardioprotective effects of acidified sodium nitrite in myocardial ischemia with reperfusion. J. Pharmacol. Exp. Therap., 252, 35–41. Karasawa, A., Guo, J.-P, Ma, X.-I. and Lefer, A.M. (1991) Beneficial effects of transforming growth factor- and tissue plasminogen activator in splanchnic artery occlusion and reperfusion in cats. J.Cardiovas. Pharmacol., 18, 95–105. Kelm, M. and Schrader, J. (1990) Control of coronary vascular tone by nitric oxide. Circ. Res., 66, 1561–1575. Korthuis, R.J., Grisham, M.B., Zimmerman, B.J., Granger, D.N. and Taylor, A.E. (1988) Vascular injury in dogs during ischemia-reperfusion improvement with ATP-MgC12 pretreatment. Am. J. Physiol., 254, H702– 708. Kubes, P. and Granger, D.N. (1992) Nitric oxide modulates microvascular permeability. Am. J. Physiol., 262, H611–5. Kubes, P., Hunter, J. and Granger, D.N. (1992) Ischemia/reperfusion-induced feline intestinal dysfunction: importance of granulocyte recruitment. Gastroenterology, 103, 807–812. Kubes, P., Suzuki, M. and Granger, D.N. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA, 88, 4651–4655. Kurtel, H., Tsao, P. and Granger, D.N. (1992) Granulocyte accumulation in postischemic intestine: role of leukocyte adhesion glycoprotein CD11/CD18. Am.J.Physiol., 262, G878–82. Lefer, A.M. (1987) Interaction between myocardial depressant factor and vasoactive mediators with ischemia and shock. Am.J.Physiol., 252, R193–R205. Lefer, A.M. and Lefer, D.J. (1993) Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu. Rev. Pharmacol., 33, 71–90. Lefer, A.M. and Ma, X.-I. (1991) Endothelial dysfunction in the splanchnic circulation following ischemia and reperfusion. J.Cardiovas. Pharmacol., 17 (Suppl. 3), S186–S190. Lefer, A.M. and Ma, X.-I. (1993) Cytokines and growth factors in endothelial dysfunction. Crit. Care Med., 21 (Suppl.), S9–S14.
314
ALLAN M.LEFER AND ROSARIO SCALIA
Lefer, A.M., Nossuli, T.O. and Hayward, R. (1997b) Peroxynitrite reduces myocardial infarct size and preserves coronary endothelium following ischemia and reperfusion. FASEB J., 11. Lefer, A.M., Tsao, P., Aoki, N. and Palladino, M.A.Jr. (1990) Mediation of cardioprotection by transforming growth factor-. Science, 249, 61–64. Lefer, A.M., Weyrich, A.S. and Buerke, M. (1994) Role of selectins, a new family of adhesion molecules, in ischaemiareperfusion injury. Cardiovasc. Res., 28, 289–294. Lefer, D.J., Klunk, D.A., Lutty, G.A., Merges, C, Schleimer, R.P., Bochner, B.S. and Zweier, J.L. (1993) Nitric oxide (NO) donors reduce basal ICAM-1 expression on human aortic endothelial cells (HAECs). Circulation, 88[part 2], 1–565. Lefer, D.J., Nakanishi, K., Johnston, W.E. and Vinten-Johansen, J. (1993) Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs. Circulation. 88. 2337–2350. Lefer, D.J., Scalia, R., Campbell, B., Nossuli, T., Hayward, R., Salamon, M., Grayson, J. and Lefer, A.M. (1997a) Peroxynitrite inhibits leukocyte-endothelial cell interactions and protects against ischemia-reperfusion injury in rats. J.Clin. Invest., 99, 684–691. Liao, J.K., Shin, W.S., Lee, W.Y. and Clark, S.L. (1995) Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J.Biol. Chem., 270, 319–324. Lieberthal, W., Wold, E.F., Rennke, H.G., Valeri, C.R. and Levinsky, N.G. (1989) Renal ischemia and reperfusion impair endothelium-dependent vascular relaxation. Am.J.Physiol., 256, F894–F900. Lorant, D.E., Patel, K.D., Mclntyre, T.M., McEver, R.P., Prescott, S.M. and Zimmerman, G.A. (1991) Coexpression of GMP–140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J.Cell Biol., 115, 223–234. Ma, X.-I, Lefer, D.J., Lefer, A.M. and Rothlein, R. (1992) Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion. Circulation, 86, 937–946. Ma, X.-I, Tsao, P.S. and Lefer, A.M. (1991a) Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J.Clin. Invest., 88, 1237–1243. Ma, X.-I, Tsao, P.S., Viehman, G.E. and Lefer, A.M. (1991b) Neutrophil-mediated vasoconstriction and endothelial dysfunction in low-flow perfusion-reperfused cat coronary artery. Circ. Res., 69, 95–106. Ma, X.-I, Weyrich, A.S., Lefer, D.J. and Lefer, A.M. (1993) Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res., 72, 403–412. Mathies, G., Sherman, M.P., Buckberg, G.D., Haybron, D.M., Young, H.H. and Ignarro, L.J. (1992) Role of L-argininenitric oxide pathway in myocardial reoxygenation injury. Am. J.Physiol, 262, H616–H620. McCall, T., Whittle, B.J.R., Boughton-Smith, N.K. and Moncada, S. (1988) Inhibition of fMLP induced aggregation of rabbit neutrophils by nitric oxide. Br.J.Pharmacol, 95, 517P. McEver, R.P., Beckstead, J.H., Moore, K.L., Marshall-Carlson, L. and Bainton, D.F. (1989) GMP-140, a platelet alphagranule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J.Clin. Invest., 84, 92–99. Moilanen, E., Vuorinen, P., Kankaanranta, H., MetsaKetela, T. and Vapatalo, H. (1993) Inhibition by nitric oxidedonors of human polymorphonuclear leukocyte function. Br.J.Pharmacol, 109, 852–858. Moncada, S., Palmer, R.M.J. and Higgs, E.H. (1990) Nitric Oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev., 43, 109–142. Mulligan, M.S., Policy, M.J., Bayer, R.J., Nunn, M.F., Paulson, J.C. and Ward, PA. (1992) Neutrophil-dependent acute lung injury: Requirement for P-selectin. J.Clin. Invest., 91, 577–587. Murohara, T., Parkinson, S.J., Waldman, S.A. and Lefer, A.M. (1995) Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. Arterioscler. Thromb. Vasc. Biol, 15, 2068–2075. Nakanishi, K., Vinten-Johansen, J., Lefer, D.J., Zhao, Z., Fowler, W.C.,111, McGee, D.S. and Johnston, W.E. (1992) Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am.J.Physiol, 263, H1650–H1658.
NITRIC OXIDE IN MYOCARDIAL AND SPLANCHNIC ISCHEMIA/REPERFUSION
315
Ohlstein, E.H. and Nichols, A.J. (1989) Rabbit polymorphonuclear neutrophils elicit endothelium-dependent contraction in vascular smooth muscle. Circ. Res., 65, 917–924. Pabla, R., Buda, A.J., Flynn, D.M., Blesse, S.A., Shin, A.M., Curtis, M.J. and Lefer, D.J. (1986) Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ. Res., 78, 65–72. Parks, D.A. and Granger, D.N. (1986) Contributions of ischemia and reperfusion to mucosal lesion formation. Am.J.Physiol, 250, G749–53. Pry or, W.A. and Squadritto, G.L. (1995) The chemistry of peroxy nitrite: a product from the reaction of nitric oxide and superoxide. Am. J. Physiol, 268, L699–L722. Quillen, I.E., Sellke, F.W., Brooks, L.A. and Harrison, D.G. (1990) Ischemia-reperfusion impairs endotheliumdependent relaxation of coronary microvessels but does not affect large arteries. Circulation, 82, 586– 594. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1991) Modulation of platelet aggregation by an L-arginine-nitric oxide pathway. Trends Pharmacol Sci, 12, 87–88. Rosenblum, W.I., Nelson, G.H. and Shimizu, T. (1992) L-arginine suffusion restores response to acetylcholine in brain arterioles with damaged endothelium. Am. J.Physiol, 262, H961–964. Rubanyi, G.M. and Vanhoutte, P.M. (1986) Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am.J.Physiol, 250, H822–827. Rubanyi, G.M., Ho, E.H., Cantor, E.H., Lumma, W.C. and Botelho, L.H. (1991) Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem. Biophys. Res. Commun., 181, 1392–1397. Schulz, R. and Wambolt, R. (1995) Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischaemia-reperfusion injury. Cardiovasc. Res., 30, 432–439. Siegfried, M.R., Carey, C, Ma, X.-I. and Lefer, A.M. (1992b) Beneficial effects of SPM-5185, a cysteine-containing NO donor in myocardial ischemia-reperfusion. Am.J.Physiol., 263, H771-H777. Siegfried, M.R., Erhardt, J., Rider, T., Ma, X.-I. and Lefer, A.M. (1992a) Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J.Pharmacol. Exp. Therap., 260, 668–675. Siegfried, M.R., Ma, X.-I. and Lefer, A.M. (1992c) Splanchnic vascular endothelial dysfunction in rat endotoxemia: Role of superoxide radicals. Europ. J.Pharmacol., 212, 171–176. Springer, T.A. (1990) Adhesion receptors of the immune system. Nature, 346, 425–434. Stewart, D.J., Pohl, U. and Bassenge, E. (1988) Free radicals inhibit endothelium-dependent dilation in the coronary resistance bed. Am. J.Physiol, 255, H765–H769. Szabo, C., Zingarelli, B. and Salzman, A.L. (1996) Role of poly-ADP ribosyltransierase activation in the vascular contractile and energetic failure elicited by exogenous nitric oxide and peroxynitrite. Circ. Res., 78, 1051– 1063. Tiefenbacher, C.P., Chilian, W.M., Mitchell, M. and DeFily, D.V. (1996) Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrohydrobiopterin. Circulation, 94, 1423–1429. Tsao, P.S. and Lefer, A.M. (1990) Time course and mechanism of endothelial dysfunction in isolated ischemic and hypoxic perfused rat hearts. Am. J.Physiol, 259, H1660–H1666. Tsao, P.S. and Lefer, A.M. (1991) Recovery of endothelial function following myocardial ischemia and reperfusion in rats. J.Vasc. Med. Biol., 3, 5–10. Tsao, P.S., Aoki, N., Lefer, D.J., Johnson, G. and Lefer, A.M. (1990) Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation, 82, 1402–1412. Tsao, P.S., Ma, X.-I. and Lefer, A.M. (1992) Activated neutrophils aggravate endothelial dysfunction after reperfusion of the ischemic feline myocardium. Am. Heart J., 123, 1464–1471. Van Benthuysen, K.M., McMurtry, I.F. and Horowitz, L.D. (1987) Reperfusion after acute coronary occlusion in dogs impairs endothelial dependent relaxation to acetylcholine and augments contractile reactivity in vitro . J.Clin. Invest., 79, 265–274. Wang, P., Zheng, F. and Chaudry, I.H. (1995) Endothelium-dependent relaxation is depressed at the macro-and microcirculatory levels during sepsis. Am. J.Physiol., 269 R988-R994.
316
ALLAN M.LEFER AND ROSARIO SCALIA
Wang, P., Zheng, F.B. and Chaudry, I.H. (1993) Endothelial cell dysfunction occurs very early following traumahemorrhage and persists despite fluid resuscitation. Am. J.Physiol., 265, H973–H979. Weyrich, A.S., Ma, X.-I. and Lefer, A.M. (1992) The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation, 86, 279–288. Weyrich, A.S., Ma, X.Y., Lefer, D.J., Albertine, K.H. and Lefer, A.M. (1993) In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J.Clin. Invest., 91, 2620–2629. Zweier, J.L., Flaherty, J.T. and Weisfeldt, M.L. (1987) Observation of free radical generation in the post-ischemic heart. Proc. Natl. Acad. Sci. USA. 84, 1404–1407.
18 Nitric Oxide and Circulatory Shock Christoph Thiemermann The William Harvey Research Institute, St.Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, United Kingdom Tel: +44 171 982 6119; Fax: +44 171 251 1685; E-Mail:
[email protected]
Nitric oxide (NO) is generated by three different isoforms of NO synthase, two of which are expressed constitutively (in endothelium: eNOS, brain: nNOS), while one is induced by endotoxin or cytokines (iNOS). Expression of iNOS in many organs/tissues in septic shock results in an enhanced formation of NO which contributes to circulatory collapse and possibly organ injury/dysfunction and host defence. Inhibition of NOS activity in shock has beneficial and adverse effects, which have tentatively been linked to inhibition of iNOS and eNOS activity, respectively. Although inhibition of NOS activity attenuates the circulatory failure in endotoxin (or septic) shock in many species, it is less clear whether an enhanced formation of NO by iNOS contributes to the organ injury or mortality associated with shock. Studies subjecting mice in which the iNOS gene has been inactivated by gene-targeting to endotoxemia support the notion that NO from iNOS contributes to hypotension and host defence, but provide controversial results regarding the role of iNOS in organ injury and mortality. The role of NO in the pathophysiology of humans with shock is less well investigated. Clearly, degree of iNOS induction in patients with septic shock is lower that in rodents with endotoxemia. Nevertheless, in patients with septic shock (placebo-controlled multi-center study, 156 patients per group with matched SAPS II scores), inhibition of NOS activity with NG-methyl-L-arginine (L-NMMA) improved haemodynamics and reduced the time to resolution of shock, without causing any major side effects. Key words: circulatory shock, multiple organ failure, selective iNOS inhibitors, aminoguanidine, aminoethyl-isothiourea.
318
CHRISTOPH THIEMERMAN
INTRODUCTION Septic shock, regardless of its aetiology, is defined as sepsis (systemic response to infection) with hypotension resulting in impaired tissue perfusion and oxygen extraction (Parrillo, 1990). The definition of septic shock is independent of the presence or absence of a multiple organ dysfunction syndrome (MODS), which is defined as impaired organ function such that homeostasis cannot be maintained without intervention (Baue, 1993). MODS may either occur as is a direct result of a well-defined insult to a specific organ (e.g. primary MODS) or as a consequence of an exaggerated host response (secondary MODS). This enhanced host response termed systemic inflammatory response syndrome (SIRS) may occur in response to infection, multiple trauma, haemorrhage, ischaemia and immune-mediated organ injury (Baue, 1993). Current therapeutic approaches for septic shock include antimicrobial chemotherapy, volume replacement, inotropic and vasopressor support, oxygen therapy and mechanical ventilation as well as haemodialysis and haemofiltration. These have, however, failed to make a substantial impact on the high mortality associated with septic shock (Nathanson et al., 1994) and, hence, septic shock remains the major cause of death in noncoronary intensive care units with an estimated mortality ranging between 50 and 80%. As shock is also by far the most common cause of prolonged admission to an intensive care unit, the clinical and socioeconomic importance of this illness is substantial. Since the discovery in 1990 that an enhanced formation of endogenous nitric oxide (NO) contributes to (i) the hypotension caused by endotoxin and TNF (Vane and Thiemermann, 1990; Kilbourn et al., 1990a,b), (ii) the vascular hyporesponsiveness to vasoconstrictor agents (Julou-Schaeffer et al., 1990; Rees et al., 1990), and (iii) the protection of liver integrity in rodents with sepsis (Billiar et al., 1990), there has been an ever increasing interest in the role of NO in the pathophysiology of animals and man with septic shock. The overproduction of NO in animal models of circulatory shock is due to an early activation of eNOS (which is transient, e.g. after bolus administration of endotoxin) and (more importantly) the delayed induction of iNOS activity in macrophages (host defence), vascular smooth muscle (hypotension, vascular hyporeactivity, maldistribution of blood flow) and parenchymal cells (contributing to organ dysfunction or organ integrity) (Thiemermann, 1994, 1995; Szabo, 1996; Rees, 1995). The formation of NO by eNOS (and potentially also by iNOS) also exerts beneficial effects in shock including vasodilatation, prevention of platelet and leukocyte adhesion, improvement of microcirculatory blood flow and augmentation of host defence. Thus, it is not surprising that basic and clinical scientists have advocated the use of contrasting therapeutic approaches including (i) inhibition of NOS activity, (ii) enhancement of the availability of NO (NO-donors, NO-inhalation) or (iii) a combination of both approaches (Thiemermann, 1994, 1995; Szabo, 1996; Rees, 1995). NITRIC OXIDE AND THE PATHOPHYSIOLOGY OF ENDOTOXIN SHOCK The circulatory failure associated with shock of various aetiologies is characterised by severe hypotension (peripheral vasodilatation), hyporeactivity of the vasculature to vaso-constrictor agents, myocardial dysfunction, maldistribution of organ blood flow and reduced tissue oxygen extraction. There is now good evidence that an enhanced formation of NO contributes to several of these pathophysiological features of septic shock. For instance, an enhanced formation of NO due to activation of eNOS (acute phase of shock) and particularly following the induction of iNOS in the vascular wall (late phase of shock) importantly contributes to the hypotension in animals (rat, dog, pig, sheep, baboons) and man with septic shock. Interestingly, endotoxin does not cause hypotension in mice in which the gene for iNOS has been inactivated (“iNOS knock-out” mice) (MacMicking et al., 1995). Thus, the hypothesis (Thiemermann and Vane, 1990) that an enhanced formation of endogenous NO importantly contributes to the hypotension
NO AND CIRCULATORY SHOCK
319
associated with endotoxic shock, is now supported by numerous studies (in various different species from rodents to man) using different pharmacological (e.g. prevention of iNOS expression, inhibition of iNOS activity with non-selective or iNOS-selective inhibitors, use of agents which scavenge NO etc.) or molecular biological approaches (e.g. gene-targeting of the iNOS gene). The peripheral vascular failure in animals and man with septic shock also results in a progressive attenuation of the presser effects afforded by norepinephrine and other vasoconstrictor agents (epinephrine, vasopressin, angiotensin II, serotonin, histamine, calcium, potassium). This vascular hyporeactivity contributes to the therapy-refractory hypotension in septic shock. Clearly, the hyporeactivity of blood vessels obtained from animals exposed to endotoxic or hemorrhagic shock (for several hours) to catecholamines is largely—but not exclusively—due to an enhanced formation of NO secondary to the induction of iNOS. In endotoxemia, an NO-mediated vascular hyporeactivity occurs in conductance, resistance as well as venous vessels (see Parratt and Stoclet, 1995 for review). Prolonged periods of septic shock also result in the development of an endothelial dysfunction, which is characterised by the impairment of “endothelium-dependent vasodilatation” and therefore presumably eNOS activity. The mechanism(s) of this endothelial dysfunction may include the downregulation of the expression of the eNOS gene by pro-inflammatory cytokines such as TNF, endothelial cell damage due to cytotoxic effects of NO, peroxynitrite or oxygen-derived radicals, and (to a lesser extent) the inactivation of NO by oxygen radicals (see Thiemermann, 1994, 1995). The role of NO in the development of the organ injury/dysfunction (MODS) associated with shock is still controversial. There is evidence that shock is associated with a maldistribution of organ blood flow which may well lead to a reduction in oxygen delivery to specific areas within an organ (Baue, 1993). Regardless of any local reduction in oxygen delivery (e.g due to hypotension and hence a reduction in perfusion pressure), shock also leads to the development of a marked defect in tissue oxygen extraction which is likely to contribute importantly to the development of MODS. Although the role of NO from iNOS in this defect in tissue oxygen extraction is not very well investigated, there is evidence (primarily from in vitro studies) that the excessive generation of NO by iNOS causes direct cytotoxic effects. For instance, large amounts of NO cause an autoinhibition of mitochondrial respiration by inhibiting several key enzymes in the mitochondrial respiratory chain (NADH-ubiquinone reductase, succinate-ubiquinone oxidoreductase) or in the Krebs’ cycle (e.g. cis-acconitase) resulting in a shift in glucose metabolism from aerobic to anaerobic pathways (Morris and Billiar, 1994; Thiemermann, 1995). NO and superoxide anion generate peroxynitrite anions (Beckmann et al., 1990), which causes strand breaks in DNA (Zingarelli et al., 1996). The occurrence of DNA strand breaks triggers a futile, energy-consuming repair cycle by activating the nuclear enzyme poly (ADP)ribosyltransferase (PARS). Activation of PARS results in the rapid depletion of the intracellular concentration of NAD+ (its substrate) slowing the rate of glycolysis, electron transfer and ATP formation which ultimately results in cell death (“PARS suicide hypothesis”) (Schraufstetter et al., 1986). Inhibitors of PARS activity (e.g. 3-aminobenzamide, nicotinamide) attenuate the inhibition of cellular respiration caused by peroxynitrite (Zingarelli et al., 1996). The generation of mice deficient in iNOS (iNOS mutant or “iNOS knock-out” mice) has helped to shed a further light into the physiological and/or pathophysiological importance of the generation of NO by iNOS (Wei et al., 1995; MacMicking et al., 1995 ; Laubach et al, 1995). Most importantly, these studies provide strong evidence that the enhanced formation of NO by iNOS (e.g. in macrophages) importantly contributes to host defence against infection. For instance, MacMicking and colleagues demonstrate that iNOSdeficient mice failed to restrain the replication of Listeria monocytogenes in vivo or lymphoma cells in vitro. Moreover, iNOS-deficient mice (but not wild-type or heterozygous mice) were highly susceptible to infection with the protozoa parasite Leishmania major and exhibited reduced non-specific inflammatory responses to carageenin (Wei et al., 1995). The importance of NO as a mediator of host defence is also
320
CHRISTOPH THIEMERMAN
highlighted by studies demonstrating that non-selective inhibitors of NOS activity increase mortality in mice challenged with live bacteria (infection) rather than endotoxin (endotoxaemia). In contrast, the hypotension (see above) and the early (but not the late) mortality caused by endotoxin is reduced in iNOS deficient mice, while the degree of liver injury is unaltered (MacMicking et al., 1995; Laubach et al., 1995). Taken together, these studies support the view that an enhanced formation of NO by iNOS defends the host against infectious agents and tumour cells, while an excessive induction of iNOS in other tissues (e.g. vasculature) may cause shock and possibly tissue injury. PREVENTION OF THE EXPRESSION OF INOS PROTEIN In 1990, dexamethasone was the first drug shown to prevent the expression of iNOS protein and activity caused by endotoxin in cells and tissues (Radomski et al., 1990; Rees et al., 1990). Since then, the list of xenobiotics which prevent the induction of iNOS activity and protein is ever growing and now includes antibodies to TNF , soluble TNF receptors, the endogenous IL-1 receptor antagonist, IL-4, IL-10, IL-11, IL-13, PAF-receptor antagonists, dihydropyridine-type calcium channel antagonists, glibenclamide, Nacetylserotonin (an inhibitor of the salvage pathway for the generation of BH4), 2,4-diamino-6hydroxypyrimidine (DAHP, an inhibitor of the activity of GTP cyclohydrolase and, hence, BH4 biosynthesis), tyrosine kinase inhibitors (genistein, tyrphostins, erbstatin), inhibitors of the activation of the nuclear transcription factor NF B (rotenone, PDTC, butyrolated hydroxyanisole) or inhibitors of I Bprotease (TPCK); to name but a few (see Szabo and Thiemermann, 1995). It should, however, be pointed out that many agents which prevent the expression of iNOS protein have to be administered prior to (or shortly after) endotoxin to prevent induction of iNOS, circulatory failure or MODS. In contrast, once hypotension (and presumably iNOS induction) has occurred, the administration of these agents show no or only minor beneficial effects (depending on their mechanism of action) on haemodynamics and organ function. Moreover, most of the above agents exert many effects, other than the prevention of the expression of iNOS protein and, hence, it is difficult to delineate which of their beneficial effects in animal models of shock are due to the inhibition of iNOS activity or secondary to other effects. For instance, calpain inhibitor I (inhibitor of the proteolysis of I B and, hence, of the activation of NF B) and dexamethasone, but not the serine and cysteine protease inhibitor chymostatin, attenuate (i) the circulatory failure (hypotension and vascular hyporeactivity to norepinephrine), (ii) the multiple organ dysfunction (liver and pancreatic injury/dysfunction, increase in lactate, hypoglycemia), and (iii) the induction of iNOS and cyclooxygenasc-2 (COX-2) protein and activity (in lung and liver) of rats with endotoxic shock (Ruetten and Thiemermann, 1987). Although the inhibition of the activation of NF B by calpain inhibitor I (and possibly dexamethasone) prevented (i) the circulatory failure as well as the development of organ injury/dysfunction in this study, and (ii) the expression of iNOS protein, the causal link between these two events remains unclear, for NF B plays a role in the transcription of many other genes (e.g. COX-2, adhesion molecules etc.). Agents, such as inhibitors of the activation of NF B or tyrosine kinase, which interfere with the expression of one (iNOS) or more (e.g. adhesion molecules) proteins which play a role in the pathophysiology of shock may well lead to novel therapeutic approaches for diseases associated with local or systemic inflammation, they are less suitable to delineate the role of iNOS in the pathophysiology of shock.
NO AND CIRCULATORY SHOCK
321
INHIBITION OF NOS ACTIVITY In contrast to therapeutic approaches aimed at preventing the expression of iNOS protein, agents which inhibit the activity of NOS offer the opportunity for a late intervention in animals and patients which have developed hypotension and early signs of the onset of organ dysfunction. The discovery of an L-arginineanalogues which inhibits NOS activity, NG-methyl-L-arginine (L-NMMA), provided the first tool to explore beneficial or side effects of NOS inhibitors in shock. The subsequent discovery of the NOS inhibitors NGnitro-L-arginine (L-NA) and its methyl ester (L-NAME; Moore et al, 1990), which in contrast to L-NMMA were cheap and readily available, stimulated numerous studies aimed at evaluating the role of NO in septic shock by using (high doses of) L-NAME. This was somewhat unfortunate, as L-NAME is a more potent inhibitor of eNOS than iNOS activity and, hence, caused many adverse effects resulting from the inhibition of eNOS activity including excessive vasoconstriction (e.g. fall in cardiac output, pulmonary hypertension etc) and enhanced adhesion of platelets and neutrophils to the endothelium (Thiemermann, 1995). Thus, LNAME reduces oxygen delivery and exacerbates organ injury in (many, but not all) animal models of endotoxic or septic shock. These results are not necessarily solely due to the use of very large amounts of LNAME, but rather a reflection of the fact that L-NAME is a more selective inhibitor of eNOS than iNOS activity. In rats with endotoxemia, even infusion of very low doses of L-NAME (e.g. 0.03 to 0.3 mg/kg/h) result in a dose-related increase in blood pressure (due to inhibition of eNOS activity) without reducing the rise in the plasma levels of nitrite/nitrate (an indicator of iNOS activity) or the organ injury caused by endotoxin (Wu et al., 1996). The hypothesis that the basal release of NO by eNOS has an important role in the regulation of regional blood flow and adhesion of blood-borne cells to the endothelium (beneficial effects of NO), while the excessive generation of NO by iNOS “in the wrong place at the wrong time” contributes to some aspects of the pathophysiology of shock (harmful effects of NO), has stimulated the search for selective inhibitors of iNOS activity. The following paragraphs highlight some aspects of the chemistry and pharmacology of NOS inhibitors which are more potent inhibitors of iNOS than eNOS activity. For a more detailed and complete account of the chemistry and iso-enzyme selectivity of NOS inhibitors, the interested reader is referred to a recent, excellent review of this topic (Southan and Szabo, 1996). L-NMMA is a competitive inhibitor of the binding of L-arginine to NOS and, hence, excess of L-arginine reverses the inhibition of NOS activity by L-NMMA. Although L-NMMA inhibits all isoform of NOS to a variable degree, it is a more potent inhibitor of iNOS than eNOS activity in cultured cells (Gross et al., 1990). As L-NMMA is only a moderately selective inhibitor of iNOS activity, it is not entirely surprising that L-NMMA exerts both beneficial as well as adverse effects in models of shock, which have been tentatively linked to its ability to inhibit iNOS and eNOS activity, respectively. Thus, the effects of LNMMA in any given model of shock depend on (i) the selectivity of iNOS inhibition achieved with a given dose of L-NMMA, (ii) the degree of iNOS activity in a given model of shock and (iii) the time point of the administration of L-NMMA. As the degree of iNOS induction caused by endotoxin varies between species, L-NMMA is more likely to exert a beneficial effect in shock when used in low doses (greater selectivity) in a species (e.g rat) with a relatively substantial degree of iNOS induction, while adverse effects of L-NMMA are more common when large doses of this L-arginine analogue are used in models/species which do exhibit only a minor degree of iNOS induction. Moreover, when L-NMMA is given prior to endotoxin (e.g. at a time point when there is no induction of iNOS activity), effects due to inhibition of eNOS activity (adverse effects) may predominate. In contrast, when given after (injection of endotoxin) the onset of hypotension, infusions of relatively low doses of L-NMMA (3 to 10 mg/kg/h) have been convincingly demonstrated to exert beneficial hemodynamic effects in rodents (mice, rat), sheep and baboon models of endotoxemia and sepsis. In the baboon, administration of live E.coli bacteria (2 109 colony forming units)
322
CHRISTOPH THIEMERMAN
resulted (after 4 h) in a significant increase in the serum levels of biopterin, neopterin and nitrate, suggesting that administration of live bacteria results in the induction of GTP cyclohydrolase I and iNOS within 4 h (Strohmeier et al., 1995). In this models, infusion of L-NMMA (5 mg/kg/h) attenuated (i) the rise in the serum levels of nitrate and creatinine (an indicator of renal dysfunction), (ii) the hypotension and fall in peripheral vascular resistance and (iii) the substantial 7-day mortality caused by severe sepsis in this species (Daryl Rees and Heinz Redl, personal communication). These findings clearly document that the circulatory failure caused by septic shock in baboons is largely mediated by an enhanced formation of NO by iNOS and that inhibition of iNOS with L-NMMA (or other more selective inhibitors of iNOS activity) improves outcome in this model. Aminoguanidine was the first relatively selective inhibitor of iNOS activity discovered (Corbett et al., 1992). Aminoguanidine is a more potent inhibitor of iNOS than eNOS activity in vitro and in vivo (Misko et al., 1993; Griffith et al., 1993; Joly et al., 1994; Wu et al., 1995). Aminoguanidine attenuates the delayed hypotension in rats (Wu et al., 1995) and rabbits (Seo et al, 1996) with endotoxin shock and improved survival in mice challenged with endotoxin (Wu et al., 1995). In rats subjected to endotoxemia, aminoguanidine also decreased the (i) degree of bacterial translocation presumably by preventing the injury to the gut mucosal barrier (Sorrell et al., 1996), (ii) the disruption of the blood brain barrier (Boje, 1996), the increase in pulmonary transvascular flux (Arkovitz et al., 1996), (iv) the liver injury/dysfunction (Wu et al., 1996), (v) as well as the decrease in total cytochrome P450 content (liver) and the subsequent reduction of the metabolism of ethylmorphin and metazolam (Muller et al., 1996). In contrast, aminoguanidine did neither attenuate the impairment in gluconeogenesis (Ou et al., 1996), nor the cardiac depresssion caused by endotoxin in the rat (Klabunde and Coston, 1995). Unfortunately, there is little information regarding the effects (and side effects) of aminoguanidine in models of shock or sepsis in larger animals. Moreover, the interpretation of the mechanism(s) by which aminoguanidine exerts its beneficial effects in shock is, however, difficult, as aminoguanidine is not a very specific inhibitor of iNOS activity, as this agent elicits many effects, which appear to be unrelated to the inhibition of iNOS activity (non-specific effects) (see Thiemermann, 1997 for review). S-substituted isothioureas (ITUs) are non-amino acid analogues of L-arginine and also potent inhibitors of iNOS activity with variable isoform selectivity (Garvey et al., 1994; Szabo et al., 1994; Southan et al., 1995). The most potent isothioureas are those with only short alkyl chains on the sulphur atom and no substituents on the nitrogen atoms. For instance, S-ethyl-ITU is a potent competitive inhibitor of all isoforms of NOS, while aminoethyl-ITU and S-methyl-ITU are more selective inhibitors of iNOS than of eNOS activity (Southan et al., 1995). Although S-substituted isothioureas also inhibit nNOS activity, they do not cross the blood brain barrier and, hence, may well be useful tools to elucidate the role of an enhanced formation of NO from iNOS in disease states including circulatory shock and inflammation. In rodent models of endotoxin shock, S-methyl-ITU or Aminoethyl-ITU reduce the circulatory failure (hypotension and vascular hyporeactivity to norepinephrine) and the liver injury/dysfunction (Szabo et al., 1994; Thiemermann et al., 1995). In blood vessels obtained from rats with endotoxemia, S-methyl-ITU also attenuated the vasodilator effect and the rise in vascular cGMP caused by L-arginine (Martinez et al., 1996). Moreover, S-methyl-ITU also reduced the vascular leak in the pulmonary vasculature of rats with endotoxic shock (Arkovitz et al., 1996). In a porcine model of endotoxemia, injection of aminoethyl-ITU (10 mg/kg i.v. at 3 h after endotoxin) restored hepatic arterial blood flow (from reduced to normal levels) and increased hepatic oxygen consumption, without affecting cardiac output (Saetre et al., 1997). Like aminoguanidine, isothioureas are also likely to elicit effects which are unrelated to their ability to inhibit NOS activity. For instance, aminoethyl-ITU is a radical scavenger and exerts beneficial effects in models of disease/pathology known to be mediated by oxygen-derived free radicals. Moreover, aminoethyl-ITU also
NO AND CIRCULATORY SHOCK
323
prevents the expression of iNOS protein caused by endotoxin in cultured macrophages and in the rat in vivo (Ruetten and Thiemermann, 1996). The number of novel NOS inhibitors which differ in chemistry and selectivity towards certain isoenzymes of NOS is ever increasing (see Southan and Szabo, 1996). In the context of this brief review the NOS inhibitor, L-NG-(l-iminoethyl)lysine, deserves to be mentioned, for this agent exhibits a 30-fold selectivity for iNOS over bNOS. Moreover, L-NG-(1-iminoethyl)lysine exerts potent anti-inflammatory effects in a rat model of adjuvant arthritis (Connor et al., 1995). Moreover, certain amidines including 2iminopiperidine, butyramine, 2-aminopyridine, propioamidine and acetamidine inhibit NOS activity. Interestingly, both 2-iminopiperidine and butyramidine are more potent inhibitors of iNOS activity than LNMMA in murine macrophages (Southan et al., 1996). Recently, an analogue of acetamidine termed 1400W [N-(3-(aminomethyl)benzyl)acetamidine] has been reported to be a slow, tight binding inhibitor of human iNOS. The inhibition by 1400W of the activity of human iNOS was (i) extremely potent (Kd value ~7nM), (ii) dependent on the co-factor NADPH and (iii) either irreversible or extremely slowly reversible. Most notably, 1400W was approximately 5000-fold more potent as an inhibitor of iNOS activity than of eNOS activity. Moreover, the inhibition by this agent of the activity of eNOS or nNOS activity was reversible by L-arginine, while iNOS inhibition was not. In a rat model of vascular injury caused by endotoxin, 1400W was 50-fold more potent as an inhibitor of iNOS than eNOS activity (Garvey et al., 1997). Thus, 1400W appears to be the most potent and selective inhibitor of iNOS activity known to date and, hence, will be an ideal tool to elucidate the role of NO from iNOS in shock and other diseases associated with the induction of iNOS. NITRIC OXIDE SYNTHASE INHIBITION IN HUMANS WITH SEPTIC SHOCK Although our understanding of the role of NO in animal models of circulatory shock has improved substantially over the past years, our knowledge regarding the biosynthesis and importance of NO in the pathophysiology of patients with shock (of various aetiologies) is still very limited. Indeed, a Medline search covering the time period from 1987 to November 1995 revealed that only 8 to 14% of all of the publications which included the key word ‘nitric oxide’ also included the key word ‘human’ (Preiser and Vincent, 1996). Endotoxin and cytokines (when given in combination) causes the expression of iNOS as well as the formation of NO in various human cells (primary or cell lines) including hepatocytes, mesangial cells, retinal pigmented epithelial cells and lung epithelial cells (Morris and Billiar, 1994; Preiser and Vincent, 1996). Elevated plasma levels of nitrite/nitrate occur in patients receiving IL-2 chemotherapy. In contrast, there is also evidence that the plasma levels of nitrite/nitrate are lower in patients after trauma, surgery and in patients with HIV infections. Interestingly, the increase in iNOS activity in leukocytes obtained from patients with sepsis appears to correlate with the number of failing organs, but not with blood pressure. Taken together, these studies support the conclusion that septic shock in man is associated with an enhanced formation of NO. It should, however, be stressed that the increase in the plasma levels of nitrite/ nitrate elicited by endotoxin, cytokines or bacteria in rodents (10-fold) is substantially higher than the observed increases in the plasma levels of these metabolites of NO in other animal species (pig, sheep etc) or humans. Early reports of beneficial haemodynamic effects of L-NMMA in humans with septic shock (Petros et al., 1994) stimulated a placebo-controlled multi-center study involving 312 patients with septic shock, which was designed to evaluate the effects of L-NMMA on the resolution of shock at 72 h (primary endpoint). The severity of illness according to the SAPS II score was similar between placebo and the LNMMA group. Infusion of L-NMMA enhanced mean arterial blood pressure and systemic vascular resistance index and decreased cardiac output (from elevated towards normal levels). L-NMMA had no
324
CHRISTOPH THIEMERMAN
effect on left ventricular systolic work index indicating that the fall in cardiac output was not due to an impairment in cardiac contractility. In patients which had an elevation in mean pulmonary artery pressure, infusion of L-NMMA resulted in a further transient increase in mean pulmonary artery pressure. Interestingly, L-NMMA did not affect the thrombocytopenia or the renal dysfunction caused by sepsis. Most notably, 41% of patients treated with L-NMMA, but only 21% of patients treated with placebo, recovered from shock within 72 h. There was also a strong trend for a reduction in mortality (at day 14) in patients treated with L-NMMA (Robert Grover, personal communication). CONCLUDING REMARKS In the last years numerous agents have been reported to be more potent inhibitors of iNOS than eNOS activity, and some of these have been evaluated in animal models of endotoxemia. There is good evidence that inhibition of iNOS activity attenuates the circulatory failure in endotoxin (or septic) shock in many species. Although some inhibitors of iNOS activity reduce the organ injury/dysfunction associated with endotoxic or septic shock, it is still unclear whether these effects are directly related to the ability of these agents to inhibit iNOS activity, or secondary to improvements in haemodynamics (e.g. L-NMMA) or (at least in part) due to non-specific effects (e.g aminoguanidine, aminoethyl-isothiourea). Studies using mice in which the iNOS gene has been inactivated by gene-targeting to elucidate the role of iNOS in endotoxemia support the notion that NO from iNOS contributes to hypotension and host defence, but provide controversial results regarding the role of iNOS in organ injury and mortality (Wei et al., 1995; Laubach et al., 1996, MacMicking et al., 1995). Our knowledge about the physiological role of NO from iNOS in sepsis (e.g. host defence) is relatively limited, and hence it remains difficult to predict the adverse effects of (even very selective) inhibitors of iNOS activity. Many of the reported adverse effects of NOS inhibition in shock appear to be secondary to the inhibition of eNOS activity (e.g. with large doses of L-NAME), while the infusion of lower doses of L-NMMA (3 to 10 mg/kg/h given after the onset of shock) results in beneficial haemodynamic effects in animals and man with shock, without causing any (apparent) side effects. Any potential adverse effects of non-selective NOS inhibitors may be overcome by combining these agents with NO-donors (e.g. SNAP), which may improve regional haemodynamics and inhibit the adhesion of platelets and PMNs to the endothelium in the absence of NO-synthesis by endothelial cells (due to eNOS inhibition) (Wright et al, 1992). Moreover, the rise in pulmonary vascular resistance caused by L-NMMA (e.g in patients with sepsis and pre-existing pulmonary hypertension) can be overcome by combining the systemic administration of this NOS-inhibitors with NO gas inhalation therapy. Indeed, in anaesthetised pigs with endotoxaemia, NO-gas inhalation alone was sufficient to improve pulmonary haemodynamics, gas exchange and arterial blood gases, while L-NMMA attenuated the circulatory failure. The combination of both therapies, however, was superior to either alone in improving survival (Klemm et al., 1995). The recent discovery of an analogue of acetamidine (1400W), which is a very selective inhibitors of iNOS activity, may enable future studies aimed at using this (or similar pharmacological tools) to elucidate the role of NO from iNOS in the multiple organ failure and mortality associated with septic shock. ACKNOWLEDGEMENTS The author is a Senior Fellow of the British Heart Foundation (FS/96018).
NO AND CIRCULATORY SHOCK
325
REFERENCES Arkovitz, M.S., Wispe, J.R., Garcia, V.F. and Szabo, C. (1986) Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J.Pediatr. Surg., 31, 1009–15. Baue, A.E. (1993) The multiple organ or systems failure syndrome. In Pathophysiology of shock, sepsis and organ failure, edited by G.Schlag & H.Redl, pp. 1004–18. Berlin: Springer. Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A. and Freeman, B. (1990) Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA, 87, 1620–24. Billiar, T.R., Curran, R.D., Harbrecht, B.G., Stuehr, D.J., Demetris, A.J. and Simmons, R.L. (1990) Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. J.Leukoc. Biol, 48, 565–569. Boje, K.M. (1996) Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis. Brain Res., 720, 75–83. Conner, J.R., Manning, P.T., Settle, S.L., Moore, W.M., Jerome, G.M., Webber, R.K. et al. (1995) Suppression of adjuvant-induced arthritis by selective inhibition of inducible-nitric oxide synthase. Eur. J.Pharmacol., 273, 15–24. Corbett, J.A., Tilton, R.G., Chang, K., Hasan, K.S., Ido Y, Wang J.L. et al. (1992) Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes, 41, 552–558. Garvey, E.P., Oplinger, J.A., Furfine, E.S., Kiff, R.J., Laszlo, F, Whittle, B.J.R. and Knowles, R.G. (1997) 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J.Biol Chem., 272, 4959–63. Garvey, P.E., Oplinger. J.A., Tanoury, G.J., Sherman, P.A., Fowler, M., Marshall, S. et al. (1994) Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J.Biol. Chem., 269, 26669–76. Griffith, M.J., Messent, M., MacAllister, R.J. and Evans, T.W. (1993) Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br. J.Pharmacol., 110, 963–8. Gross, S.S., Stuehr, D.J., Aisaka, K., Jaffe, E.A., Levi. R. and Griffith, O.W. Macrophage and endothelial nitric oxide synthesis: cell-type selective inhibition by NG-aminoarginine, NG-nitroarginine and NG-methyl-arginine. Biochem Biophys Res Commun, 170, 96–103. Joly, G.A., Ayres, M., Chelly, F. and Kilbourn, R.G. (1994) Effects of NG-methyl-L-arginine, NG-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem. Biophys, Res. Commun., 199, 147–54. Julou-Schaeffer, G., Gray, G.A., Fleming, I., Schott, C., Parratt, J.R. and Stoclet, J.C. (1990) Loss of vascular responsiveness induced by endotoxin involves the L-arginine pathway. Am.J.Physiol., 259, H1038–43. Kilbourn, R.G., Gross, S.S., Jubran, A., Adams, J., Griffith, O.W., Levi, R. et al. (1990) NG-methyl-L-arginine inhibits tumour necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc. Natl Acad. Sci. USA , 87, 3629–32. Kilbourn, R.G., Juburan, A., Gross, S.S., Griffith, O.W., Levi, R., Adams, J. et al. (1990) Reversal of endotoxinmediated shock by NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem. Biophys. Res. Commun., 172, 1132–8. Klabunde, R.E. and Coston, A.F. (1995) Nitric oxide synthase inhibition does not prevent cardiac depression in endotoxic shock. Shock, 3, 73–8. Klemm, P., Thiemermann, C., Winklmaier, G., Martorana, PA. and Henning, R. (1995) Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxic shock. Br. J. Pharmacol., 114, 363–368 Laubach, V.E., Sheseley, E.G., Smithies, O. and Sherman, PA. (1995) Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci. USA, 92, 10668– 92. MacMicking, J.D., Nathan, C., Horn, G. et al. (1995) Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell, 82, 641–650.
326
CHRISTOPH THIEMERMAN
Martinez, M.C., Muller, B., Stoclet, J.C. and Andriantsitohaina, R. (1996) Alteration by lipopolysaccharide of the relationship between intracellular calcium levels and contraction in rat mesenteric artery. Br. J. Pharmacol., 118, 1218–22. Misko, T.P, Moore, W.M., Kasten, T.P, Nickols, D.A., Corbett, J.A., Tilton, R.G. et al. (1993) Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J.Pharmacol., 233, 119–125. Morris, S.M. and Billiar, T.R. (1994) New insights into the regulation of inducible nitric oxide synthase. Am. J.Physiol., 266, E829–39. Muller, C.M., Scierka, A., Stiller, R.L., Kim, Y.M., Cook, D.R., Lancaster, J.R. et al. (1996) Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology, 84, 1435–42. Nathanson, C., Hoffmann, W.D., Suffredini, E.F., Eichacker, PQ. and Banner, R.L. (1994) Selected treatment strategies for septic shock based on proposed mechanism of pathogenesis. Ann. Intern. Med., 120, 771– 83 Ou, J., Molina, L., Kim, Y.M. and Billiar, T.R. (1996) Excessive NO production does not account for the inhibition of hepatic gluconeogenesis in endotoxemia. Am.J.Physiol., 271, 621–8. Parillo, J.E. (1990) Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann. Intern. Med., 113, 227–242. Petros, A., Lamb, G., Leone, A., Moncada, S., Bennett, D. and Vallance, P. (1994) Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res., 28, 34–39. Preiser, J.C. and Vincent, J.L. (1996) Nitric oxide involvement in septic shock: Do human beings behave like rodents? In Yearbook of Intensive Care and Emergency Medicine, edited by J.L.Vincent, pp. 358–365, Berlin: Springer. Radomski, M.W., Palmer, R.M.J. and Moncada, S. (1990) Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA., 87, 10043–10047. Rees, D.D., Cellek, S., Palmer, R.M.J. and Moncada, S. (1990) Dexamethasone prevents the induction of nitric oxide synthase and the associated effects on the vascular tone: an insight into endotoxic shock. Biochem. Biophys. Res. Commun., 173, 541–47. Rees, D.D., Cellek, S., Palmer, R.M.J. and Moncada, S. (1990) Dexamethasone prevents the induction of nitric oxide synthase and the associated effects on the vascular tone: an insight into endotoxic shock. Biochem. Biophys. Res. Commun., 173, 541–47. Rees, D.D. (1995) Role of nitric oxide in the vascular dysfunction in septic shock. Biochem. Soc. Trans., 23, 1025–9. Ruetten, H. and Thiemermann, C. (1996) Prevention of the expression of inducible nitric oxide synthase by aminoguanidine or aminoethyl-isothiourea in macrophages and in the rat. Biochem. Biophys. Res. Commun., 225, 525–530. Saetre, T., Gundersen, Y., Thiemermann, C., Lilleansen, P. and Aasen, A.O. (1997) Aminoethyl-isothiourea, a selective inhibitor of inducible nitric oxide synthase activity, improves liver circulation and oxygen metabolism in a porcine model of endotoxaemia. Shock; in press. Schraufstatter, I., Hinshaw, D., Hyslop, P., Spragg, R. and Cochrane, C. (1986) Oxidant injury of cells. DNA strand breaks activate polyadenosine diphosphate ribose polymerase and lend to depletion of nicotinamide adenine dinucleotide. J. Clin. Invest. 77, 1312–19. Seo H.G., Fujiwara, N., Kaneto, H., Asashi, M., Fujii, J. and Taniguchi, N. (1996) Effect of the nitric oxide synthase inhibitor, S-ethyl-isothiourea, on cultured cells and cardiovascular functions of normal and lipopolysaccharide-treated rabbits. J.Biochem., 119, 553–8. Sorrells, D.L., Friend, C., Koltuksuk, U., Courcoulas, A., Boyle, P., Garrett, M. et al. (1996) Inhibition of nitric oxide with aminoguanidine reduces bacterial translocation after endotoxin challenge in vivo. Arch. Surg., 131, 1155–63. Southan, G.J., Szabo, C. and Thiemermann, C. (1995) Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br.J.Pharmacol., 114, 510–16. Southan, G.J., Szabo, C., O’Conner, M.P., Salzman, A.C. and Thiemermann, C. (1995) Amidines are potent inhibitors of nitric oxide synthases: Preferential inhibition of the inducible isoform. Eur. J. Pharmacol., 291, 311–318. Southan, G.J. and Szabo, C. (1996) Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol., 51, 383–394.
NO AND CIRCULATORY SHOCK
327
Strohmeier, W., Werner, E.R., Redl, H., Wachter, H. and Schlag, G. (1995) Plasma nitrate and pteridine levels in experimental bacteremia in baboons. Pteridines, 6, 8–11. Szabo, C., Southan, G.J. and Thiemermann, C. (1994) Beneficial effects and improved survival in rodent models of septic shock with S-methyl-isothiourea sulfate, a novel, potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl. Acad. Sci. USA, 91, 12472–76. Szabo, C. and Thiemermann, C. (1995) Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv. Pharmacol., 34, 113–54. Szabo, C. (1995) Alterations in nitric oxide production in various forms of circulatory shock. Horizon, 1, 2–32. Thiemermann, C., Ruetten, H., Wu, C.C. and Vane, J.R. (1995) The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br. J. Pharmacol., 116, 2845–2851. Thiemermann, C. and Vane, J.R. (1990) Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat. Eur.J.Pharmacol., 182, 591–5. Thiemermann C. (1994) The role of L-arginine:nitric oxide pathway in circulatory shock. Adv. Pharmacol., 28, 45–79. Thiemermann, C., Ruetten, H., Wu, C.C. and Vane, J.R. (1995). The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br.J.Pharmacol., 116, 2845–2851. Thiemermann, C. (1998). The use of selective inhibitors of inducible nitric oxide synthase. Sepsis, 1, 123–129. Wei, X., Charles, I.G., Smith, A. et al. (1995) Altered immune responses in mice lacking inducible nitric oxide synthase. Nature, 375, 408–411. Wright, C.E., Rees, D.D. and Moncada, S. (1992) Protective and pathological roles of nitric oxide in endotoxic shock. Cardiovasc. Res., 26, 48–57. Wu, C.C., Chen, S.J., Szabo, C., Thiemermann, C. and Vane, J.R. (1995) Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br.J.Pharmacol., 114, 1666–1672. Wu, C.C., Ruetten, H. and Thiemermann, C. (1996) Comparison of the effects of aminoguanidine and NG-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxemia in the rat. Eur.J.Pharmacol., 300, 99–104. Zingarelli, B., O’Conner, M., Wong, H., Salzman, A.L. and Szabo, C. (1996). Peroxynitrite-mediated DNA breakage activates polyadenosine diphosphate ribosyl sythetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J.Immunol., 156, 350–358.
19 Kidney Diseases Peter Gross, Heike Dorniok, Doreen Reimann and Maria Plug Department of Medicine, Universitatsklinikum C.G.Carus, Fetscherstaβe 76 LD-01307 Dresden, FRG
The occurrence of constitutive (NOS III) or inducible (NOS II) isoforms of NO-synthase has been described in virtually all vascular and most tubular segments of the normal kidney, including intrarenal arteries and arterioles involved in the regulation of renal perfusion. Stimulation of nitric oxide by intrarenal infusion of acetylcholine decreases renal vascular resistance and increases renal blood flow. NOS I is present in the macula densa; it is instrumental in blunting the tubulo-glomerular feedback in the condition of salt loading. In postischemic acute renal failure, nitric oxide reportedly reaches high concentrations during the incipient hypoxic phase. These concentrations may cause damage to cell membranes. Conversely during the reperfusion phase endogenous nitric oxide may be beneficial to the postischemic kidney. In uremia and dialysis nitric oxide is increased explaining the phenomenon of uremic bleeding. However in some uremic patients endogenous NOS inhibitors may accumulate, reducing NO generation and possibly contributing to hypertension. IgAnephropathy in patients and glomerulonephritis in experimental models have been found to be conditions of increased nitric oxide, which usually has beneficial rather than detrimental effects upon the kidney. Incipient diabetes mellitus induces a preferential increase of NO-generation at sites of diabetic nephropathy, preventable by aminoguanidine. The nephrotoxicity of cyclosporine A is associated with defective renal vasodilatation in response to acetylcholine, implying a lack of nitric oxide. In humans L-arginine fails to correct this defect however. In summary, several kidney diseases will be amenable to nitric oxide based therapies in the future. Key words:Acute renal failure, uremia, glomerulonephritis, IgA-nephropathy, diabetes mellitus, cyclosporine A.
KIDNEY DISEASES
329
INTRODUCTION The kidney is one of the most densely vascularized organs of the body. Its function depends on the maintenance of perfusion pressures within narrow limits. However, these limits vary substantially from segment to segment of the renal vasculature. Accordingly, the kidney utilizes an array of vascular control mechanisms to regulate segmentai perfusion as needed. One major regulatory mechanism is related to renal nitric oxide. In this chapter we shall discuss published evidence on the role of nitric oxide in renal disease. As an introduction we will briefly outline the normal functions of NO in the kidney. Recent histochemical work by Bachmann et al. (1995) has delineated the localization of NO-synthases in the normal kidney of the rat, the mouse and the human. The authors observed a strong signal of neuronal NO-synthase (NOS I) in the macula densa. They described an intimate spatial relation between NOS I positive cells of the macula densa and their adjacent renin containing cells in the endothelium of afferent arterioles. In the renal vasculature the constitutive NO synthase (NOS III) was located in the endothelium of cortical and medullary blood vessels. Glomerular arterioles showed strong labelling in the endothelia of both afferent and efferent arterioles. At the capillary level the glomerular tuft showed endothelia positive for NOS III. In addition to the prominent findings of NO synthase in renal vascular structures a more subtle presence of NOS I and NOS III has been described in virtually all renal tubular epithelia (summarized in: Hill-Kapturczak et al., 1995). Studies in normal kidneys have shown that the renal response to calcium mobilizing hormones such as bradykinin or acetylcholine is a release of NO that leads to vasodilatation (Welch et al., 1991). These findings probably reflect the widespread distribution of NOS III in renal blood vessels that was mentioned just previously. Recent interest has centered on the role of NOS I in the macula densa. Wilcox and Welch (1996) showed a blunting of the tubuloglomerular feedback response in the salt loaded rat and this was mediated by nitric oxide. In other words, the salt loaded state enhanced nitric oxide of macula densa origin and this permitted an improved afferent arteriolar blood flow, an enhanced single nephron glomerular filtration rate and enhanced NaCl excretion. As far as a potential role for NOS in renal tubular epithelia is concerned, observations in isolated tubular cells (Neuringer et al., 1991) as well as in isolated perfused kidneys (Gabbai et al., 1992) have been obtained. They suggest that NO may have direct tubular effects to increase reabsorptive transport. Nonetheless a general stimulation of renal NOS III by infusion of bradykinin or acetylcholine will be followed by natriuresis and diuresis. Thus the vascular effects of nitric oxide in the kidney will override any tubular effects. POST-ISCHEMIC ACUTE RENAL FAILURE The role of nitric oxide in the pathophysiology of acute renal failure is ambiguous. Acute renal failure is a condition of renal vasoconstriction, decreased glomerular filtration rate, tubular obstruction and tubular epithelial cell damage. Most available studies of models of post-ischemic acute renal failure have suggested that NOS activity is increased in this condition (Robinette and Conger, 1993; Waz et al., 1994). Yaqoob et al., (1996b) analyzed the effects of hypoxia—which is held to be the initiating event in post-ischemic acute renal failure—on tubular epithelial cells in vitro. They induced hypoxia in freshly isolated proximal tubules of the rat and they directly monitored NO generation with an amperometric NO sensor. Within 7 min. of the induction of hypoxia, NO release started to rise dramatically and thereafter this increase was maintained Correspondence: Peter Gross, M.D., Nephrologie, Klinik für Innere Medizin III, Universitatsklinikum C.G. Carus, Fetscherstr. 76, D-01307 Dresden, F.R.G., Tel:0049 351 458 2645; Fax:0049 351 458 533.
330
PETER GROSS ET AL.
during a stable phase of elevation (Figure 19–1). Cell membrane damage as assessed by measurements of lactate dehydrogenase (LDH) was first detectable about 8 min. after the start of NO release. The NOS inhibitor L-NAME prevented the hypoxia induced increase in NO in a dose dependent manner and this occurred in parallel to incremental cytoprotection. Noiri et al., (1996) used bilateral crossclamping of the renal pedicle for 45 min. to induce ischemia and they studied the kidneys 24 hrs after reperfusion. Eight hours before the crossclamping the authors injected the rats with antisense oligonucleotides targeting the inducible NOS (NOS II). As a result of the injection a selective knock-down of NOS II in proximal tubules prevailed at the time of ischemia. This was followed by complete functional protection of the kidney from renal failure, an effect that could not be imitated by giving the nonspecific NOS inhibitor L-NAME. The observed effects were attributed to specific rescue of tubular epithelium from lethal injury; as demonstrated in the study, application of antisense constructs did not affect endothelial NOS (NOS III). In a different study in vivo, Conger et al., (1996) examined the role of NO in a rat model of norepinephrine induced acute renal failure one week after its induction by infusing norepinephrine. They concluded that NOS activity was maximally stimulated in their model. The NOS isoform involved in the stimulation was NOS III, not NOS II. It was suggested that the increased NOS activity was a response to the ischemia induced renal vasoconstrictor tone. Administration of the NO inhibitor L-NAME precipitated further profound vasoconstriction in an already malperfused kidney. Considering the discrepant results of Yaqoob et al. (1996b) and Conger et al. (1996) we would like to point to the difference in time of observation in the two studies: Whereas Yaqoob et al (1996b) performed measurements within minutes of induction of hypoxia, Conger et al. (1996) studied nitric oxide one week after the initiation of hypoxia by norepinephrine. Together these experimental models indicate a sequence of NO functions in the evolution of postischemic acute renal failure. In this chain of events different isoforms of NOS in different tissues appear to be involved in succession. Furthermore the importance of the balance between nitric oxide and superoxide for hypoxia-reoxigenation injury merits consideration as pointed out by Yaqoob et al (1996a). In summary the role of nitric oxide in post-ischemic acute renal failure is dependent on time after injury and tissue compartment involved. More specific antagonists of the isoforms of NOS will be required in the future before any therapeutic strategies in patients with acute renal failure can be considered. Radiocontrast nephropathy is a specific kind of post-ischemic acute renal failure. Diabetes mellitus and arterio-sclerosis are known conditions that put patients at risk for radiocontrast nephropathy and these underlying disturbances have been characterized for their defective endothelium-dependent vasorelaxation. In a recently described animal model in the rat the radiocontrast agent iothalamate when injected alone increased outer medullary blood flow by approximately 100% (Agmon et al., 1994). Pretreatment by the NO inhibitor L-NAME reduced basal medullary blood flow and transformed the medullary vasodilator response to radiocontrast into a prolonged vasoconstriction. Acute renal failure developed consistently. It was associated with selective necrosis of medullary thick ascending limbs. A comparable set of experiments in radiocontrast nephropathy was also reported by Andrade and Seguro (1996). It is therefore conceivable that endothelial NO-synthase (NOS III) is impaired in patients at risk for radiocontrast nephropathy. This impairment may be a crucial element in the pathogenesis of the subsequent acute renal failure. Future studies with L-arginine or with intrarenally effective NO donors in patients at risk will be helpful in clarifying the therapeutic potential of these agents. UREMIA AND DIALYSIS It is still an unresolved question whether nitric oxide generation is increased in uremia leading to pathologic changes, or whether the opposite applies because of endogenous inhibitors of NO formation.
KIDNEY DISEASES
331
Figure 19±1. (A) Recording of NO concentration in the incubation medium of freshly harvested isolated rat proximal tubules during normoxia (lower curve) and hypoxia (upper curve). (B) Effect of 7.5 min and 15 min of normoxia (C) and hypoxia (H) on LDH release. (Reprinted by permission of the publisher from Yaqoob et al., 1996).
In 1993 Noris et al. (1993) found that L-NMMA normalized the prolongued bleeding time of uremic rats. Extending their study to include patients in chronic renal failure they observed higher NO generation in uremic platelets than in control. They also observed higher cGMP concentrations in uremic platelets and higher L-arginine concentrations in uremic serum versus control. Moreover uremic plasma potently induced NO synthesis by cultured endothelial cells. On the basis of these findings, Noris et al. (1993) proposed a role for enhanced nitric oxide synthesis in uremia to contribute to platelet dysfunction, uremic bleeding and dialysis hypotension. Recent measurements of intradialytic blood levels of nitric oxide in patients
332
PETER GROSS ET AL.
undergoing chronic hemodialysis (Roccatello et al (1996a) showed higher baseline levels of NO in dialysis patients than in controls and levels increased further during the dialysis procedure. In addition exposure of blood cells to dialysis membrane material has been shown to initiate NO release from neutrophils (Roccatello et al., 1996b) and from vascular endothelial cells that had been in contact with such blood cells (Amore et al., 1995a). However, Vallance et al. (1992) found that uremic patients cannot eliminate endogenous dimethylarginines (DMA), normally excreted in urine. One of the DMA’s, NG,NG-dimethylarginine (ADMA) inhibits NO synthesis in a manner similar to L-NMMA. Uremic patients had higher plasma concentrations of ADMA than control; plasma concentrations of ADMA changed in parallel to the plasma creatinine concentration. Synthetic ADMA as well as urine extracts containing ADMA inhibited NOS II isolated from induced macrophages in a dose dependent manner and similar to L-NMMA. The authors proposed that uremia is associated with an accumulation of endogenous ADMA, inhibiting NO generation and thereby eventually contributing to hypertension and immundysfunction of renal failure. Some of the discrepancies between the studies mentioned previously may be explained by work of Arese et al. (1995). They tested the effects of uremic plasma from patients on NO generation by several different cell lines in culture expressing NOS II and NOS III. They found that 79% of uremic plasma samples inhibited NOS II and NOS III, while 20% stimulated the latter. Plasma taken after a hemodialysis session usually showed a reduced inhibitory capacity; in several cases of “inhibitory plasma” postdialysis plasma samples even stimulated NOS activity. These results indicate that uremia may be a condition in which activating and inhibiting stimuli of NOsynthases compete with each other. This and the possibility of differences in ADMA formation or access to compartimentalized NOS are likely explanations for the discrepancies of results in different studies. GLOMERULONEPHRITIS Glomerulonephritites are a group of renal disorders in which immune glomerular inflammation—usually mediated by cytokines—predominates. Therefore NO-synthases would be expected to have a role in at least some forms of glomerulonephritis. The available evidence indeed shows that nephritic glomeruli often generate increased amounts of NO which seems to be primarily derived from infiltrating macrophages. Thus Kashem et al. (1995) studying the renal biopsies of 28 patients with IgA glomerulonephritis were able to demonstrate the presence of NOS II in most, a finding that was completely absent in renal tissue from control. Observations suggested a macrophage related origin of the NOS II. Of note the authors were able to correlate the expression of NOS II with the degree of adjacent tubulo-interstitial damage in IgA glomerulonephritis. In fact a recent study by Tetsuka et al. (1996) indicated that nitric oxide may enhance the degree of inflammation in the kidney by co-inducing cyclooxigenase-2 expression causing formation of PGE2, an inflammatory mediator. Cattell et al. (1990), Jansen et al. (1994) and Sever et al. (1992) determined nitrite production in models of an accelerated nephrotoxic glomerulonephritis in rats. This was done by measuring the urinary nitrite excretion rate in vivo and by assessing the nitrite generation rate in vitro in cultured glomeruli. The latter were isolated from experimental animals. It was observed that nitrite generation by isolated nephritic glomeruli increased approximately 100-fold during the 24 h induction phase of this glomerulonephritis. Over the following 7 days, nitrite generation returned to baseline. Parallel findings to those in isolated glomeruli were obtained in measurements of urinary nitrite. In these particular models the induction phase of glomerulonephritis is characterized by an influx of macrophages into the glomeruli. Isolated macrophages from the glomeruli of nephritic kidneys were indeed found to show stimulated nitric oxide production and this was attributable to NOS II (Cattell et al., 1991). In a subsequent
KIDNEY DISEASES
333
study from the same laboratory Waddington et al. (1996) used a single i.v. injection of arginase to test the role of stimulated NO generation in the pathophysiology of their nephritic model. Arginase is an enzyme that depletes intracellular stores of L-arginine. In the study of Waddington et al. (1996) arginase reduced NO generation by 50%. Surprisingly NO suppression by arginase worsened the manifestations of glomerulonephritis. Thus there was increased proteinuria and intraglomerular thrombus formation in response to arginase. Waddington et al. (1996) concluded that the stimulation of nitric oxide in their model was protective rather than detrimental. A comparable set of experimental observations has also led Munger et al. (1994) to propose a beneficial role of nitric oxide in their animal model of nephrotoxic glomerulonephritis. They reduced endogenous nitric oxide formation 90% by giving the nonspecific NOS inhibitor L-NAME during the phase of granulocyte infiltration of the glomeruli. In response to the treatment with L-NAME the measured parameters of glomerulonephritis worsened:the glomerular filtration rate and the renal blood flow were strongly reduced whereas proteinuria and leucocytic infiltration of the kidney increased. However the results of this study may not simply reflect the direct effects of NO inhibition on the nephritic glomerulus, since the model was simultaneously characterized by systemic hypertension (153±6 mmHg versus 118±7), which lasted several days. Systemic hypertension is usually associated with intrarenal hypertension and the latter may worsen glomerulonephritis in itself. A more extended experiment than that of Munger et al. (1994) was reported by Tikkanen et al. (1994). They studied a model of Heymann-nephritis in the rat to which they gave treatment with L-NAME during 12 weeks of observation. The L-NAME treated rats became hypertensive, too, as was observed in the model of Munger et al. (1994). 12 weeks of L-NAME failed to improve the glomerulonephritis in the model of Tikkanen et al. (1994); instead proteinuria, peritubular infiltrates of monocytes and histologie damage of the kidneys all worsened in response to L-NAME. Tikkanen et al. (1994) concluded that nitric oxide was antiproliferative and antiinflammatory in their model and therefore protective to the kidney. Recently, Gabbai et al. (1996) studied experimental tubulointerstitial nephritis by giving L-NAME and L-NIL—two different NOS inhibitors—to test the role of nitric oxide. L-NAME worsened kidney function and renal pathologic morphology and it augmented antigenspecific IgG, as well as cytokines induced such as interferon y, IL-4 and IL-2. According to their data interstitial injury and functional deterioration are prevented by NO in experimental interstitial nephritis. There is only one experimental model of glomerulonephritis in which nitric oxide appeared to be detrimental while NO inhibition was therapeutic. Ketteler et al. (1993b) performed experiments in Thy-I glomerulonephritis in rats. This model is believed to resemble IgA-nephropathy in humans. Thy-I glomerulonephritis is induced by an injection of anti-thymocyte antibodies. The latter bind to an antigen on renal glomerular mesangial cells. As a consequence of the binding complement is activated and lysis of mesangial cells ensues causing a glomerulonephritis. Ketteler et al. (1993a) gave L-NMMA 60 min before the injection of anti-thymocyte antibodies. L-NMMA prevented lysis of mesangial cells even though the binding of antibodies to mesangial cells and the influx of macrophages were unaltered. L-NMMA also improved proteinuria, expression of TGF-, fibronectin and tenascin. When the experiments were repeated in rats on a protein-restricted diet—presumably causing a degree of depravation of L-arginine—similar improvements of the pathologic changes of the model were observed even when no L-NMMA was given. Taken together the role of nitric oxide in different models of glomerulonephritis is not uniform. In addition to the classical pathways of NO-stimulation and effect additional mechanisms such as autoinduction of NOS-II by NO (Pfeilschifter, 1995) or induction of cyclooxigenase-2 expression by NO (Tetsuka et al., 1996) may be involved. In the majority of the reported models the evidence suggests a protective role of endogenous nitric oxide to the kidney. It is surprising therefore that few if any attempts
334
PETER GROSS ET AL.
have been made to test the potential therapeutic benefit from NO precursors such as L-arginine, or NO donors supplemented to models of glomerulonephritis. DIABETES MELLITUS According to recent evidence nitric oxide overproduction is involved in the genesis of early diabetic nephropathy, whereas subsequent NO deficiency may contribute to the late changes of glomerulosclerosis. Diabetic nephropathy is closely correlated with the magnitude and duration of antecedent hyperglycemia. One of several mechanisms involved in this process is related to NOS stimulation by glycated protein. Nonenzymatic glycation of long-lived proteins occurs during hyperglycemia. Amore et al. (1997) investigated the effects of glycated albumin on the production of nitric oxide by endothelial cells in vitro. Glycated albumin induced a dose response related increase of NO-synthase activity that was as much as 16fold higher than baseline (Figure 19–2). The effect was still detectable with low concentration of glycated albumin, resembling the concentrations occurring in vivo in diabetic patients. The observed effects were attributable to induction of NOS IL In another set of experiments Sabbatini et al. (1992) infused glycated serum proteins into normal rats. This was found to cause glomerular hyperfiltration, one of the early signs of incipient diabetic nephropathy. In the rat model of streptozotocin induced diabetes early renal changes consisted of significantly higher renal blood flow and glomerular hyperfiltration. In this early stage of diabetes there were also an increased urinary cGMP-excretion rate as well as increased concentrations of nitrite in plasma and urine (Bank and Aynedjian, 1993; Cooper et al., 1993; Dai et al., 1993). Treatment with the NOS inhibitors L-NA or L-NAME diminished glomerular filtration rate and renal blood flow of the diabetic rats to significantly greater extent than in normal control (Bank and Aynedjian 1993; Cooper et al., 1993; Mattar et al., 1994; Tolins et al., 1992). Exogenous NO in the form of nitroglycerin did not confer an additional effect on hemodynamics of diabetic animals (Cooper et al., 1993). The results were interpreted to indicate that NO generation was submaximal in the early stages of streptozotocin-induced diabetes in the rat. In measurements of renal hemodynamics made 6 weeks after induction of streptozotocin diabetes, Tolins et al. (1992) observed an upward shift of the renal curve of blood flow autoregulation. In this way diabetic rats had a higher renal blood flow than controls at low perfusion pressures. Because these changes were inhibitable by L-NAME the results were again taken as evidence of an NO-mediated diabetic effect (Tolins et al., 1992). Corbett et al. (1992) described aminoguanidine as a preferential inhibitor of NOS II Testing the effects of aminoguanidine in diabetic rats they observed the changes induced by aminoguanidine on blood flow or vascular leakage of albumin to be restricted to tissues manifesting vascular dysfunction of diabetes. The results were taken to show that diabetes induces a preferential increase of NO-generation in tissues and vascular beds that are the sites of diabetic vasculopathy. In the later stages of diabetes it is likely that nitric oxide release from the renal vasculature is reduced, similar to observations made in systemic arteries in patients with diabetes (Johnstone et al., 1993). In the same vein, Wang et al. (1993) studying isolated glomeruli in culture obtained from rats 2 to 3 weeks after induction of diabetes found basal cGMP as well as stimulated cGMP to be no larger in diabetic glomeruli than in control. Craven et al. (1994) also showed a progressive impairment of NO-dependent cGMP-generation by glomeruli of diabetic rats depending on the duration of the diabetes. The impaired NO-dependent cGMP-formation and/or decreased NO-synthases of advanced diabetes may contribute to diabetic glomerular capillary hypertension, in this way participating in the pathogenesis of diabetic glomerular injury (Zatz et al., 1986). Taken together the experimental data strongly indicate an overproduction of nitric oxide contributing to the incipient stage of diabetic nephropathy. Accordingly it will be interesting to find out from ongoing clinical trials whether aminoguanidine in patients with diabetes proves to be therapeutic or not.
KIDNEY DISEASES
335
Figure 19±2. Dose response curve of NOS activity of murine endothelial cells after incubation with graded concentrations of glycated albumin. (Reprinted by permission of the publisher from Amore et al., 1997).
NEPHROTOXICITY OF CYCLOSPORINE A Systemic hypertension and vasoconstriction of the renal microcirculation are well known side-effects of cyclosporine A (Mason, 1990). Several studies provide evidence that cyclosporine A impairs formation of nitric oxide or its vasodilatory effects (Stephan et al., 1995), directly or by enhanced endothelial superoxide anion-generation, which causes inactivation of nitric oxide (Rubanyi and Vanhoutte, 1986; Diederich et al., 1994). Several authors have shown that NOS-inhibition worsens the nephrotoxicity of cyclosporine A (Amore et al., 1995; Pollock and Polakowski, 1996; Gardner et al., 1996). Gardner et al. (1996) treated rats with cyclosporine A plus the NOS inhibitor L-NAME for 3 weeks. Cyclosporine A dosage was chosen in such a way that cyclosporine A blood levels were within the therapeutic range for human renal transplant patients. Rats treated with cyclosporine A alone showed proximal tubular collapse and vacuolization. However rats receiving the combination of cyclosporine A plus L-NAME had vascular abnormalities consisting of endothelial and arteriolar medial hyperplasia. The relation between cyclosporine A and nitric oxide has also been studied by supplementing L-arginine. Gallego et al. (1993) administered cyclosporine A without and with L-arginine to rats. After 15 days of cyclosporine A the rats showed inhibitions of endothelium-dependent vasodilatation, diuresis, natriuresis and urinary cGMP-excretion rate. The response of the cyclosporine A treated rats to endothelium-independent agents such as sodium nitropresside and atrial natriuretic peptide was unaltered. The toxic effects of cyclosporine A were acutely overcome by administration of the amino acid L-arginine. The coadministration of L-arginine for 15 days prevented the functional effects of cyclosporine A toxicity. L-arginine normalized endotheliumdependent vasorelaxation impaired by cyclosporine A in isolated femoral arteries (Gallego et al., 1994). Bobadilla et al. (1994) also gave cyclosporine A together with L-arginine to rats. L-arginine caused vasodilatation and improved the glomerular filtration rate by approximately 115%, both in comparison to measurements made under cyclosporine A alone.
336
PETER GROSS ET AL.
Much of the evidence of an impairment of the NO-pathway in endothelial cells in response to cyclosporine A rests on the demonstration of defective acetylcholine induced vasorelaxation (Gallego et al., 1993; Gallego et al., 1994; Diederich et al., 1994; Stephan et al., 1995). No direct measurements of NO or of one of its stable metabolites have been reported. It is therefore remarkable that recent reports have suggested an effect of cyclosporine A to increase the expression of nitric oxide synthase. Amore et al. (1995) observed an increased expression of mRNA for NOS III and NOS II in cyclosporine A toxicity in the kidney, as did Nakayama et al. (1996) but not Pichier et al. (1996). It is possible therefore that cyclosporine A may have direct effects to inhibit NO activity or that increased superoxide-generation and subsequent NO-inactivation (Diederich et al., 1994) are involved in the demonstrated impairment of the NOpathway. With respect to the beneficial effects of L-arginine in experimental cyclosporine A induced nephrotoxicity it is disappointing that such effects have not been reproducable in humans. Gaston et al., (1995) tested 12 renal transplant recipients, 6 of whom were treated with cyclosporine A. They infused 30 g of L-arginine over 120 min and they compared the results obtained with those in 6 transplant recipients on azathioprine, not receiving cyclosporine A. The latter group responded to L-arginine infusion with a decrease of the mean arterial blood pressure, a decrease of renal vascular resistance, an increased renal blood flow and an improved glomerular filtration rate. In contrast, L-arginine—while decreasing mean arterial blood pressure—failed to improve renal blood flow or glomerular filtration rate in the transplant recipients receiving cyclosporine A. The observed effects were specifically related to L-arginine, because branched-chain amino acids did not change any of the parameters measured. A recent study in 11 adolescent kidney transplant recipients receiving cyclosporine A who were given L-arginine for 6 weeks also failed to show a benefit in terms of renal blood flow, glomerular filtration rate or proteinuria (Zhang et al., 1995). Even though L-arginine-related effects may involve insulin stimulation and its subsequent effects on nitric oxide (Giuliano et al., 1997) it is obvious that L-arginine is insufficient in humans to overcome the effects of cyclosporine A on the nitric oxide pathway. MISCELLANEOUS Glomerulosclerosis The endogenous progression of renal insufficiency to endstage renal failure, a process of progressive renal glomerulosclerosis, has been of substantial interest to nephrologists. Because glomerulosclerosis is associated with hyperperfusion of residual renal tissue the question has been raised whether nitric oxide contributed to glomerulosclerosis. An accepted animal model to study glomerulosclerosis is 5/6 nephrectomy in rats. Aiello et al. (1994) studying homogenized renal tissue from 5/6 nephrectomy found basal release of NO to be significantly lower than control. Gehlen et al. (1994) assessed mRNA of NOS II, NOS III and soluble guanylate cyclase A and B by 3 weeks after the induction of 5/6 nephrectomy in the rat. No significant changes from control were found. Functional studies of the effects of NO supplementation have been reported by Ingram et al. (1994), Corner et al. (1996) and Cianciaruso et al. (1996). Ingram et al. (1994) concluded that the reduction of proliferating cell nuclear antigen as well as that of endothelin-1 mRNA in renal cortical tissue from 5/6 nephrectomized rats receiving 2 weeks of supplementation with Larginine indicated a beneficial effect counteracting glomerular hypertrophy of residual tissue. Corner et al., (1996) treated 5/6 nephrectomized rats for 5 months with molsidomine, a donor of nitric oxide. Molsidomine prevented the hypertension of 5/6 nephrectomy and prolongued survival. Rats receiving molsidomine had less proteinuria and higher creatinine clearance than vehicle treated controls. However in the absence of any control treatment with an NO-independent antihypertensive it is not certain that the
KIDNEY DISEASES
337
observed benefit was primarily related to NO rather than to its antihypertensive effect. Cianciaruso et al., (1996) gave oral L-arginine to 11 patients with renal insufficiency for 6 months in a controled manner. In the group treated with L-arginine urinary excretion rate of nitrate rose significantly thereby demonstrating increased formation of nitric oxide. However the systemic blood pressure, the glomerular filtration rate and the proteinuria were similar in L-arginine treated and control patients. The study therefore failed to show a protective effect of L-arginine supplementation on the outcome of renal function in patients with glomerular disease. Taken together published data favour the view that the nitric oxide pathway is not of major importance in glomerulosclerosis or in the endogenous progression of renal insufficiency. Pregnancy and Preeclampsia The question has been